UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

(Mark One)

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, ~~2024~~2025 □ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

Commission File Number: 001-34632

CRYOPORT, INC.

(Exact Name of Registrant as Specified in its Charter)

Nevada

88-0313393

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

112 Westwood Place, Suite 350

Brentwood, TN 37027

(Address of principal executive offices, including zip code)

(949) 470-2300

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Stock, $0.001 par value		CYRX		The NASDAQ Stock Market LLC (The Nasdaq Capital Market)

Securities registered pursuant to Section 12(g) of the Act: Warrants to purchase Common Stock

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes □ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No □

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No □

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☐	Accelerated filer	☒

Non-accelerated filer	☐	Smaller reporting company	□

		Emerging growth company	□

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The aggregate market value of common stock held by non-affiliates of the registrant as of June 30, 2025 ~~2024~~ was $0.34 billion based on the closing sale price of such common equity on such date (excluding 1,~~061~~308,~~389~~004 shares of common stock held by directors and officers, and any stockholders whose ownership exceeds ten percent of the shares outstanding as of June 30, ~~2024~~ 2025).

As of February 28 27, ~~2025~~2026, there were 49,~~910~~856,~~391~~135 shares of the registrant’s common stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrant’s proxy statement for the ~~2024~~2026 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K where indicated. Such proxy statement will be filed with the U.S. Securities and Exchange Commission within 120 days of the registrant’s fiscal year ended December 31, ~~2024~~ 2025.

Table of Contents

TABLE OF CONTENTS

		Page
PART I
Item 1.	Business	4
Item 1A.	Risk Factors	2214
Item 1B.	Unresolved Staff Comments	3527
Item 1C.	Cybersecurity	3827
Item 2.	Properties	3628
Item 3.	Legal Proceedings	3628
Item 4.	Mine Safety Disclosures	3628
PART II
Item 5.	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	3728
Item 6.	[Reserved]	3830
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	3830
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk	4840
Item 8.	Financial Statements and Supplementary Data	4941
Item 9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	4941
Item 9A.	Controls and Procedures	4941
Item 9B.	Other Information	5042
Item 9C.	Disclosure Regarding Foreign Jurisdictions that Prevent Inspections	5042
PART III
Item 10.	Directors, Executive Officers and Corporate Governance	5244
Item 11.	Executive Compensation	5244
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	5244
Item 13.	Certain Relationships and Related Transactions, and Director Independence	5244
Item 14.	Principal Accountant Fees and Services	5244
PART IV
Item 15.	Exhibits and Financial Statement Schedules	5345
Item 16.	Form 10-K Summary	5648
Signatures		5749

Table of Contents

FORWARD-LOOKING STATEMENTS

References to the “Company,” “Cryoport,” “we,” “us,” “our” and other similar words refer to Cryoport Inc. and its consolidated subsidiaries, unless the context suggests otherwise. This Annual Report on Form 10-K (this “Form 10-K”) contains certain forward-looking statements. These forward-looking statements involve a number of risks and uncertainties. These forward-looking statements can generally be identified as such because the context of the statement will include certain words, including but not limited to, “believes,” “may,” “will,” “expects,” “intends,” “estimates,” “anticipates,” “plans,” “seeks,” “continues,” “predicts,” “potential,” “likely,” or “opportunity,” and also contains predictions, estimates and other forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the current beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Readers of this Form 10-K should not put undue reliance on these forward-looking statements, which speak only as of the time this Form 10-K was filed with the Securities and Exchange Commission (the “SEC”). Reference is made in particular to forward-looking statements regarding our expectations about future business plans, new products or services, regulatory approvals, strategies, development timelines, prospective financial performance and opportunities, including potential acquisitions; expectations about future benefits of our acquisitions and our ability to successfully integrate those businesses and our plans related thereto; ~~liquidity~~expectations ~~and~~about ~~capital~~future ~~resources;~~benefits ~~plans~~ relating to ~~our~~the ~~cost~~CRYOPDP ~~reduction~~divestiture and ~~capital~~strategic ~~realignment~~partnership ~~measures~~with ~~and~~DHL ~~expectations~~(as ~~about~~defined ~~resulting~~in ~~annual~~the ~~cost~~Form ~~savings~~10-K); liquidity and ~~financial~~capital ~~impact~~resources; assumptions relating to the impairment of assets; plans relating to any ~~repurchases~~repurchase of our common stock and/or convertible notes; projected trends in the ~~market~~markets in which we operate; ~~our~~including the anticipated expansion of cell and gene therapy market; expectations relating to current supply chain impacts, tariffs, and other trade restrictions; inflationary pressures and the effect of foreign currency fluctuations; anticipated regulatory filings or approvals with respect to the products of our clients; expectations about securing and managing strategic relationships with global couriers or large clinical research organizations; plans and expectations regarding the potential or benefits of our existing and future products and technologies; our future capital needs and ability to raise capital on favorable terms or at all; results of our research and development efforts; and approval of our patent applications.

Although we believe that our opinions and expectations reflected in the forward-looking statements are reasonable as of the date of this Form 10-K, we cannot guarantee future results, levels of activity, performance or achievements, and our actual results may differ substantially from the views and expectations set forth in this Form 10-K. You should be aware that these statements are projections or estimates as to future events and are subject to a number of factors that may tend to influence the accuracy of the statements, including, but not limited to, risks and uncertainties associated with the ~~effect~~effects of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, ~~and~~ the effects of foreign currency fluctuations, trends in the products markets, variations in the Company’s cash flow, market acceptance risks, the effects of tariffs and other trade restrictions, and technical development risks. Additional risks and uncertainties relating to the CRYOPDP divestiture include the risk that any disruption resulting from the CRYOPDP divestiture may adversely affect our businesses and business relationships, including with employees and suppliers. Other factors that might cause such a difference include, but are not limited to, those discussed in this Form 10-K, including in “Risk Factors” in “Part I, Item 1A — Risk Factors” and in “Part II, Item 7 — Management’s Discussion and Analysis of Financial Condition and Results of Operations,” as well as those discussed in reports filed with the SEC after the date of this Form 10-K.

Past financial or operating performance is not necessarily a reliable indicator of future performance, and you should not use our historical performance to anticipate results or future period trends. We can give no assurances that any of the events anticipated by the forward-looking statements will occur or, if any of them do, what impact they will have on our results of operations and financial condition. Except as required by law, we do not undertake to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this Form 10-K.

Table of Contents

PART I

Item 1. Business

Overview

We are a leading global ~~leader~~provider inof integrated, temperature-controlled supply chain solutions for the life sciences ~~industry~~, with a strong focus on supporting the ~~Cell~~rapidly ~~and~~growing ~~Gene~~cell ~~Therapy~~and ~~market~~gene therapy (“CGT”) market. Our ~~broad~~solutions ~~array~~are ofpurpose-built ~~products~~to ~~and~~support ~~services~~a ~~are~~broad ~~designed~~range toof ~~mitigate~~global ~~risks~~life ~~and~~sciences ~~ensure~~markets, ~~the~~including ~~safe~~biopharmaceutical and ~~reliable~~pharmaceutical ~~storage~~companies, ~~and~~the ~~delivery~~animal ofhealth ~~critical~~markets, ~~therapies~~reproductive ~~and~~medicine, ~~other~~academic ~~high~~institutions, ~~value~~research, ~~biologic~~and ~~materials~~government agencies. WeOur ~~support~~solutions ~~the~~help ~~entire~~our ~~continuum~~customers ~~from~~ensure ~~biomaterial~~the ~~collection~~safe, tocompliant ~~final~~storage, handling, and delivery of high value, ~~‘Enabling~~temperature ~~the~~sensitive ~~Future~~biological ofmaterials, ~~MedicineTM.~~including cell and gene therapies and immunotherapies.

~~Our~~We ~~integrated~~place particular emphasis on the CGT market, our fastest growing market, by delivering highly specialized, end-to-end supply chain ~~platform~~solutions ~~leverages~~that ~~advanced~~support ~~temperature-controlled~~cell ~~packaging~~and gene therapy programs from preclinical research, ~~systems~~through clinical trials, and ~~informatics~~ultimately to ~~deliver~~the ~~essential~~global ~~solutions~~commercialization ~~for~~of ~~companies~~approved intherapies. ~~the~~As ~~CGT~~of ~~ecosystem~~December 31, 2025, ~~including:~~Cryoport supported 760 clinical trials, and 20 commercially approved cell and gene therapies.

●Our ~~BioLogistics~~integrated temperature-controlled supply chain solutions combine advanced logistics, biostorage, kitting and labelling, clinical sample management, collection and cryopreservation services for cell therapies starting materials, cryogenic systems manufacturing, and an industry-leading informatics platform that integrates all our solutions. Our capabilities for supporting cell and gene therapies enables our end-to-end Chain of Compliance® which includes chain-of-custody, chain-of-condition and chain-of-identity for some of the most complex therapies in development, clinical trials, and commercialization today.

●Our ~~BioStorage/BioServices~~solutions are designed to maintain the viability, identity, and quality of these patient-specific and high-value therapies playing a critical role in enabling timely treatment, reducing the risk of therapy failure, and supporting positive patient outcomes.

●The ~~Cryopreservation~~Company delivers its integrated life sciences services and products through three operating units:

●Cryoport ~~Cryogenic~~Systems ~~systems~~provides advanced temperature-controlled BioLogistics, BioServices, and cryopreservation solutions, supporting clinical and commercial workflows through specialized transport, cGMP storage, kit production, labeling, packaging, and commercial therapy fulfillment.

CryoGene delivers long-term temperature-controlled BioStorage and related value-added services for preclinical and early-stage clinical programs for biopharmaceutical products.

WeMVE ~~have~~Biological aSolutions ~~market~~(MVE) ~~leading~~designs ~~role~~and inmanufactures ~~supporting~~industry-leading ~~the~~cryogenic ~~CGT~~systems, ~~market~~including ~~and~~freezers, ~~other~~dewars, ~~markets~~and intransport ~~the~~systems ~~life~~used ~~sciences~~globally ~~industry~~for ~~that~~the ~~require~~storage ~~comprehensive,~~and ~~technology-centric~~movement ~~supply~~of ~~chain~~biological ~~solutions~~materials for ~~high-value~~the ~~products~~life ~~and materials~~sciences.

•Together, Asthese ofbusinesses ~~December~~form 31an end-to-end, ~~2024~~digitally integrated supply chain solution that supports the safe, weregulatory ~~supported~~compliant, ~~701~~handling ~~clinical~~of ~~trials~~critical ~~and~~biological 19materials ~~commercial~~from ~~cell~~pre-clinical ~~and~~through ~~gene~~commercially ~~therapies~~approved products.

•During ~~Our~~the ~~integrated~~second ~~solutions~~quarter ~~help~~of ~~ensure~~fiscal year 2025, we completed the ~~integrity~~divestiture of ~~cellular~~our ~~material~~specialty ~~throughout~~courier CRYOPDP business to designated affiliates of DHL Supply Chain International Holding B.V. (“DHL”) for $133.0 million. The transaction also included the ~~supply~~repayment ~~chain~~of ~~from~~approximately $77.2 million of outstanding intercompany loans owed by CRYOPDP to us. We also entered into certain related agreements in connection with the ~~time~~transaction, ~~biological~~including ~~materials~~a master partnership agreement. The divestiture and strategic partnership with DHL are ~~extracted~~expected ~~from~~to ~~the~~enhance ~~patient~~our ~~for~~ability to develop our business, particularly in the ~~cell~~Europe, the Middle East, and ~~gene~~Africa ~~manufacturing~~(EMEA) ~~process~~and Asia-Pacific (APAC) regions, and to provide differentiated and high-value services aligned with our long-term growth strategy. The CRYOPDP business is classified as discontinued operations and, unless otherwise noted, the ~~delivery~~description of ~~the~~our ~~therapies~~business in this Form 10-K relates solely to our continuing operations. See Note 5 – Discontinued Operations to our consolidated financial statements included under Part II, Item 8 “Financial Statements and Supplementary Data” for additional information about the ~~point~~divestiture of ~~care~~the CRYOPDP business.

• These solutions include BioLogistics, BioServices, and Cryopreservation services, all of which are critical for the development and delivery of these lifesaving therapies.

• Our newly introduced Cryopreservation services (IntegriCell®) provide enhanced cryopreservation and characterization services to maintain the quality of cellular therapy starting materials.

• Our informatics, led by the Cryoportal® Logistics Management Platform, provides visibility of real-time monitoring and tracking and Chain-of-Compliance®. It also provides the process control and information that ensures quality and regulatory compliance. The Cryoportal® Logistics Management Platform has integration capabilities with clients, partners and vendors through Application Program Interfaces (API).

• MVE Biological Solutions, the global leader for cryogenic systems used in the life sciences for storage and transportation, is known for its reliability, safety, high-quality manufacturing, and innovation. This inhouse manufacturing capability protects Cryoport Systems by ensuring the reliable supply of essential purpose-built cryogenic equipment and technology that enables us to quickly scale our services capabilities as the CGT market grows and expands worldwide.

We have a global presence through our directly operated global supply chain centers, logistics centers and depots, biostorage/bioservices, and cryoprocessing centers. We have partner networks in the Americas, EMEA (Europe, the Middle East, and Africa) and APAC (Asia-Pacific) regions. In addition, our MVE Biological Solutions business unit operates three cryogenic systems manufacturing centers in the U.S. (2) and China (1).

The Markets We Serve

We are an integrated temperature-controlled supply chain solutions and have developed industry-leading products and services that seamlessly integrate into a comprehensive supply chain platform supporting the life sciences market, including the biopharma/pharma, animal health, and reproductive medicine markets. With a historical focus on biopharmaceuticals, high-value temperature-controlled products and commodities, animal health vaccines, and reproductive medicine materials, we have developed best practices and industry standards for these critical areas within the life sciences supply chain.

Table of Contents

InOur ~~the~~Reportable biopharmaceutical space, we have concentrated on emerging fields, particularly cell and gene therapies. These therapies are among the most sensitive pharmaceutical products, requiring stringent distribution standards supported by informaticsSegments

~~Cryoport~~We ~~Products~~report ~~and~~our ~~Services~~financial performance in two segments that include five core areas:

We continuously work to expand and improve our products and services across the life sciences supply chain with innovative, technology-centric solutions.


		Percentage of 2025
Reportable Segment	Core Solutions	Total Revenue
Life Sciences Services	BioLogistics Solutions	54.8%
	BioStorage Solutions
	BioServices Solutions
	Cryopreservation Services
Life Sciences Products	Cryogenic Systems Manufacturing	45.2%

See Note 19 – Segment Reporting to our consolidated financial statements included under Part II, Item 8 “Financial Statements and Supplementary Data” for additional information about our segments.

Life Sciences Services

Our strategy for the Life Sciences Services segment is developed around three pillars that serve as the foundation for the Company’s fully integrated temperature-controlled supply chain solutions: our Cryoportal^® digital logistics management platform, our Chain of Compliance^® and quality principles, and our Global Supply Chain Center Network.

The Cryoportal Digital Logistics Management Platform. This platform serves as the digital ‘nerve center’ for the Company’s fully integrated temperature-controlled supply chain solutions. From the collection of patient- or donor-derived starting material through biostorage, transport, distribution, and final delivery, Cryoport’s solutions work together to reduce risks and complexity, improve visibility, and enhance reliability for clients operating in highly regulated environments. The Cryoportal combines advanced temperature-controlled logistics and informatics by integrating with clients, partners, and vendor systems through application programming interfaces (APIs), enabling seamless data exchange and consistent execution across global temperature-controlled supply chains.

~~Our~~As ~~suite~~the scope and importance of ~~market~~digital ~~leading~~capabilities ~~products~~expanded, Cryoport established its Enterprise Technology Group (ETG) in 2024 to unify its digital platforms, monitoring, intelligent packaging, Internet of Things (IoT)-enabled monitoring, automation, and ~~services~~data ~~include~~analytics into a single, ~~but~~cohesive ~~are~~digital ~~not~~framework ~~limited~~and ecosystem. This evolution aligns with Cryoport’s technology-led growth initiatives, toincluding global infrastructure expansion and the ~~following:~~introduction of new advanced solutions and platforms such as IntegriCell®, CryoVerse, Bioservices and our Global Supply Chain Network.

Cryoport ~~Express®~~continues ~~Shippers~~to -expand ~~Cryoport~~the ~~Express®~~foundations ~~Shippers~~for ~~range~~its ~~from~~fully ~~liquid~~integrated ~~nitrogen~~solutions ~~dry~~through ~~vapor~~ongoing ~~shippers~~enhancements ~~(-150℃)~~ to ~~our~~the ~~C3™ Shippers (2-8℃)~~Cryoportal, ~~which~~broader ~~are~~deployment ~~powered~~of byits ~~phase-change~~Smartpak® ~~materials.~~Condition ~~The~~Monitoring ~~Cryoport~~System ~~Express®~~and ~~Shippers~~Tec4med ~~are precision~~IoT-~~engineered~~based ~~assemblies~~monitoring ~~that are reliable~~solutions, ~~cost-effective,~~ and ~~reusable~~deeper orintegration ~~recyclable.~~of ~~Our~~quality ~~liquid~~systems ~~nitrogen~~such ~~dry~~as ~~vapor~~Chain ~~Cryoport~~of ~~Express®~~Compliance. ~~Shippers~~We ~~utilize~~plan anto ~~innovative~~further ~~application~~support ofthese ~~‘dry~~capabilities ~~vapor’~~through ~~liquid~~the ~~nitrogen~~development ~~technology~~ and, ~~most~~application ~~often,~~of ~~include~~artificial aintelligence ~~SmartPak™~~(“AI”) ~~Condition~~and ~~Monitoring~~advanced ~~System.~~analytics ~~Cryoport~~to ~~Express®~~aggregated ~~Shippers~~platform ~~meet~~data, ~~IATA~~enabling ~~requirements~~the ~~for~~Company ~~transport,~~to ~~including~~manage ~~Class~~and ~~6.2~~anticipate ~~infectious~~network ~~substances~~risks, ~~are~~improve ~~also~~operational ~~ISTA~~performance, ~~(International~~and ~~Safe~~support ~~Transit~~predictive, ~~Association)~~data-driven ~~“Transit~~decision-making ~~Tested”~~across ~~certified and carry~~ the ~~“CE”~~temperature-controlled ~~(“Conformité~~supply ~~Européenne”) mark demonstrating conformance with European Union (“EU”) health, safety, and environmental protection standards~~chain.

~~Cryoport~~By ~~ELITE™~~embedding ~~Shippers~~digitalization, -data ~~The first product~~intelligence, inand ~~this~~automation ~~high-performance~~across ~~line~~its ofsolutions, Cryoport ~~ELITE™~~aims ~~Shippers,~~to iscontinue ato ~~best-in-class~~enhance ~~-80°C~~its ~~shipper~~scalability, ~~that~~further ~~has~~strengthen ~~superior~~its ~~temperature~~regulatory ~~management properties as well as incorporating next generation protection~~integrity, ~~handling,~~ and ~~data~~support ~~collection~~the ~~and~~continued ~~management~~growth ~~systems~~and ~~including~~commercialization ~~our SmartPak™ Condition Monitoring System. The Cryoport ELITE™ -80°C Gene Therapy Shipper was developed in conjunction with one~~ of the ~~leaders~~CGT inmarket ~~the~~as ~~gene~~these ~~therapy~~lifesaving ~~space~~cures ~~for~~are ~~clinical and commercial gene therapy distribution and was launched during the second quarter of 2023~~developed.

~~Cryoport~~Chain ~~Express®~~of ~~Cryogenic~~Compliance ~~HV3~~and ~~Shipping~~Quality. ~~System~~Our ~~(HV3)~~Chain –of ~~During~~Compliance ~~the~~framework ~~first~~is ~~quarter~~integrated ofthroughout ~~2025,~~our weservices ~~introduced~~to ~~the~~ensure ~~HV3~~that ~~which~~critical ~~provides~~biological ~~optimized~~materials ~~hold~~are ~~times for interior payloads~~handled, ~~improved storage efficiency~~stored, and transported in full ~~compliance~~accordance with ~~airline~~applicable ~~requirements including narrow bodied aircraft. Tailored to meet the specific needs of advanced therapies~~regulatory, ~~the HV3 ensures enhanced payload security~~quality, ~~superior~~and ~~temperature~~procedural ~~control,~~requirements ~~payload~~throughout ~~integrity~~the ~~and~~entire ~~extended~~ temperature-controlled ~~stability~~supply ~~at cryogenic temperatures~~chain. ~~Its~~ ~~innovative~~It ~~enclosure~~extends ~~design~~beyond ~~and~~traditional ~~configuration eliminates the need for palletization on narrow~~chain-~~bodied~~of-custody ~~aircraft, ensuring compliance with regional carriers~~ and ~~reducing flight rejections and delays. This enhancement also opens additional shipping lanes, making it easier for life~~chain-~~saving~~of-condition ~~therapies~~by toembedding ~~reach~~ more ~~remote~~compliance, ~~destinations. Designed with the end-user in mind~~documentation, ~~the HV3 features robust wheels~~ and anprocess ~~integrated,~~control ~~front-facing~~into ~~handle~~every tophysical ~~ensure~~and ~~easy~~digital ~~mobility~~touchpoint atincluding ~~any~~storage ~~stage~~and ofdistribution ~~transit.~~equipment management.

Smartpak II® Condition Monitoring System and Tec4Med – Cryoport’s Smartpak II® Condition Monitoring System (“Smartpak II®”) delivers comprehensive visibility into the location and conditions of valuable materials throughout the entire shipment process. The system also provides critical data to validate that sample integrity is maintained during transit. The Smartpak II® monitors key parameters, including location, temperature, shock, orientation, and pressure, with immediate alerts enabling swift intervention when necessary. Seamlessly integrating with our Cryoportal® Logistics Management Platform, the Smartpak II® provides visibility of near real-time reporting, combining condition monitoring, logistics management, and shipper qualification performance into a single data stream for enhanced oversight and reliability.

We acquired Tec4Med, a company providing cold-chain packaging temperature and location monitoring, warehouse monitoring as well as bench top monitoring for laboratories and research facilities during the fourth quarter of 2023. Technological innovations from Tec4Med include:

• The SmartHub is an intelligent Beacon-Gateway Monitoring System and can be integrated into any logistics process at box, pallet, container, truck or warehouse level. In doing so, it enables full supply chain visibility in real-time.

• The CryoBeacon serves as an intelligent temperature and humidity data logger with advanced capabilities. It effectively records all data internally and offers two methods of data retrieval: manual access through the Tec4App and automated retrieval via the SmartHub gateway. Designed for multiple applications, the CryoBeacon can be utilized repeatedly for different shipments.

With our solutions, our clients have the peace of mind that comes with knowing exactly where their shipments are, at all times, ensuring that they can deliver high-quality pharmaceutical products to their clients with confidence. By adopting risk mitigation measures, our clients can proactively identify and address potential threats to their operations and supply chain. This saves valuable resources that can be redirected toward other critical areas of their business, allowing them to operate

Table of Contents

~~more~~Through ~~efficiently~~the integration of validated temperature-controlled supply chain systems, standardized operating processes and ~~effectively. Through~~procedures, ~~Tec4Med~~continuous ~~technology~~condition monitoring, ~~they~~chain-of-custody ~~can~~tracking, ~~optimize~~chain-of-condition ~~their~~monitoring ~~operations~~and real-time informatics, our Chain of Compliance provides end-to-end visibility and ~~build~~traceability aof ~~more~~every ~~resilient~~component ~~business~~and ~~for~~every ~~the~~process ~~long~~from ~~term~~initial material collection through final delivery to points of care. WeThis ~~intend~~approach supports our adherence to ~~leverage~~ISO ~~the~~21973:2020, ~~Tec4Med~~ISO ~~technology~~9001:2015, ~~across~~global ~~many~~regulatory ofstandards, ~~Cryoport’s~~including ~~products~~Good Manufacturing Practice (“GMP”), and ~~services~~applicable ininternational ~~the~~transport ~~coming~~and ~~years~~quality requirements.

Enabled by the Cryoportal and supported by highly trained staff, the Chain of Compliance captures and aggregates environmental, shipping, biostorage, and handling data into a unified record that supports audit readiness, deviation management, and regulatory reporting. By proactively managing risk and ensuring consistent execution across complex, global supply chains, the Chain of Compliance helps protect biological material integrity, reduce variability, and support reliable patient treatment outcomes.

~~Cryoport~~All ~~accessories~~our –operations ~~Our purpose-built accessories~~ are ~~integral~~also certified to ~~our~~ISO ~~comprehensive~~9001:2015 ~~integrated~~for ~~temperature-controlled~~quality ~~supply~~management ~~chain~~systems, ~~solutions.~~ISO ~~Designed~~13485:2016 tofor ~~seamlessly~~medical ~~integrate~~devices, ~~with~~where ~~our~~applicable, ~~advanced~~and ~~shipping~~ISO ~~systems,~~21973:2020 ~~our~~for ~~accessories~~the ~~safeguard~~transportation ~~materials~~of ~~and~~cells ~~minimize~~for ~~risks~~therapeutic atuse. ~~every~~These ~~stage~~certifications ofsupport sstandardized ~~their~~processes ~~journey—spanning~~across ~~critical~~our ~~phases~~Global ofSupply ~~development~~Chain ~~and~~Center ~~manufacturing.~~Network ~~From~~demonstrating our ~~proprietary~~commitment ~~Safepak®~~to ~~and~~risk ~~SoftRackTM~~management, ~~Systems~~traceability, toand ~~specialized~~continuous ~~labels,~~improvement. ~~cassette~~In ~~racks~~addition, ~~and~~our ~~cryovial~~quality ~~boxes,~~framework ~~each~~incorporates ~~accessory~~Good isDistribution ~~meticulously~~Practice ~~engineered~~(“GDP”) toand ~~help~~GMP ~~ensure~~principles, ~~security~~validated equipment and ~~preserve~~processes, ~~the~~supplier ~~integrity~~qualification, ofand ~~critical~~ongoing ~~therapies~~training and ~~biomaterials~~auditing ~~throughout~~programs. Together with the ~~supply~~Chain ~~chain.~~of ~~Our~~Compliance ~~accessories~~framework, ~~include:~~these ~~Safepak®~~standards ~~System~~are ~~1800,~~intended ~~Safepak®~~to ~~XL,~~ensure ~~Soft~~the ~~Rack™~~integrity, ~~Cryostrap®~~safety, and ~~Cryoport~~compliance ~~Elite®~~of ~~Ultra~~biological ~~Cold~~materials ~~Shipping~~throughout ~~Systems'~~storage, ~~Payload~~handling, ~~Holding~~and ~~System among others~~transportation.

~~Cryoport~~Global ~~BioStorage/Bioservices~~Supply –Chain Center Network. We ~~offer~~operate ~~biostorage~~a ~~and~~Global ~~bioservices~~Supply ~~solutions~~Chain Center Network through ~~two~~which ofwe provide our ~~business~~BioLogistics, ~~units~~BioStorage, ~~CRYOGENE~~BioServices, and ~~Cryoport~~Cryopreservation ~~Systems~~services, supporting the end-to-end requirements of the life sciences industry. This integrated network is purpose-built to manage the complexity, regulatory requirements, and time- and temperature-sensitive nature of cell and gene therapies, regenerative medicines, and other biological materials.

Our global infrastructure includes strategically located Global Supply Chain Centers across the Americas, EMEA, and APAC regions. These facilities are further complemented by a qualified partner network of transportation providers that extend our reach while operating under Cryoport’s qualification, monitoring, and compliance standards. These transportation partners include integrators, life sciences specialty couriers, and local service providers, enabling reliable coverage across major clinical, commercial, and research markets worldwide.

~~CRYOGENE~~On -this ~~Acquired in 2019~~foundation, CRYOGENE provides biostorage solutions primarily for the provision of pre-clinical temperature-controlled biological materials management services to the life sciences industry. With a focus on pre-clinical commodities, it is one of the medical research industry’s leading biorepository, focusing on the secure storage of biological specimens and associated supplies. Utilizing the latest freezer and cryogenic storage technologies and computer inventory control software, CRYOGENE can cost-effectively fulfill life sciences bio-storage and distribution requirements. Our services include comprehensive specimen storage, processing, collection, and retrieval at our CRYOGENE operations in Houston, Texas, and San Antonio, Texas, the latter which was opened during the first quarter of 2024. Both facilities are FDA registered for storage and distribution and compliant with Current Good Tissue Practice (CGTP), Current Good Manufacturing Practices (cGMP), and the American Association of Tissue Banks (AATB). In January 2025, we ~~announced~~provide ~~a strategic partnership with~~ the ~~Moffitt~~following ~~Cancer~~core ~~Center~~solutions ~~(MCC), a leading National Cancer Institute-designated comprehensive cancer center, whereby CRYOGENE will establish a state-of-the-art biorepository center~~ in ~~conjunction with MCC’s planned 775-acre global innovation life sciences campus in Pasco County, Florida. CRYOGENE facilities in Florida are expected to be fully validated and open during~~ the ~~second~~Life ~~half~~Sciences ofServices ~~2026.~~segment:

BioLogistics Solutions. Our BioLogistics solutions provide highly specific, temperature-controlled transportation services for CGT and other critical biological materials. These services are designed to meet the stringent requirements of advanced biologics, where deviations in temperature and other variables, shock, handling, or timing can compromise product integrity and patient outcomes. Our BioLogistics solutions are ISO 21973:2020 certified—the first standard to specifically address, in detail, the requirements for the CGT supply chain, with a focus on transportation, and that recognizes CGT products are significantly more fragile and valuable than most small molecule and biological therapies.

●Through purpose-built Cryoport ~~Systems~~Express® ~~Bioservices~~and -Cryoport InElite® ~~June~~shipping ~~2022~~systems, wecontinuous ~~launched~~condition ~~its~~monitoring ~~first~~and ~~two Global Supply Chain Centers in Houston~~tracking, ~~Texas~~customs and ~~Morris~~trade ~~Plains~~compliance support, ~~New~~integrated ~~Jersey. These state~~temperature-~~of-the-art~~controlled ~~facilities combine our existing~~ logistics ~~processes~~management and ~~capabilities~~consulting ~~with our BioServices infrastructure – all under one roof~~services, aswe ~~Cryoport~~deliver ~~Systems’~~reliable ~~Global~~global ~~Supply Chain Center Network. These Global Supply Chain Centers offer a new and fully integrated approach designed to support cell and gene therapies including comprehensive~~ temperature-controlled ~~temperature~~transport ~~storage,~~while ~~kitting,~~maintaining ~~labelling,~~full ~~fulfillment~~visibility, ~~sample~~intervention ~~management~~capability, ~~drug~~and ~~return,~~compliance ~~and~~throughout ~~Qualified~~transit. ~~Person~~Our ~~(QP)~~BioLogistics ~~drug~~capabilities ~~product~~are ~~release,~~tightly ~~along~~integrated with ~~advanced~~our ~~BioLogistics. Cryoport Systems’~~ BioServices ~~facilities~~and inCryopreservation ~~the~~services ~~United~~through ~~States are registered with~~ the ~~FDA as Tissue Establishments~~Cryoportal, ~~complying~~which ~~with~~provides ~~FDA~~a ~~CFR 1271.10. In April 2022~~unified, ~~we acquired Cell&Co BioServices in Clermont~~end-~~Ferrand, France with additional bioservices operations in Pont~~to-~~du-Château,~~end ~~France~~solution tofor ~~accelerate the setup of~~ our ~~BioServices~~clients ~~capabilities~~thereby inreducing ~~the~~risks ~~EMEA~~that ~~region.~~come ~~Our~~from ~~sites~~disjointed ~~are~~or ~~ISO~~discrete ~~9001~~point ~~and ISO 20387 accredited and all GMP IT systems are 21CFR Part 11, and GAMP-5 compliant (both US and EU)~~services.

~~Cryopreservation Services (IntegriCellTM) -~~ In ~~conjunction~~November ~~with our acquisition of Cell Matters in July 2022~~2025, we ~~developed~~commenced ~~our~~BioLogistics ~~IntegriCellTM~~services ~~service~~at ~~platform.~~our ~~The~~new ~~IntegriCellTM~~Global ~~platform~~Supply isChain aCenter ~~fully~~in ~~standardized~~Paris, ~~scalable~~France, ~~apheresis~~with ~~cryo-processing~~BioServices ~~platform~~operations ~~that~~expected ~~can~~to becommence ~~expanded~~in onthe afourth ~~global~~quarter ~~basis~~of 2026. ~~The~~In ~~platform~~late ~~services~~2026 ~~include~~another ~~apheresis/leukapheresis~~Global ~~collection~~Supply ~~via~~Chain ~~partners,~~Center ~~CryoshuttleTM~~is ~~transportation~~scheduled ~~services,~~to ~~cryo-process~~be ~~optimization, cryopreservation services, and BioServices. We have recently~~ opened ~~our first two facilities~~ in ~~Liège,~~Santa ~~Belgium and Houston~~Ana, ~~Texas~~California. ~~These two facilities became operational during the fourth quarter of 2024.~~

~~Cryoport~~BioStorage ~~Consulting~~Solutions. ~~Services~~Our –BioStorage ~~Cryoport Consulting Services functions in an expert advisory capacity to offer~~ solutions toprovide ~~address risk factors present in~~ temperature-controlled ~~supply~~biostorage ~~chain~~ and ~~logistics. To develop tailored scalable solutions, our cross~~value-~~functional~~added ~~team~~services ~~collaborates~~that ~~with~~support ~~our~~life ~~clients~~sciences toresearchers’ ~~understand~~requirements ~~their~~for ~~supply~~pre-clinical ~~chain,~~studies ~~logistics,~~and ~~time,~~programs ~~shipper,~~across ~~and~~the ~~packaging~~life ~~concerns~~sciences. ~~Cryoport~~These ~~Consulting~~services ~~Services~~are ~~employs~~primarily afocused ~~structured~~on ~~approach~~longer-term tostorage ~~managing, executing,~~ and ~~developing~~related ~~risk~~services ~~mitigation~~in ~~plans.~~support ~~Our~~of ~~clients~~preclinical ~~benefit~~and ~~from~~early-stage ~~our~~clinical ~~quality~~trials. ~~driven~~These ~~processes~~services ~~and~~are ~~solutions~~ delivered bythrough our ~~high~~CryoGene ~~integrity~~operations ~~team~~in ~~leveraging~~the ~~industry-standard~~Americas, ~~best practices and years of experience partnering~~ with ~~leading~~facilities ~~life~~in ~~science companies from early clinical through post-commercialization. Service solutions range from comprehensive physical~~Houston, ~~thermal~~TX and ~~shipping~~San ~~qualifications~~Antonio, ofTX ~~shipping~~that ~~systems~~are registered and~~/or~~ ~~packaging~~accredited ~~to developing user-friendly custom packaging solutions focused on the challenges unique to our life science clients.~~

Table of Contents

~~CRYOPDP Temperature-controlled Logistics - CRYOPDP is a premier global specialty courier dedicated~~ to ~~the~~applicable ~~life sciences industry that we acquired in 2020~~U.S. ~~CRYOPDP~~Food ~~operates with expertise an exhaustive range of temperature-controlled logistics services including temperature-controlled packaging~~ and ~~premium~~Drug ~~transport~~Administration ~~solutions. In recent years~~(FDA), ~~CRYOPDP~~International ~~further~~Organization ~~expanded~~for ~~organically~~Standardization ~~as well as through acquisitions in Ireland~~(ISO), ~~Belgium~~GMP, ~~Spain, Australia~~ and ~~the~~tissue-handling ~~United States~~standards. ~~Through~~CryoGene ~~the~~is ~~acquisition~~scheduled ofto ~~CRYOPDP,~~open weits ~~expanded~~third ~~our~~biorepository ~~global~~in ~~presence~~Tampa, ~~and~~FL ~~provided~~in ~~Cryoport~~mid 2027 with ~~inhouse~~a ~~specialty~~primary ~~courier~~purpose ~~capabilities~~of tosupporting ~~complement~~Moffitt ~~our~~Cancer ~~network of global partners~~Center.

~~MVE~~BioServices ~~Biological~~ Solutions. Our BioServices solutions provide temperature-controlled ~~The~~storage ~~acquisition~~and ofvalue-added ~~MVE~~services, ~~Biological~~such ~~Solutions~~as inbiostorage, ~~2020~~kitting, ~~enabled~~and ~~Cryoport~~fulfillment, that toare ~~become~~integrated ~~the~~directly ~~leading~~into ~~global~~clients’ ~~provider~~workflows ofto ~~cryogenic~~support ~~systems~~clinical and ~~solutions.~~commercial ~~MVE~~activity ~~Biological~~across ~~Solutions~~the ~~supplies~~life ~~cryogenic~~sciences, ~~systems~~ globally. ~~and~~Our BioServices infrastructure is andesigned ~~important~~to ~~part~~scale ofalongside our ~~global~~clients ~~supply~~as ~~chain~~cell ~~platform.~~and ~~With~~gene ~~its~~therapies ~~long~~advance ~~history~~from ofclinical ~~producing~~development ~~the~~to ~~most~~global ~~reliable,~~commercialization. ~~highest~~BioServices ~~quality~~includes ~~products~~solutions insuch ~~the~~as ~~industry~~sterile and cGMP kit production, itqualified ~~has~~person ~~set~~(QP) ~~the~~drug ~~standard~~product ~~for~~release ~~the~~services, ~~manufacture~~labeling, ofsecondary ~~cryogenic~~packaging, ~~systems~~order ~~including~~fulfillment, ~~freezer~~storage, clinical sample management, and ~~shipper~~related ~~solutions~~value-added ~~used~~services. ~~for~~These ~~storage~~services ~~and/or~~are ~~distribution~~delivered ofthrough ~~critical~~our ~~biological~~Cryoport ~~material,~~Systems ~~for~~operations 60in ~~years.~~the ~~Two~~Americas ~~examples~~and ofEMEA, ~~MVE~~with ~~Biological~~facilities ~~Solutions~~registered ~~advance~~and ~~development~~accredited ~~achievements~~to ~~are:~~applicable FDA, ISO, and GMP standards.

●Cryopreservation ~~MVE~~Services ~~Biological~~(IntegriCell). ~~Solutions’~~Our ~~Fusion®~~Cryopreservation ~~Cryogenic~~Services, ~~System~~offered –under ~~The~~our ~~MVE~~IntegriCell ~~Fusion~~platform, isproviding astandardized, ~~self~~scalable cryopreservation and cryo-~~sustaining~~processing ~~cryogenic~~services ~~freezer.~~for ~~The~~cellular ~~MVE~~starting ~~Fusion®~~materials, ~~can~~is ~~operate~~our asnewest services offering. This platform addresses a ~~stand-alone~~critical ~~unit,~~industry ~~requiring~~challenge norelated ~~on-going~~to ~~liquid~~the ~~nitrogen~~collection ~~supply~~and orpreservation ~~connection~~of toleukapheresis anmaterial, ~~external~~which ~~liquid~~is ~~nitrogen~~the ~~source~~starting input for most cell-based therapies. ~~Fusion®~~By ~~cryogenic~~standardizing ~~freezers~~and ~~are~~automating athis ~~perfect~~cryopreservation ~~solution~~process, ~~for~~IntegriCell ~~remote~~is ~~geographic~~intended ~~locations~~to reduce variability in starting materials, ~~isolated~~improve ~~laboratories~~consistency, ~~high~~enhance ~~elevation~~quality ~~facilities,~~across orthe ~~facilities~~clinical ~~without~~spectrum ~~existing~~and ~~liquid~~provide ~~nitrogen~~clinical ~~infrastructure~~collection and commercial manufacturing flexibility, alleviating logistical and manufacturing bottlenecks.

●The ~~MVE~~IntegriCell ~~Biological~~platform ~~Solutions’~~integrates ~~Vario®~~apheresis ~~Cryogenic~~collection ~~System~~through –qualified ispartners, ~~an innovative~~ cryogenic ~~freezer~~transport, ~~system~~cryo-process ~~that~~optimization, ~~can~~cryopreservation, ~~support~~and ~~temperatures~~associated ~~anywhere~~BioServices ~~between~~into ~~-20°C~~a ~~and~~single, ~~-150°C~~harmonized solution. InIntroduced ~~addition~~in tolate ~~providing greater flexibility~~2024, the ~~Vario®~~platform ~~series~~currently ofoperates ~~cryogenic~~from ~~freezer~~two ~~systems~~purpose-built ~~provide~~facilities ~~effective~~located ~~and~~in ~~consistent~~Houston, ~~temperature~~Texas, ~~profiles~~and ~~with~~Liège, ~~less~~Belgium, ~~than~~to 1%support ofglobal ~~the~~clinical ~~power~~and ~~consumption~~commercial ~~and~~cell atherapy ~~70%~~programs. ~~reduction~~During inthe ~~overall~~second ~~operating~~half ~~cost~~of ~~savings~~2025, ~~compared~~IntegriCell tobegan ~~traditional~~onboarding ~~mechanical~~biopharma ~~freezers~~companies.

~~Competitive~~IntegriCell ~~Advantages~~is expected to function as an integral part of Cryoport’s broader ecosystem, complementing our BioLogistics and BioServices offerings to support the evolving needs of the cell therapy market.

~~With~~Life ~~our~~Sciences first-to-market integrated platform of technology-driven supply chain solutions serving the life sciences industry, we have established a lead over potential competitors by focusing on de-risking critical processes in the life sciences including those central to the manufacture and distribution of cell and gene therapies. Working with our in-depth knowledge of information technology, cryopreservation services, packaging, temperature-controlled logistics, BioServices, and cryogenic systems, our management, technical, business development and service support teams approach our growing markets with valued insights, adaptability, innovation, and a mindset of problem resolution which provides clients with certainty of performance.Products

~~Through~~Our ~~our~~Life ~~experience,~~Sciences weProducts ~~know~~segment ~~that~~includes ~~supply~~our ~~chain~~cryogenic ~~processes~~systems ~~can~~manufacturing ~~have a large impact on temperature sensitive product/commodity conditions~~solutions. ~~We therefore seek to exceed the most demanding standards in the industry, such as, among others, ISO 13485, ISO 21973, ISO 9001, ISTA, and IATA.~~

~~Cryoport~~Cryogenic Systems’ ~~Cryoportal® Logistics Management Platform (Cryoportal®) is an important backbone technology~~Manufacturing. ~~The~~We ~~Cryoportal®~~are ~~handles~~a ~~order~~leading ~~entry,~~global ~~keeps~~manufacturer ~~track~~ of ~~our~~cryogenic ~~global~~systems ~~inventory, and provides algorithms~~ for ~~predictive~~the ~~analysis~~storage onand ~~every~~transportation ~~shipment~~of ~~while~~biological ~~in transit~~materials, ~~globally.~~through ~~Cryoport~~MVE ~~Systems’~~Biological ~~customer~~Solutions ~~service~~(“MVE”) ~~team~~and ~~monitors~~its ~~every~~portfolio ~~in-transit~~of ~~shipment~~cryogenic ~~24/7/365~~freezer and, bydewar ~~leveraging~~systems. ~~the~~MVE ~~Cryoportal®,~~has ~~they~~manufacturing ~~have~~facilities ~~the~~located ~~unique~~in ~~ability~~the toUnited ~~see~~States ~~issues that arise~~ and ~~take corrective measures up to and including intervention to potentially save a shipment in trouble~~China.

AMVE, ~~key~~with ~~driver~~more inthan ~~differentiating~~65 ~~our~~years ~~service~~of ~~platform~~experience isdesigning ~~the~~and ~~fact~~manufacturing ~~that~~cryogenic westorage ~~are~~and ~~the~~transport ~~only~~systems, ~~organization~~offers ~~that has~~ a ~~fully~~broad ~~integrated~~portfolio ~~supply~~of ~~chain~~cryogenic ~~platform~~systems ~~that~~and ~~encompasses~~accessories ~~products,~~in ~~services,~~multiple sizes and ~~informatics~~configurations ~~within~~designed ato ~~single~~meet ~~organization~~a ~~which~~broad isrange ~~anchored~~of bycapacity, ~~our~~workflow, ~~Chain~~and ofapplication ~~Compliance® solution~~requirements. ~~Our~~MVE’s ~~integrated~~cryogenic ~~temperature-controlled~~systems ~~supply chain solutions~~ are ~~built~~utilized ~~for~~by ~~purpose~~biorepositories, ~~fully~~clinical ~~integrate~~laboratories, ~~products~~biopharmaceutical companies, ~~services~~research institutions, ~~and~~animal ~~informatics~~breeding and ~~are~~IVF ~~focused~~clinics onfor the ~~management of irreplaceable therapies~~cryopreservation, ~~vaccines,~~transport and ~~biological~~storage ~~materials~~of ~~such as~~ biological ~~samples and reproductive~~ materials.

~~Segment~~MVE’s ~~Reporting~~product offerings include:

~~Operating~~• ~~segments~~MVE ~~are~~Series ~~identified~~Freezers, ~~as components of an enterprise about~~ which ~~separate~~are ~~discrete~~liquid- ~~financial~~and ~~information~~vapor-phase iscryogenic ~~available~~freezers for ~~evaluation~~high-capacity bybiological ~~the chief operating decision maker in making decisions regarding resource allocation and assessing performance~~storage. ~~The chief operating decision maker is our Chief Executive Officer.~~

•

High-Efficiency (HE) Series, which are vapor-phase cryogenic freezers designed for approximately –190°C storage, featuring advanced control systems for temperature monitoring and inventory management.

•

MVE Fusion^® Freezers, which are self-sustaining cryogenic freezers that do not require a continuous liquid nitrogen supply and make cryogenic storage available on a convenient basis and in places otherwise not accessible by traditional cryogenic systems.

•

MVE Vario^TM Cryogenic System, which is a configurable cryogenic freezer platform capable of supporting temperatures ranging from approximately –20°C to –150°C and allowing for biostorage flexibility.

•

Aluminum Dewars and Cryogenic Shippers, which are lightweight, portable vessels used for temporary storage and transportation of biological materials at cryogenic temperatures.

Table of Contents

~~Effective~~• inVapor ~~the~~Shipper ~~fourth~~Series: ~~quarter~~Aluminum oftransport ~~2024,~~dewars ~~the~~designed ~~Company~~for ~~realigned~~domestic ~~the reportable segment information that the CODM regularly reviews to evaluate the business, make key operating decisions~~ and ~~allocate~~international ~~resources~~shipment ~~which resulted in the identification~~ of ~~two~~biological ~~reportable~~samples, ~~segments:~~incorporating ~~Life~~rapid ~~Sciences~~charging ~~Services and Life Sciences Products~~technology. Previously the Company had one reportable segment and the CODM utilized consolidated financial results to evaluate performance and has transitioned to utilizing disaggregated financial information between the Life Sciences Services and Life Science Products segments.

~~Adjusted~~• ~~earnings~~Doble ~~before interest~~Series, ~~income~~which ~~taxes,~~are ~~depreciation~~hybrid ~~and~~dewars ~~amortization~~that ~~(“adjusted~~function ~~EBITDA”)~~as ~~for~~vapor ~~each~~shippers ~~operating~~during ~~segment~~transport ~~is the profit measure used by the CODM in measuring the performs of the business~~ and ~~in the annual budget and forecasting process. Adjusted EBITDA is defined by the Company~~ as ~~earnings~~storage ~~before~~vessels ~~interest,~~upon ~~income taxes~~arrival, ~~depreciation,~~reducing ~~amortization~~the ~~and~~need ~~certain~~for ~~items~~immediate ~~that~~sample ~~do not contribute directly to management’s evaluation of its operating results~~transfer. ~~Asset information by reportable segment is not provided to the CODM.~~

WeIn ~~have~~October ~~three~~2025, ~~operating~~MVE ~~segments~~launched ~~that~~its ~~are~~integrated ~~aggregated~~condition asmonitoring ~~Life~~systems ~~Sciences~~for ~~Services~~dewars ~~which~~to ~~provides~~provide ~~temperature~~real-~~controlled~~time ~~logistics~~monitoring ~~and~~of their cryogenic ~~biostorage~~environments ~~within~~to ~~the~~provide ~~life~~for ~~science~~the ~~industry~~monitored ~~through~~and ~~direct~~recorded ~~sales.~~safety ~~Revenues~~and ~~from~~integrity ~~this segment include an immaterial amount~~ of ~~product~~stored ~~revenues~~materials. ~~The~~These ~~Company’s~~condition ~~Life~~monitoring ~~Sciences~~systems ~~Products~~are ~~segment~~powered ~~manufactures~~by ~~and sells cryogenic freezers~~Tec4med®, ~~cryogenic~~a ~~dewars~~Cryoport ~~and~~company ~~accessories~~providing ~~within~~IoT ~~the~~technology ~~life~~that ~~science~~specializes ~~industry~~in ~~through~~real-time ~~direct~~condition ~~sales~~monitoring orand adata-driven ~~distribution~~traceability ~~network.~~in ~~Revenues~~the ~~from~~regulated ~~this~~life ~~reportable~~sciences, ~~segment~~distinct ~~are~~from ~~exclusively~~the ~~life~~Cryoportal ~~sciences~~and ~~product revenues~~SmartPak.

In ~~addition~~2026, ~~the~~MVE ~~CODM~~plans ~~manages~~to ~~and~~introduce ~~evaluates the operating performance of the segments, as described above, on~~ a ~~pre-corporate~~proprietary ~~cost~~connected ~~allocation basis. Accordingly~~platform, ~~for segment reporting purposes,~~ the ~~company~~MVE ~~does~~CryoVerse™ ~~not allocate corporate costs~~Ecosystem, ~~which~~delivering ~~include~~real-time ~~certain~~monitoring ~~aspects~~and ofcloud ~~the~~visibility ~~Company’s~~to ~~executive~~protect ~~management,~~critical ~~legal,~~biological ~~compliance,~~materials ~~human~~while ~~resources,~~simplifying ~~information~~operations ~~technology~~ and ~~finance~~strengthening ~~departments, to its reportable segments~~compliance.

MVE is a foundational company. Our manufacturing capability represents a critical component of our integrated Life Sciences Services core solutions, ensuring reliable access to the highest quality, purpose-built cryogenic systems and equipment, supporting our scalability as the CGT market grows worldwide.

Our Life Sciences Markets

We serve a broad range of global life sciences markets, including biopharmaceutical and pharmaceutical companies, the animal health markets, reproductive medicine, academic institutions, research, and government agencies. We ensure the safe, compliant storage, handling, and delivery of high value, temperature sensitive biological materials across their entire respective lifecycles. The range of these materials include cells, tissues, DNA, RNA, plasmids, blood, bodily fluids, clinical specimens, cloned materials, oligonucleotides, lentivirus, retrovirus, adenovirus, pathogenic microorganisms, microorganisms, eggs, sperm, embryos, cell and gene therapies, immunotherapies, etc. We have a particular emphasis on cell and gene therapies, our fastest growing market. These cell and gene therapies represent some of the most complex and sensitive products in modern medicine, requiring digital data driven, integrated, advanced technology-supported supply chain solutions—an area where we have established industry leadership.

The Global Cell and Gene Therapy Market

The global CGT market is thought to be entering a phase of accelerated commercial expansion, supported by a continuously maturing clinical pipeline and a favorable regulatory environment. Global sales in the CGT market increased to approximately $14.5 billion in 2024, up from $4.2 billion in 2019, representing a historical 28% compound annual growth rate (“CAGR”). Industry analysts project continued momentum, with the CGT market expected to grow at an estimated 34% CAGR through 2028. Regulatory approvals are accelerating, increasing from one to two annually between 2018 and 2021 to a record seven to eight approvals in 2023 and 2024, respectively, and an additional 5 approvals in 2025. In June 2025, the FDA eliminated Risk Evaluation and Mitigation Strategy (“REMS”) requirements for approved BCMA- and CD19-directed autologous CAR-T therapies, which is a change expected to reduce administrative and logistical barriers, thereby expanding patient access. The clinical pipeline remains robust, with over 1,100 active cell and gene therapy clinical trials globally, excluding China, in 2025, increasingly weighted toward late-stage Phase II and III programs as sponsors are prioritizing cell and gene therapies closer to commercialization.

Strategic industry trends include growing interest in allogeneic, or off-the-shelf, therapies, which now represent roughly one-third of our global clinical pipeline, as well as increased demand for standardized, scalable, and compliant supply chain solutions to support the specialized storage, handling, and transportation requirements of cell and gene therapy products from clinical development through commercialization.

The growth in our clinical trial pipeline has driven increased demand for specialized infrastructure and services, including temperature-controlled BioLogistics, BioStorage, BioServices, Cryopreservation services and cryogenic systems, which support the complex requirements of cell and gene therapy products.

The CGT market is characterized by a high degree of regulatory oversight and operational complexity due to the sensitivity of biological materials and the need to maintain product quality and integrity from collection through delivery to patients. The growth in demand for supply chain services in the CGT market is driven by the personalized nature of many therapies, the requirement for precise

Table of Contents

temperature and condition control, and the complexity of coordinating multi-step manufacturing and delivery processes. As a result, we believe our cryogenic systems, advanced informatics, temperature-controlled logistics solutions, critical bioservices and cryopreservation services offerings and global networked operational capabilities, that we are well positioned to continue to benefit from these industry trends.

Key Accomplishments in 2025

●

Increased total revenue by $19.4 million, or 12.4%, to $176.2 million

●

Increased revenue from the support of commercial cell and gene therapies by $7.4 million, or 28.6%, to $33.4 million, supporting 20 commercial cell and gene therapies as of December 31, 2025

●

Supporting 760 clinical trials, of which 86 were in Phase III as of December 31, 2025

●

Established strategic relationship with DHL Group, which included divestiture of our CRYOPDP specialty courier business

●

Established Enterprise Technology Group (ETG) to drive digital initiatives, integrated software, technology, and AI implementations across the Company

●

Launch of Cryoport Express Cryogenic HV3 Shipping System, enhancing payload protection, optimizing storage efficiency and expanded usability

●

First organization globally to be certified to ISO 21973:2020 Biotechnology - transportation of cells for therapeutic use certification

●

Globally Certified to ISO 9001:2015 standard

●

Opened Global Supply Chain Center in Paris, France with BioLogistics services in November 2025; with BioServices operations expected to commence in the fourth quarter of 2026

●

Continued global industry recognition of Cryoport’s leadership in delivering innovative solutions that support the safe, efficient, and effective delivery of CGT worldwide:

-

Best Cell & Gene Therapy Supplier – Cell Processing Systems at the Asia-Pacific Cell & Gene Therapy Excellence Awards (APCGTEA) 2025, voted by professionals across the CGT community

-

Supply Chain Excellence Award at the 2025 CPHI Pharma Awards, recognizing leadership and innovation in pharmaceutical supply chain management

-

Simon Ellison Supply Chain Innovation Award at the Advanced Therapies Awards 2025, honoring exceptional contributions to advancing supply chain solutions for advanced therapies

-

BioTech Breakthrough Award – “BioServices Innovation of the Year” for the Safepak^® Soft System 1800, highlighting innovation in bioservices packaging and protection technologies

●

Launch of MVE’s integrated Condition Monitoring Services powered by Tec4med and the MVECloud^TM, a secure web- and mobile-based platform

●

Launch of MVE’s next generation dry vapor shippers

●

Expanded MVE’s manufacturing line in Chengdu, China to support cryogenic freezer manufacturing with production expected to commence during the first quarter of 2026

●

MVE’s three global manufacturing facilities are the first cryogenic systems manufacturing facilities to be registered with the FDA; all applicable MVE-manufactured cryogenic freezers and dewars are listed with the FDA

●

Strategic collaboration with Moffitt Cancer Center, Tampa, Florida; awarded exclusive BioStorage services rights

Customers and Distribution

We believe that our platform of integrated temperature-controlled supply chain solutions, expertise, and geographic footprint enables us to take advantage of the growing demand for effective and efficient global transport and biostorage of temperature sensitive life sciences commodities. This is especially the case for cell and gene therapies that require tightly controlled temperatures through the development, biostorage, transportation, and delivery processes to maintain efficacy and safety.

During the year ended December 31, 2024, no customer accounted for more than 10% of our total revenues. During the year ended December 31, 2023, one customer accounted for 10.5% of our total revenues. During the year ended December 31, 2022, no single customer accounted for over 10% of our total revenues.9

~~Our~~Table ~~geographical~~of ~~revenues, by origin, for the years ended December 31, 2024, 2023 and 2022, were as follows:~~Contents


	2024		2023		2022
Americas	55.3	%	54.5	%	54.0	%
Europe, the Middle East and Africa (EMEA)	26.1	%	26.1	%	28.2	%
Asia Pacific (APAC)	18.6	%	19.4	%	17.8	%

Our major customer types include biotechnology and pharmaceutical companies, contract research organizations, contract development and manufacturing companies, central laboratories, fertility clinics, animal health companies, universities and research facilities.

During the year ended December 31, 2025, one customer in our Life Sciences Services reportable segment accounted for 10.2% of our total revenue. During the years ended December 31, 2024 and 2023, no single customer accounted for over 10% of our total revenue.

Our geographical revenue, by origin, for the years ended December 31, 2025, 2024 and 2023, were as follows:


	2025		2024		2023
Americas	74.5	%	72.4	%	69.9	%
Europe, the Middle East and Africa (EMEA)	14.3	%	17.2	%	16.4	%
Asia Pacific (APAC)	11.2	%	10.3	%	13.7	%

Customer types

Our major customer types include Biotechnology and Pharmaceutical Companies, Contract Research Organizations, Contract Development & Manufacturing Companies, Central Laboratories, Fertility Clinics, Animal Health Companies, Universities & Research Facilities.

Sales and Marketing

We serve clients across the life sciences industry, with a particular focus on the rapidly evolving ~~Cell~~CGT ~~and Gene Therapy~~ market. Our global sales and marketing efforts are centered on addressing each customer’s unique challenges and anticipating their future needs through our specialized temperature-controlled supply chain solutions. Our marketing teams create and execute targeted digital campaigns that align with our commercial strategy, showcasing our innovative portfolio of solutions and capabilities. These initiatives are designed to fuel business development, program management, and consulting activities, while also enhancing awareness of our advanced temperature-controlled supply chain solutions.

Table of Contents

Competition

We believe Cryoport is unique in its ~~product~~services and ~~services~~product offerings. Collectively, Cryoport’s specialized expertise in providing advanced temperature-controlled supply chain solutions for the Life Sciences including, but not limited to, proprietary technologies, regulatory expertise, global infrastructure, embedded customer relationships, and a data-driven operating model create substantial competitive advantages. Our deep proficiency in supporting the Life Sciences with an emphasis on the CGT Market for over 12 years, operational knowledge, compliance track record, and extended customer validation cycles required to compete at scale reinforce Cryoport’s durable competitive advantage in the Life Sciences and especially the rapidly growing CGT market. However, we do have competition in various segments of our business from companies that offer ~~products~~services and/or ~~services~~products that could be considered competitive to certain components or elements of our platform of temperature-controlled supply chain solutions, ~~including~~for the Life Sciences. Life Sciences Services competition is primarily with specialty couriers, who fall into the category of coopetition and include companies such as World Courier ~~Group, Inc., Marken~~ (a ~~UPS~~Cencora company), ~~Biocair~~UPS ~~and~~Healthcare, Quick (a Kuehne+Nagel company), ~~along~~and ~~with~~Biocair. In addition, life science companies ~~that~~may ~~offer~~develop ~~products~~their ~~such~~own asin-house ~~Azenta~~temperature-controlled ~~Life~~supply ~~Sciences~~chain solutions, systems, and/or ICprocedures ~~Biomedical~~to ~~and~~cover their specific needs. Competition for our cryopreservation services in particular includes companies such as the American Red Cross and Gift of Life Biologics. InLife ~~addition,~~Sciences ~~life~~Products ~~science~~competition is with companies ~~may~~offering ~~develop~~cryogenic ~~their~~systems ~~own~~products ~~in-house~~such ~~temperature-controlled~~as ~~supply~~Azenta ~~chain~~Life ~~solutions~~Sciences, ~~systems~~Phase 2, and ~~procedures~~IC toBiomedical. ~~cover~~Cryoport ~~their~~is ~~specific~~a ~~needs~~leader in both its Life Sciences Services and Life Sciences Products reporting segments.

Engineering and Development

Our ~~research~~engineering and development activities are focused on advancing our integrated, temperature-controlled supply chain platform through the development of proprietary digital systems, intelligent packaging, condition monitoring, automation, and ~~engineering~~data ~~efforts~~analytics. ~~are~~Our ~~focused~~Enterprise onTechnology ~~continually~~Group ~~investigating~~coordinates ~~new~~platform ~~technologies~~architecture, Internet of Things–enabled monitoring, and informatics capabilities that ~~can~~support ~~improve~~real-time ~~our~~visibility, ~~services~~chain-of-custody and chain-of-identity, and regulatory compliance across global operations. These efforts include ongoing enhancements to the ~~features~~Cryoportal® digital logistics management platform, deployment of Smartpak® and IoT-based monitoring solutions powered by Tec4med, and the integration of advanced analytics and artificial intelligence to improve operational performance, risk management, and scalability. We also apply engineering resources to product development within our ~~products~~cryogenic systems manufacturing operations, supporting the design, validation, and ~~solutions~~continuous inimprovement ~~order~~of cryogenic freezers, dewars, and transport systems. Collectively, these engineering and development initiatives are intended to ~~address~~strengthen ~~market~~the ~~needs~~reliability, traceability, and efficiency of our solutions as we support the expanding global CGT Market and other parts of the Life Sciences.

~~Cryoport Data Management Systems~~10

~~Tec4Med~~Table and SkyTrax™ Condition Monitoring Systems - Cryoport’s Tec4Med and SkyTrax™ Condition Monitoring Systems are connected data platforms for the temperature sensitive supply chain. Tec4med provides an integrated suite of hardware and user-friendly software delivering intelligent supply chain data and predictive analytics. The Tec4med eco-system enables end-to-end supply chain visibility and optimization, unifying a digitization of the supply chain. The Tec4Cloud FDA 21 CFR Part 11 compliant web platform delivers actionable supply chain data (including multi-channel alerts) and can be white label customized with client branding. SkyTrax™ is a next generation proprietary-designed Condition Monitoring System, custom-built for the cell and gene industry. In addition to being 4G/LTE compliant, cellular network agnostic, with a full sensor array to track location, temperature, humidity, light, shock, orientation, and geofencing, with Bluetooth and Wi-Fi capabilities. The Cryoport team is currently developing a product roadmap for a unified approach to the suite of condition monitoring solutions.Contents

Cryoportal® 2.0 and UnITy™ - Cryoport Systems’ Cryoportal® 2.0. Logistics Management Platforms was launched during the second quarter of 2023 and is ISO 21973 compliant as a supply chain management platform. In addition to managing all aspects of a given client shipment, it also manages the Chain of Compliance™ based aspects of our packaging. The Cryoportal® 2.0 is complemented by CRYOPDP’s UnITy™ Transportation Management System. UnITy™ provides functionalities in addition to transport management that include warehousing management, quality management, customer experience portal, mobile apps for track and trace during transport and storage as well as integration with transportation agents and business partners. The combination of these two powerful informatics platforms provides Cryoport clients with a comprehensive status of their clinical or commercial distribution activities, while supporting regulatory requirements and further sets Cryoport apart from competition.

Manufacturing and Raw Materials

Manufacturing - We source components for our products from multiple suppliers, including those that manufacture to our engineering specifications, using, in part, proprietary technology and ~~know-how~~knowledge to mitigate supply chain risks. We also use “off-the-shelf” products, which we may modify to meet our requirements. For some components, there are relatively few alternate sources of supply and the establishment of additional or replacement suppliers may or may not be accomplished immediately. When this occurs, we endeavor to mitigate risk by locating an alternative qualified supplier and, as appropriate, increasing our inventory level.

Our vendor/partner relationships allow us to concentrate on further advancing and expanding our platform of systems, products, and solutions for the life sciences to meet the growing and varied demands for validated temperature-controlled solutions in the life sciences industry. We endeavor to keep our supply structure up to date and agile as it provides us the opportunity to rapidly scale to support our client’s commercialization, systems, products, and solutions requirements; however, we are ever mindful of the work we must do to improve our current sourcing and to continue to mitigate risks therein.

Raw Materials - Various raw materials are used in the manufacture of our products and in the development of our technologies. Most raw materials are generally available from several alternate distributors and/or manufacturers. Where we have experienced significant difficulty in obtaining these raw materials, we have established alternative global sources or work with existing suppliers to overcome any deficiencies.

Table of Contents

Patents, Copyrights, Trademarks, and Proprietary Rights

To remain competitive, we develop and maintain protection on the proprietary aspects of our platform of technologies. We rely on a combination of patents, copyrights, trademarks, trade secret laws and confidentiality agreements to protect our intellectual property rights.

ToWe ~~remain~~file ~~competitive~~patent applications to protect innovations arising from our research, development and design. As of December 31, 2025, we ~~develop~~owned approximately 74 issued patents and ~~maintain~~have ~~protection~~more onthan 110 pending patent applications throughout the ~~proprietary~~world. Our patents generally protect certain aspects of our ~~platform~~products ofand ~~technologies~~related technology. We ~~rely~~also onown acommon ~~combination~~law ofand ~~patents,~~registered ~~copyrights,~~ trademarks, ~~trade~~in ~~secret~~the ~~laws~~U.S. and ~~confidentiality~~in ~~agreements~~certain foreign countries to protect the names of our ~~intellectual~~company, ~~property~~certain ~~rights~~products, and key service brands. We own certain copyrights relating to certain aspects of our systems, products and services.

We file patent applications to protect innovations arising from our research, development and design. As of December 31, 2024, we owned approximately 95 issued patents and have more than 140 pending patent applications throughout the world. Our patents generally protect certain aspects of our products and related technology. We also own common law and registered trademarks in the U.S. and in certain foreign countries to protect the names of our company, certain products, and key service brands. We own certain copyrights relating to certain aspects of our systems, products and services.

Our success is influenced, in part, by our ability to continue to develop proprietary products and technologies. It is desirable to obtain patent coverage for these products and technologies; however, some are protected as trade secrets. We intend to file trademark and patent applications covering any newly developed products, methods and technologies. However, there can be no guarantee that any of our pending or future filed applications will be issued as patents or registered as trademarks. There can be no guarantee that the various patent and trademark governmental agencies from around the world or some third party will not initiate an interference proceeding involving any of our pending applications or issued patents. Finally, there can be no guarantee that our issued patents or future issued patents, if any, will provide adequate protection from competition.

Patents provide some degree of protection for our proprietary technology. However, the pursuit and assertion of patent rights involve complex legal and factual determinations and, therefore, are characterized by significant uncertainty. In addition, the laws governing patent issuance, and the scope of patent coverage continue to evolve. Moreover, the patent rights we possess or are pursuing generally cover our technologies to varying degrees. As a result, we cannot ensure that patents will issue from any of our patent applications, or that any of the issued patents will offer meaningful protection. In addition, our issued patents may be successfully challenged, invalidated, circumvented, or rendered unenforceable so that our patent rights may not create an effective barrier to competition. We must also pay maintenance fees at set intervals for our patents to not expire prematurely. The laws of some foreign countries may not protect our proprietary rights to the same extent as the laws of the United States. There can be no assurance that any patents issued to us will provide a legal basis for establishing an exclusive market for our products or provide us with any competitive advantages, or that patents of others will not have an adverse effect on our ability to do business or to continue to use our technologies freely. As with all patents, we may be subject to third parties filing claims that our technologies or products infringe on their intellectual property. We cannot predict whether third parties will assert such claims against us or whether those claims will hurt our business. If we are forced to defend against such claims, regardless of their merit, we may face costly litigation and diversion of management’s attention and resources. As a result of any such disputes, we may have to develop, at a substantial cost, non-infringing technology or enter into licensing agreements. These agreements may be unavailable on terms acceptable to such third parties, or at all, which could seriously harm our business or financial condition.

Table of Contents

With respect to our trademarks, we file and pursue trademark registrations on words, symbols, logos, and other source identifiers that clients use to associate our products and services with us. Although our registered trademarks carry a presumption of validity, they can be challenged and possibly invalidated and as such, we cannot guarantee that any trademark registration is infallible.

We also rely on trade secret protection of our intellectual property. We attempt to protect trade secrets by entering into confidentiality agreements with employees, consultants and third parties, although, in the past, we have not always obtained such agreements. It is possible that these agreements may be breached, invalidated, or rendered unenforceable, and if so, our trade secrets could be disclosed to our competitors. Despite the measures we have taken to protect our intellectual property, parties to such agreements may breach confidentiality provisions in our contracts or infringe or misappropriate our patents, copyrights, trademarks, trade secrets and other proprietary rights. In addition, third parties may independently discover or invent competitive technologies, or reverse engineer our trade secrets or other technology. Therefore, the measures we are taking to protect our proprietary technology may not be adequate.

Table of Contents

Cryoport’s Quality Assurance and Regulatory Affairs Programs

Cryoport is committed to quality, and this is reflected in all aspects of our global organization. From our innovative design of products and services to our continuous improvement initiatives, Cryoport has implemented comprehensive quality standards that match or exceed the stringent requirements within the markets we serve. Cryoport’s Quality Management Systems have been designed, implemented, and certified to meet ISO 9001:2015 and ISO 13485 standards in key global locations, demonstrating the discipline necessary to maintain a positive compliance profile. With our strong foundation in ISO 9001:2015 and ISO 13485, we leverage industry-specific experience with applicable regulatory requirements, and industry expectations, to create processes and procedures that incorporate strong operational practices of checks with verification. Our Quality Management Systems are designed to ensure proper controls in manufacturing, temperature-controlled supply chain services, logistics, bioprocessing, customer/client education, contracting, processing, shipping and biostorage, accumulation, and communication.

Our Quality Management Systems incorporate notable good practice quality guidelines and regulations (GxP) elements, beyond those stipulated in ISO 9001:2015 and ISO 13485, to ensure our customers are supported in the manner necessary to maintain standards and to secure a positive compliance profile for Cryoport as a supplier and partner.

Through procedural requirements, Cryoport provides substantial risk-mitigation strategies throughout its full offering of products, systems, and services to support and maintain customer confidence. Metrics and key performance indicators are accumulated regularly, and are trended to predict, and mitigate, potential risks to operations. Operating and senior management utilized this information to enact decisions regarding procedures, processes, resource allocation, and corrective actions. Quality-driven initiatives are supported throughout our global organization. We are also subject to GMED, which is an international reference body in the certification of health care and medical devices quality management systems under ISO 9001, NF EN, and ISO 13485. As such, we are subject to audits by a Medical Device Single Audit Program (MDSAP) auditing organization. Cryoport’s cryogenic biostorage facilities are routinely inspected by the FDA and The Foundation for the Accreditation of Cellular Therapy (FACT) to confirm regulatory compliance to industry requirements related to drug applications, filings, and maintenance of various cryogenically stored materials.

Government Regulation

Globally, Cryoport is subject to regulations in numerous country jurisdictions and international regulations relating to manufacturing, shipments, customs, import, export, safe working conditions, environmental protection, and disposal of hazardous or potentially hazardous substances. In addition, we must ensure compliance with economic sanctions and/or restrictions on individuals, corporations, or countries, and other government regulations affecting trade that may apply to our international cross border business activities.

The shipping of biologic products, biologic commodities, diagnostic specimens, infectious substances, and dangerous goods, whether via air or ground, falls under the jurisdictions of many country, state, federal, local and international agencies. The quality of the packaging that protects such commodities is critical in determining successful shipping conditions and to ensure a commodity will arrive at its destination in a satisfactory condition. Meeting stringent regulations such as Dangerous Goods Regulations, ISTA, and IATA, as applicable, Cryoport has demonstrated compliance and adhesion to these requirements. Many of the regulations for transporting dangerous goods in the United States are determined by international rules formulated under the auspices of the United Nations. Dangerous goods are typically one-time shipments and are not a part of our routine services. When called upon to ship dangerous goods, Cryoport follows strict and stringent guidelines. International Civil Aviation Organization (“ICAO”) is the United Nations organization that develops regulations (Technical Instructions) for the safe transport of dangerous goods by air. If shipment is by air, compliance with the rules established by the IATA is required. IATA is a trade association made up of airlines and air cargo couriers that publishes annual editions of the IATA Dangerous Goods Regulations. These regulations interpret and add to the ICAO Technical Instructions to reflect industry practices. Additionally, the Centers for Disease Control (“CDC”) has regulations (published in the Code of Federal Regulations) for interstate shipping of specimens.

Our Cryoport Express® and ELITE™ Shippers meet Packing Instructions 602 and 650 and are certified for the shipment of Class 6.2 Dangerous Goods per the requirements of the ICAO Technical Instructions for the Safe Transport of Dangerous Goods by Air and IATA. Our present and planned future versions of the Cryoport SmartPak™ Condition Monitoring Systems ~~will~~are ~~likely be~~ subject to regulation by the Federal Aviation Administration (“FAA”), Federal Communications Commission (“FCC”), FDA, IATA and possibly other agencies which may be difficult to determine on a global basis. Additionally, our Chain of Compliance™ processes comply fully with ISO 21973:2020 guidelines.

Table of Contents

Storage of biological materials that are classified as drug products for human therapeutic use (either for investigational use or commercially approved) or materials used in the manufacture of drug products for human therapeutic use, is regulated by the FDA under Title 21 Code of Federal Regulations (“CFR”) part 210 & 211. Facilities must be compliant with current GMP regulations which are enforced by the FDA through registration and audit. When drug products are exported to other countries, biostorage upon receipt must meet relevant local regulations.

Our MVE Biological Solutions cryogenic stainless-steel freezers and aluminum dewars are certified to the Medical Device Directive (MDD) in the EU. MVE is compliant with current ~~Good Manufacturing Practices (“~~GMP”) regulations which are enforced by the FDA through registration and audit of compliance with 21 CFR Part 820 and GMP. This FDA registration and product listing is in addition to MVE’s existing ISO 13485:2016 certification.

Additionally, registrations for import are in place for various countries with these requirements.

Cryoport’s advanced integrated temperature-controlled supply chain solutions platform is designed to support the global distribution of high-value commercial biologic and cell-based products and therapies regulated by the United States Food and Drug Administration (FDA), the European Medicines Association (EMA) and other international regulatory bodies. Cryoport’s solutions are also relied upon for the support of pre-clinical, clinical trials, Investigational New Drug Applications (IND), Biologics License Applications (BLA), and New Drug Applications (NDA) with the FDA, as well as global clinical trials initiated in other geographies, where strict regulatory compliance and quality assurance is mandated.

For additional information, see “Part I, Item 1A — Risk Factors—Risks Related to Regulatory and Legal Matters” in this Form 10-K.

Environmental, Social and Governance (“ESG”) Program

Since 2022, our key ESG focus has been on measuring our Greenhouse Gas (GHG) Emissions. GHG emissions represent a clear global significance for companies, consumers, and other stakeholders. Cryoport engages an ESG advisor to assist us in creating an annual report of the previous years’ estimated global GHG emissions. The following summarizes that report.

Summary of our 2023 GHG Emissions Report

Methodology

We used the World Resource Institute’s Greenhouse Gas Protocol - Corporate Accounting and Reporting Standard (Revised Edition) to calculate the company’s GHG emissions. The standard provides accounting tools to measure, manage, and report on GHG emissions. This protocol classifies emissions into three “scopes.” Scope 1 emissions includes direct GHG emissions, which occur from sources that are owned or controlled by a company. Scope 2 emissions include indirect GHG emission from purchased electricity. Scope 3 emissions include all other indirect GHG emissions.

Organizational Boundary

The reporting boundary for the purposes of the report is Cryoport, Inc. and its consolidated subsidiaries, which includes four business units (MVE, Cryoport Systems, CRYOPDP, and Cryogene) and over 50 facility locations across 17 countries (United States, China, Netherlands, Portugal, France, Belgium, United Kingdom, Poland, Germany, Singapore, India, South Korea, Australia, Spain, Ireland, Philippines and Japan) in 2023.

Scope

The scope of the report includes our Scope 1 emissions (Direct) and Scope 2 emissions (Indirect emissions from purchased electricity), but generally excludes Scope 3 emissions (Other indirect emissions). However, we did quantify Scope 3 emissions from waste generated in operations for one business unit because the data was readily available to quantify such emissions. The following sources of emissions were included in the scope of the report for the identified business units:

Table of Contents

Cryoport’s advanced integrated temperature-controlled supply chain solutions platform is designed to support the global distribution of high-value commercial biologic and cell-based products and therapies regulated by the FDA, the European Medicines Association (EMA) and other international regulatory bodies. Cryoport’s solutions are also relied upon for the support of pre-clinical, clinical trials, Investigational New Drug Applications (IND), Biologics License Applications (BLA), and New Drug Applications (NDA) with the FDA, as well as global clinical trials initiated in other geographies, where strict regulatory compliance and quality assurance is mandated.

~~Some~~For ofadditional ~~the~~information, ~~Scope~~see 3“Part ~~emissions that contribute to our global carbon footprint~~I, ~~but~~Item ~~for~~1A ~~which~~— weRisk ~~determined~~Factors—Risks ~~that~~Related ~~data was not reasonably available for us~~ to ~~quantify~~Regulatory ~~in this report include, but are not limited to, transportation~~ and ~~distribution~~Legal ~~provided~~Matters” ~~by third parties~~ in ~~the~~this ~~performance~~Form ~~of our services; use and end~~10-~~of-life treatment of sold products; and purchased goods and services~~K.

Assumptions

We used various assumptions to quantify GHG emissions in the report. As with any projections or estimates, actual results or numbers may vary based upon factors such as variations in processes and operations, availability and quality of data, and methodologies used for measurement and estimation. Changes to emission estimates may occur if updated data or emission methodologies become available. The following are some primary assumptions or estimates that we made in the 2023 report:

Stationary Combustion – Natural Gas. Natural gas usage for heating was estimated for several company locations based on spend data and regional utility rates.

Mobile Sources – Vehicle Fuel Consumption. For fleet vehicles where actual fuel usage was not available, vehicle fuel consumption was estimated based on the miles driven and average fuel economy of the vehicle type.

Purchased Electricity (Location-Based). Electricity usage was estimated for several company locations based on either (i) square footage using average intensity for offices, or (ii) spend data and regional utility rates, depending on what information was available.

Utility Estimations. When there were gaps in electricity or natural gas data, the average of the prior and following months data was used to estimate the missing information.

Table of Contents

Results

Our 2022 and 2023 Total Emissions, as calculated in the 2022 and 2023 reports, are as follows:

[1] The Total Emissions from Waste Generated in Operations for 2022 also included information for one Cryoport Systems location.

[2] Total Emissions from Employee Business Travel and Downstream Product Travel was not quantified in the 2023 report.

The following charts show the percent of total emissions in 2022 and 2023 that was contributed by each type of emission quantified in the 2022 and 2023 reports:

Table of Contents

Carbon Footprint Intensities

The following table shows our 2022 and 2023 carbon footprint intensities in relation to square feet of our facilities, revenue, and employees as calculated in our 2022 and 2023 reports.

Next Steps

Cryoport plans to continue to calculate an annual carbon footprint. Conducting an annual carbon footprint allows Cryoport to track changes (i.e., increases or reductions in emissions, fuel usage, or energy usage by facility) and refine our processes and procedures used to estimate our carbon footprint. The Nominations and Governance Committee of the Board of Directors meets annually to review the GHG Emissions Report and will decide, along with Cryoport’s executive team, the next steps that we will take on our ESG journey.

Supporting Our People (December 31, 2024)

● Total Headcount: 1,186 (Full-Time 1,090, Part-Time 15, Contingent 81)

● Languages Spoken: 22

● Countries: 19

● Average Years of Service: 5.27 Years

Cryoport’s global team of employees are our most valuable resource, from our teams on the front line in our global supply chain and logistics centers, to our manufacturing operations, to our business development personnel, to the engineers who design our products and services, to our quality assurance and regulatory teams that assure the safety, quality, compliance, and integrity of our products.

Our success depends on the health, talent, and dedication of our global team. As we grow our team, we strive to retain, develop, and provide advancement opportunities for our employees. We endeavor to make Cryoport a superior growth workplace with a diverse, inclusive, and equitable environment where all team members have the opportunity to flourish.

Table of Contents

Diversity, Equity & Inclusion (DEI)

We are committed to diversity, equity, and inclusion for our employees across our global Company. Cryoport is an Equal Employment Opportunity employer and currently tracks gender distribution across its operations and management. We maintain clear policies related to anti-harassment, discrimination, and retaliation, and provide an anonymous, third party-managed reporting hotline for employees to report incidents of harassment, discrimination, and policy violations. We provide annual online corporate training programs on harassment, diversity and inclusion, business ethics and code of conduct. In addition, Cryoport’s recruiting process includes targeted outreach to a variety of under-represented constituents.. Cryoport has partnered with or targeted organizations like Hire Heroes, Career OneStop, recruiting at Historical Black Colleges, Accounting and Financial Women’s Alliance, and Women in Technology.

The Human Resources (“HR”) departments in each Cryoport business unit manage HR priorities, including team member career development, engagement, and health and wellness. Our Corporate HR department promotes consistency of policies across our operating companies and manages executive development and employee benefits.

As of December 31, 2024, women represented a total of approximately 35% of all employees, 32% of all managers, 38% of all directors, and 22% of all senior leadership positions (Vice President and above). Cryoport understands that there is work to be done to create a more equitable and representative senior leadership team and continue to push diversity throughout our operations.

We are committed to offering competitive compensation that accounts for geography, industry, experience, and performance. Our compensation programs and practices are designed to attract new employees, motivate, and reward performance, drive growth and support retention. Compensation at Cryoport includes base wages and generally includes incentive opportunities such as restricted stock units, equity stock options, and/or cash bonuses.

Employee Health & Safety

Safety is a priority in every aspect of our business. Across our companies, we are committed to making our workplaces and communities safer for our employees, customers, and the public. Our corporate philosophy is embedded in our day-to-day work through policies and continual education.

Cryoport’s Employee Health & Safety (EHS) programs have demonstrated strong safety performance, as evidenced by our total injury rates (TIR) and lost time injury rates (LTIR) being significantly lower than the global industry averages. Driven by our culture of continuous improvement, we are committed to continue to work toward reducing our TIR and LTIR figures even further.

To understand and improve our safety performance, we measure our operational performance across a variety of indicators—including lost-time-injury rate (LTIR)—on a daily basis. In 2024, our LTIR for our United States operations was 0.46. In addition to looking at past indicators of safety performance, we frequently evaluate the effectiveness of new metrics, including leading indicators, as we strive to improve our safety performance. Cryoport’s operating companies are responsible for implementing policies and procedures aligned with international standards that account for their business and the associated health and safety risks.

Innovating Responsibility

Cryoport recognizes that we play a role in protecting the health and safety of current and future generations through services and solutions that promote sustainability, resilience, and respect for the environment. We strive for a product base that is of the highest quality and with long life spans to minimize impact associated with the production of new products, and Cryoport reviews opportunities to eliminate materials of concern and related managed waste streams.

Product & Service Quality

As a temperature-controlled supply chain provider to the life sciences industry, Cryoport must comply with the safe transportation of regulated hazardous materials. As a result, we have designed and developed several features in its various products to comply with US DOT, IATA, ICAO, and other regulatory and guidance bodies. Additionally, safety warnings are included in our product labeling as well as our manuals. Our products are designed to conform to the following standards (where applicable):

● ISO 13485 (Section 7.3 Design and Development, ISO, QMS)

● ISO 14971 Application of Risk Management, ISO

Table of Contents

● Medical Device Directive Medical Devices Directive 93/42/EEC, and Directive 2007/47/EC amending Council Directive 93/42/EEC concerning medical devices

● Low Voltage Directive (LVD) (2014/35/EU)

● Electromagnetic Compatibility Directive (2014/30/EU)

● RoHS 2 (2011/65/EU) (we are actively working on RoHS 3 and REACH)

● Safety Requirements For Electrical Equipment For Measurement, Control, And Laboratory Use - Part 1:

● General Requirements [UL 61010-1:2012 Ed.3+R:29Apr2016]

● Safety Requirements For Electrical Equipment For Measurement, Control, And Laboratory Use – Part 1:

● General Requirements (R2017) [CSA C22.2#61010-1-12:2012 Ed.3+U1; U2]

● IEC 60601-1 - Medical electrical equipment - Part 1: General requirements for basic safety and essential performance

● IEC 61326-1:2012 - Electrical Equipment For Measurement, Control And Laboratory Use - EMC Requirements - Part 1: General Requirements

● ASME SEC. VIII Pressure Vessel Code (Fusion Only)

● EU Pressure Equipment Directive (EU97/23/EC) (Fusion Only)

● FCC 47 CFR Class B Verification (Fusion Only)

● IEC 62304 Medical device software — Software life cycle processes

These standards are integrated into our development methodology used to design new products and services within our company. The development process includes a risk management assessment done in accordance with ISO 14971 that identifies hazards and mitigates risks via design improvements, process improvements, and warnings (including labels and safety information shipped with the product).

We pride ourselves on our exceptional operational quality. In 2024, we estimate that our temperature-controlled supply chain solutions focused on cell and gene therapies had a 99.97% delivery success rate and due to this performance we estimate that 25,968 additional patients were able to receive therapies over the past 24 months. In 2024, we estimate that our CryoStork® solution had a 99.88% delivery success rate and due to this performance we estimate that 1,936 intended parents are potentially able to have successful cycles resulting in the birth of a child on an annual basis because of our CryoStork® solution.

While rare, recalls of products may become necessary. The primary responsibility for recall management lies with our Vice President of Quality Assurance and Regulatory Affairs for manufacturing. The executive team is involved in the decision and implementation processes depending upon the specifics of any recall that may be required. Customer service personnel, sales staff and other resources would then be utilized to reach all distributors and direct end users. The results of recalls are evaluated daily until the recall is closed. There were no product recalls during 2024.

Product Lifecycle Management

Cryoport’s unique products are developed with long-term use in mind. Cryoport’s products are primarily constructed of recyclable aluminum or stainless steel, and we approach the extension of product lifecycles through the following four areas:

● Longevity

● Reparability

● Reusability

● Recyclability

We strive for a product base with long life spans to minimize the impact associated with production of a new product. At our MVE Biological Solutions production facility, in 2024, we manufactured cryogenic freezer units that we estimate utilize approximately 1/1865 of the energy used by conventional mechanical freezers used for similar applications. For example, our freezer production displaced annual electricity consumption by 196,705,031 kWh from what would otherwise be consumed from alternative products. This amount of electricity could power 19,172 homes annually. This reduction in energy consumption from our freezer lines alone equates to 152,504,879 pounds of GHG emissions avoided or the emissions equivalent to 16,135 passenger vehicles driven for one year.

Cryoport regularly reviews opportunities to eliminate the use of materials considered hazardous and related managed waste streams. Cryoport does not utilize any substances of concern in our products; we do currently utilize minimal quantities of hazardous materials that are not listed as substances of concern in our operations, primarily in the form of isopropanol, epoxies, butyl cellosolve,

Table of Contents

lacquer thinner, paint, hyamine and isopropyl alcohol. These materials and the insignificant quantities of hazardous wastes generated by our production facilities are managed in compliance with all state and federal regulations. Any hazardous waste that is generated is tracked and managed with an overall goal of eliminating hazardous materials where possible. Cryoport strives to have a conflict-free supply chain and is committed to working with its suppliers to increase transparency regarding the origin of minerals contained in its products, including minerals identified as conflict minerals (tin, tungsten, tantalum, and gold), and has adopted a Conflict Minerals Policy, which is available on our website at www.cryoportinc.com on the “Investor Relations: Governance” page under the heading “Governance Documents.”

Governing Ethically

Cryoport recognizes that solid supplier relationships are essential to our ability to meet customer requirements for quality solutions. We expect our business partners to share our commitment to ethics, integrity, regulatory compliance, safety, human rights, data security, and environmental protection. By the same token, as a provider accountable to thousands of companies worldwide, we pledge, through our ESG performance, to meet or exceed our clients’ requirements for the same.

Business Ethics

We are committed to operating with honesty and transparency in accordance with the highest ethical and corporate governance standards – mutual respect, integrity and trust are the foundation of our company. Our Code of Ethical Business Conduct (the “Code of Ethics”) serves as the foundation of our corporate integrity and compliance program and applies to our directors and all employees, including our Chief Executive Officer and Chief Financial Officer. The Code of Ethics is available on our website at www.cryoportinc.com on the “Investor Relations: Governance” page under the heading “Governance Documents.” All employees across our operations are provided with training and reference materials to reinforce this commitment to integrity and ethics in our business. Our Code of Ethics is is translated into local languages for our employees where applicable and includes guidance on topics including, but not limited to the following:

● Corruption

● Anti-Trust and Anti-Competitive Behavior

● Insider Dealings

● Gifts

● Bribes (e.g., explicit prohibition of facilitation payments)

● Conflicts of Interest

● Intellectual Property

● Regulatory Compliance

● Truthful and Accurate Reporting

● Human Rights

● Equal Employment Opportunity

● Anti-harassment

● Environmental Compliance and Sustainability

● Whistleblower protections (including non-retaliation)

● Political Activity and Contributions (e.g., explicit prohibition of contribution of any kind to any candidate or political party without express prior approval of our board of directors – this covers both direct contributions and indirection support; no political contributions have been made in recent years)

● Reporting Violations of Company Policy

Our officers, directors, and managers are responsible for promoting the principles within the Code of Ethics and fostering a culture of ethical conduct. Our commitment to doing the right thing depends on our employees’ being comfortable in reporting any suspected violations of law or unethical conduct, and our leaders’ abilities to address suspected violations promptly, with respect. Our global policy against retaliation encourages employees to come forward to report concerns in good faith. When a matter is reported to a manager or our HR department, the concern is reviewed to determine whether it should be escalated to the legal department. The legal department also has criteria for further escalation, if necessary, to legal department management. Every new employee is introduced to the Code of Ethics through training and orientation.

Table of Contents

We develop and update these policies when we identify a need for employee clarification, the emergence of new laws or regulations, or other external factors. We routinely review and update the language in our policies, and how we present information, to ensure our employees understand the risks they face in their jobs, and steps they can take to mitigate those risks and report potential problems.

Our commitment to human rights is an important part of the Code of Ethics. We are committed to protecting and advancing human rights in our operations around the world. We pay fair wages and comply with wage laws in all the countries where we operate. We prohibit the use of child, compulsory, or forced labor, and we share the zero-tolerance policies adopted by the United States and other governments against slavery and human trafficking. We prohibit the trafficking of persons for any purpose and trafficking-related activities, and we expect the same from our suppliers and vendors.

In addition to our Code of Conduct, our senior leadership team actively oversees the governance of our ethics programs to help ensure that commitment is driven from the top down, and that program owners are accountable for successful program compliance.

Cryoport does not conduct clinical trials, animal testing or use human tissue of any kind in the manufacture or design of our products, and our Code of Conduct governs the ethical behavior of our employees across all of Cryoport’s global operations. Further, we do not conduct lobbying activities.

Supplier Management

Temperature-controlled supply chain support to the life sciences industry is critical to all that Cryoport does; therefore, we take an active approach to managing suppliers and partners to ensure that appropriate compliance, health, safety, labor practices, and ethical standards are employed. Our internal diligence process for third-party vendors includes a supplier questionnaire that is required for vendor approval and a regular auditing process thereafter for existing suppliers. The questionnaire is intended to verify that our suppliers have programs in place to manage material risk areas associated with the given supplier’s operations and particular consideration is paid to bribery or other forms of corrupt activity. Suppliers are not approved until this mandatory due diligence is complete and a completed assessment form is on file.

As an example, if one of our transportation suppliers employs or works with a Dangerous Goods Safety Advisor, we confirm the presence of a credentialed role responsible for overseeing activities associated with dangerous goods, including but not limited to, employee training and coaching, reporting, and monitoring of activities associated with the transportation of dangerous goods. The purpose of this inquiry is to gauge the degree of oversight over dangerous goods management by our suppliers to help ensure product and employee welfare.

Our Code of Conduct extends throughout our approved suppliers and thus sets an expectation for our suppliers to commit to operating with honesty, truthfulness and transparency in accordance to the highest ethical and corporate governance standards, as Cryoport personifies through our operations. Per our Code of Conduct, Cryoport will not tolerate the use by suppliers of forced labor in any form.

Data Privacy & Security

Cryoport uses an outside Center for Internet Security (CIS) assessment firm to evaluate our data security controls in an effort to protect our businesses and secure the information of our employees and customers. The CIS evaluation process utilizes the CIS’ Critical Security Controls Capability Maturity Model Integration (CMMI) methodology, and is an ongoing initiative used to continuously improve the CMMI rating for the Company.

Our customers rely on Cryoport to securely and reliably deliver temperature-controlled supply chain solutions globally, including providing a secure online portal for order entry, tracking, condition monitoring, and for the retrieval of historic information. Protecting the privacy of our customers and suppliers is essential to maintaining their trust, and we take a proactive approach to safeguard all data and ensure a secure environment. With the increasing presence and sophistication of online threats, we strive for continuous improvements that aim to protect our business and our customers. We regularly review our technology, policies, and practices to maintain compliance with all relevant global regulations. We do not sell customers’ data to third parties. Additionally, Cryoport employees with a computer are required to complete a annual online training courses on information security and data privacy. The courses addresses a range of topics related to information security and data privacy, including awareness regarding social engineering and cybercrimes, protecting the workplace, and protecting data.

Table of Contents

Cryoport Societal and Environmental Impact Statements

Examples of some of our positive societal and environmental impacts for 2023 and 2024 include the following:

Our positive impacts for 2023 and 2024 were based on the following:

Access to Patients. Our calculation of the number of additional patients that were able to receive therapies was based our success rate for shipments, which is higher than the average success rate in the cold chain markets of 80%, pursuant to Rodrigue, J-P (2020), The Geography of Transport Systems, Fifth Edition, New York: Routledge.

Patient Success & Satisfaction. Our calculation of the number of intended parents able to have successful cycles resulting the birth of a child is based on the weighted average chance of a live singleton birth per intended egg retrieval across women of all ages of 27.23% as reported in the 2020 Society for Assisted Reproductive Technology (SART) Clinic Summary Report (CSR).

Energy Saved – MVE Biological Solutions. Our calculation of energy reduction is based on the reduced energy consumption from MVE freezer use compared to the average energy consumed by operation of mechanical freezers, which we assumed to be 31.7 kWh/day based on product specifications from a mechanical freezer manufacturer.

Energy Saved – CRYOGENE. Our calculation of GHG emissions avoided is based on the output mission rates for GHG emissions from the EPA eGRID data (2023) for the Electric Reliability Council of Texas (ERCOT).

Employees

We refer to our employees as our “team.” They are critical to our success, and we are in constant communication and training. We believe that we have assembled a strong management and leadership team with the experience and expertise needed to execute our business strategy. As of December 31, ~~2024~~2025, we had ~~1,186~~738 employees: ~~1,090~~684 full-time, 158 part-time, and 8146 temporary, of which ~~489~~448 are located in the Americas, ~~333~~148 in EMEA and ~~364~~142 in APAC. ~~This~~We ~~increase~~anticipate ofhiring ~~over~~additional 16personnel ~~employees~~as ~~compared~~required to ~~December 31, 2023~~support ~~is, primarily as a result of the further build out of~~ our global ~~organization,~~growth ~~both~~strategy. ~~organically and through acquisitions, to support our expanded~~

Table of Contents

solutions offering and the expected growth in the markets we serve. We anticipate hiring additional personnel as required to support our global growth strategy.

Corporate History and Structure

We are a Nevada corporation originally incorporated under the name G.T.5-Limited (“GT5”) on May 25, 1990. In connection with a Share Exchange Agreement in March 2005, we changed our name to Cryoport, Inc. and acquired all of the issued and outstanding shares of common stock of Cryoport Systems, Inc., a California corporation. Cryoport Systems, Inc., which was originally formed in 1999 as a California limited liability company, was reorganized into a California corporation on December 11, 2000 and converted into Cryoport Systems, LLC, a California limited liability company, on September 17, 2020, and remains one of our operating companies under Cryoport, Inc. Our principal executive offices are located at 112 Westwood Place, Suite 350, Brentwood, TN 37027. The telephone number of our principal executive office is (949) 470-2300, and our main corporate website is www.cryoportinc.com. The information on or that can be accessed through our website is not part of this Form 10-K.

Information about our Executive Officers

The following are our executive officers as of the filing date of this Form 10-K:

Jerrell W. Shelton. Mr. Shelton, age 80, became a member of our board of directors in October 2012 and was appointed President and Chief Executive Officer of the Company in November 2012. He was appointed Chairman of the Board in October 2015. He served on the Board of Directors and standing committees of Solera Holdings, Inc. from April 2007 through November 2011. From June 2004 to May 2006, Mr. Shelton was the Chairman and CEO of Wellness, Inc., a provider of advanced, integrated hospital and clinical environments. Prior to that, he served as Visiting Executive to IBM Research and Head of IBM’s WebFountain. From October 1998 to October 1999, Mr. Shelton was Chairman, President and CEO of NDC Holdings II, Inc. Between October 1996 and July 1998, he was President and CEO of Continental Graphics Holdings, Inc. From October 1991 to July 1996, Mr. Shelton served as President and CEO of Thomson Business Information Group. Mr. Shelton has a B.S. in Business Administration from the University of Tennessee and an M.B.A. from Harvard University. Mr. Shelton’s extensive leadership, management, strategic planning and financial expertise through his various leadership and directorship roles in public, private and global companies, makes him well-qualified to serve as a member of the board of directors.

Robert S. Stefanovich. Mr. Stefanovich, age 61, became Chief Financial Officer and Treasurer for the Company in June 2011. In 2019, he was also given the title Senior Vice President. From 2011 to 2019, Mr. Stefanovich served as the Secretary of the Company. From June 15, 2012 to November 4, 2012, Mr. Stefanovich served as the Principal Executive Officer of the Company. From November 2007 through March 2011, Mr. Stefanovich served as Chief Financial Officer of Novalar Pharmaceuticals, Inc., a venture-backed specialty pharmaceutical company. Prior to that, he held several senior leadership positions, including interim Chief Financial Officer of Xcorporeal, Inc., a publicly traded medical device company, Executive Vice President and Chief Financial Officer of Artemis International Solutions Corporation, a publicly traded software company, Chief Financial Officer and Secretary of Aethlon Medical Inc., a publicly traded medical device company and Vice President of Administration at SAIC, a Fortune 500 company. Mr. Stefanovich also served as a member of the Software Advisory Group and an Audit Manager with Price Waterhouse LLP’s (now ~~PricewaterhouseCoopers) hi-tech practice in San Jose, California and Frankfurt, Germany. He received his Master of Business Administration and Engineering from University of Darmstadt, Germany.~~

Mark Sawicki, Ph.D. Dr. Sawicki became President and Chief Executive Officer of Cryoport Systems, LLC, a wholly-owned subsidiary of the Company, and the Senior Vice President and Chief Scientific Officer of the Company in September 2020 and served as the Chief Commercial Officer of Cryoport Systems from January 2015 to August 2020. Dr. Sawicki brings over 20 years of business development and sales management experience, having consistently delivered on corporate revenue and market share goals in the pharmaceutical and biotechnology industries. Dr. Sawicki previously served as the Chief Business Officer at AAIPharma Services Corporation/Cambridge Major Laboratories Inc. (now Alcami Corporation), a contract development, testing, and manufacturing organization for pharma and biotech companies. Additionally, he has served in senior business development roles at CMC Biologics, a provider of biopharmaceutical contract manufacturing services, and Albany Molecular Research Inc. (AMRI), a contract research and manufacturing organization. Dr. Sawicki holds a bachelor’s in biochemistry from the State University of New York at Buffalo and a Ph.D. in biochemistry from the State University of New York at Buffalo, School of Medicine and Biomedical Sciences. He also received graduate training at the Hauptman Woodard Medical Research Institute. Dr. Sawicki has authored a dozen scientific publications in drug discovery with a focus on oncology and immunology.13

Table of Contents

PricewaterhouseCoopers) hi-tech practice in San Jose, California and Frankfurt, Germany. He received his Master of Business Administration and Engineering from University of Darmstadt, Germany.

Mark Sawicki, Ph.D. Dr. Sawicki, age 53, became President and Chief Executive Officer of Cryoport Systems, LLC, a wholly-owned subsidiary of the Company, and the Senior Vice President and Chief Scientific Officer of the Company in September 2020 and served as the Chief Commercial Officer of Cryoport Systems from January 2015 to August 2020. Dr. Sawicki brings over 20 years of business development and sales management experience, having consistently delivered on corporate revenue and market share goals in the pharmaceutical and biotechnology industries. Dr. Sawicki previously served as the Chief Business Officer at AAIPharma Services Corporation/Cambridge Major Laboratories Inc. (now Alcami Corporation), a contract development, testing, and manufacturing organization for pharma and biotech companies. Additionally, he has served in senior business development roles at CMC Biologics, a provider of biopharmaceutical contract manufacturing services, and Albany Molecular Research Inc. (AMRI), a contract research and manufacturing organization. Dr. Sawicki holds a bachelor’s in biochemistry from the State University of New York at Buffalo and a Ph.D. in biochemistry from the State University of New York at Buffalo, School of Medicine and Biomedical Sciences. He also received graduate training at the Hauptman Woodard Medical Research Institute. Dr. Sawicki has authored a dozen scientific publications in drug discovery with a focus on oncology and immunology.

Edward J. Zecchini. Mr. Zecchini, age 65, became Chief Digital and Technology Officer (CDTO) for the Company in February 2024. Prior to joining the Company as the CDTO, Mr. Zecchini was a member of the Cryoport, Inc. Board of Directors from September 2013 through February 2024. Mr. Zecchini currently serves on the Board of TribeHealth, Inc. From 2018 to 2022, Mr. Zecchini also served as a director of the publicly traded behavioral healthcare company, Ontrak, Inc. Mr. Zecchini served as Chief Information Officer at Remedy Partners, Inc., from April 2014 to October 2019 and served as Executive Vice President and Chief Technology Officer at Sandata Technologies, LLC, from May 2010 to March 2014. Prior to that, Mr. Zecchini held senior executive positions at Touchstone Healthcare Partnership, HealthMarkets, Inc., Thomson Healthcare and SportsTicker, Inc. Mr. Zecchini has over thirty years of experience in the healthcare and information technology industries. Mr. Zecchini holds a Bachelor of Arts degree from the State University of New York at Oswego.

Available Information

Our main corporate website address is www.cryoportinc.com. The information on or that can be accessed through our website is not part of this Form 10-K. We electronically file with the SEC our Annual Report on Form 10‑K, Quarterly Reports on Form 10‑Q, Current Reports on Form 8‑K and amendments to the reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, proxy statements and the reports filed pursuant to Section 16(a) of the Exchange Act.. We make available free of charge on or through our website copies of these reports and proxy statements as soon as reasonably practicable after we electronically file these reports and proxy statements with, or furnish them to, the SEC. The SEC also maintains an internet site that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC at www.sec.gov.

ITEM 1A. RISK FACTORS

The following risk factors could materially and adversely affect our business, financial condition and results of operations. These risk factors do not identify all of the risks that we face.

Risks Related to Our Business

As an increasingly global business, we are exposed to economic, political, and other risks in different countries which could materially reduce our sales, profitability or cash flows, or materially increase our liabilities.

Since we manufacture and sell our products worldwide, our business is subject to risks associated with doing business internationally. Our future results could be harmed by a variety of factors, including:

●

changes in foreign currency exchange rates, exchange controls and currency restrictions;

●

changes in a specific country’s or region’s political, social or economic conditions;

●

political, economic and social instability, including acts of war;

●

outbreak of disease or illness in any of the countries in which we sell our products or in which we or our suppliers operate;

● tariffs, other trade protection measures, and import or export licensing requirements, including asthose aimposed ~~result~~by of the ~~recent~~United ~~changes~~States inand the ~~presidential~~reciprocal ~~administration and/~~or ~~the~~retaliatory ~~make-up~~measures oftaken ~~the~~by ~~Senate~~its ~~and~~trading ~~the House of Representatives~~partners;

Table of Contents

●

potentially negative consequences from changes in U.S. and international tax laws;

●

difficulty in staffing and managing geographically widespread operations;

●

changes in customer spending due to the increased economic uncertainties and the disruption in the capital markets;

●

requirements relating to withholding taxes on remittances and other payments by subsidiaries;

●

restrictions on our ability to own or operate subsidiaries, make investments or acquire new businesses in these jurisdictions;

●

restrictions on our ability to repatriate dividends from our foreign subsidiaries;

●

difficulty in collecting international accounts receivable;

●

difficulty in enforcement of contractual obligations under non-U.S. law;

●

transportation delays or interruptions; and

●

changes in regulatory requirements including as it relates to protection of our intellectual property.

The functional currency for most of our foreign operations is the applicable local currency. As a result, fluctuations in foreign currency exchange rates affect the results of our operations and the value of our foreign assets and liabilities, which in turn may adversely affect results of operations and cash flows and the comparability of period-to-period results of operations. Changes in foreign currency exchange rates may also affect the relative prices at which we and foreign competitors sell products in the same market. Foreign governmental policies and actions regarding currency valuation could result in actions by the United States and other countries to offset the effects of such fluctuations. Given the unpredictability and volatility of foreign currency exchange rates, ongoing or unusual volatility may adversely impact our business and financial conditions.

We depend on the availability of certain component products used in our solutions; delays or increased costs in the procurement of components manufactured by third parties could adversely affect our business operations, financial performance and results of operations, and we may experience customer dissatisfaction and harm to our reputation.

If we fail to procure sufficient components used in our products from our third-party manufacturers, we may be unable to deliver our solutions to our customers on a timely basis, which could lead to customer dissatisfaction and could harm our reputation and ability to compete. We currently acquire various component parts for our solutions from various independent manufacturers, some of which are sole sourced. We would likely experience significant delays or cessation in producing some of these components if a labor strike, natural disaster, public health crisis, act of war or other supply disruption were to occur. If we are unable to procure a component from one of our manufacturers, we may be required to enter into arrangements with one or more alternative manufacturing companies, which may cause delays in producing components or result in significant increases in costs. To date, we have not experienced any material delay that has adversely impacted our operations, but this does not mean that we will continue to have timely access to adequate supplies of essential materials and components in the future or that supplies of these materials and components will be available on satisfactory terms when needed. If our vendors for these materials and components are unable to meet our requirements, fail to make shipments in a timely manner, or ship defective materials or components, we could experience a shortage or delay in supply or fail to meet our contractual requirements, which would adversely affect our results of operations and negatively impact our cash flow and profitability. Continued delay in our ability to produce and deliver our products and services could also cause our customers to purchase alternative products and services from our competitors and/or harm our reputation.

Table of Contents

which are sole sourced. We would likely experience significant delays or cessation in producing some of these components if a labor strike, natural disaster, public health crisis, act of war or other supply disruption were to occur. If we are unable to procure a component from one of our manufacturers, we may be required to enter into arrangements with one or more alternative manufacturing companies, which may cause delays in producing components or result in significant increase in costs. To date, we have not experienced any material delay that has adversely impacted our operations, but this does not mean that we will continue to have timely access to adequate supplies of essential materials and components in the future or that supplies of these materials and components will be available on satisfactory terms when needed. If our vendors for these materials and components are unable to meet our requirements, fail to make shipments in a timely manner, or ship defective materials or components, we could experience a shortage or delay in supply or fail to meet our contractual requirements, which would adversely affect our results of operations and negatively impact our cash flow and profitability. Continued delay in our ability to produce and deliver our products and services could also cause our customers to purchase alternative products and services from our competitors and/or harm our reputation.

Our products and services may contain errors or defects, which could result in damage to our reputation, lost revenues, diverted development resources and increased service costs, litigation and product recalls. These risks may be heightened when our products or services are used in connection with human reproductive medicine.

Our products and services must meet stringent requirements and we must develop our products and services solutions quickly to keep pace with the rapidly changing market. Products and services as sophisticated as ours could contain undetected errors or defects, especially when first introduced or when new equipment or versions of our software are released. If our products and services are not free from errors or defects, we may incur an injury to our reputation, lost revenues, diverted development resources, increased customer service and support costs, product recalls and litigation. The costs incurred in correcting any product errors or defects may be substantial and could adversely affect our business, results of operations and financial condition.

Table of Contents

Due to the low temperatures at which some of our products are used and the fact that some of our products are relied upon by our customers or end users in their facilities or operations or are manufactured for relatively broad medical, transportation, or consumer use, we face an inherent risk of exposure to claims in the event that the failure, use, or misuse of our products results, or is alleged to result, in death, bodily injury, property or sample damage, or economic loss. The amount of damages for which we are potentially held liable for may be higher when our products or services are used in connection with human reproductive medicine than when they are used for other purposes. For example, in some states, damage to an embryo may be deemed wrongful death for which punitive or other damages may be awarded, which would not otherwise be available. In addition, we specialize in the secure storage of biological specimens, materials and samples covering the full range of temperatures from cryogenic through controlled room temperature. Any damage to these specimens, materials and samples may be attributed to a failure of our storage systems or services, which could lead to claims for damages made by customers and could also harm our relationship with customers and damage our reputation in the life sciences industry, resulting in material harm to our business.

Although we currently maintain product liability coverage, which we believe is adequate for product liability claims and for the continued operation of our business, it includes customary exclusions and conditions, may not cover certain specialized applications and generally does not cover warranty claims. Additionally, such insurance may become difficult to obtain or be unobtainable in the future on terms acceptable to us. A successful product liability claim or series of claims against us, including one or more consumer claims purporting to constitute class actions or claims resulting from extraordinary loss events, in excess of or outside our insurance coverage, or a significant warranty claim or series of claims against us, could materially decrease our liquidity, impair our financial condition, and adversely affect our results of operations. See “—Risks Related to Our Business—Our products and services may expose us to liability in excess of our current insurance coverage” for additional information.

In addition, regardless of merit or eventual outcome, product liability claims may result in, among other things, costs of litigation, distraction of management’s attention from our primary business, the inability to commercialize our existing or new products, decreased demand for our products or, if cleared or approved, products in development, damage to our business reputation, product recalls or withdrawals from the market, withdrawal of clinical trial participants, substantial monetary awards to patients or other claimants, or loss of revenue.

While we may attempt to manage our product liability exposure by proactively recalling or withdrawing from the market any defective products, any recall or market withdrawal of our products may delay the supply of those products to our customers and may impact our reputation. We can provide no assurance that we will be successful in initiating appropriate market recall or market withdrawal efforts that may be required in the future or that these efforts will have the intended effect of preventing product malfunctions and the accompanying product liability that may result. Additionally, any recall could result in significant costs to us and significant adverse publicity, which could harm our ability to market our products in the future. Such recalls and withdrawals may also be used by our competitors to harm our reputation for safety or be perceived by customers as a safety risk when considering the use of our products. Though it may not be possible to quantify the economic impact of a recall, it could have a material adverse effect on our business, financial condition and results of operations.

Table of Contents

adverse publicity, which could harm our ability to market our products in the future. Such recalls and withdrawals may also be used by our competitors to harm our reputation for safety or be perceived by customers as a safety risk when considering the use of our products. Though it may not be possible to quantify the economic impact of a recall, it could have a material adverse effect on our business, financial condition and results of operations.

Additionally, for some of our products we offer a limited warranty for product returns which are due to defects in quality and workmanship. We estimate our potential liability for future product returns and establish reserves on our financial statements in amounts that we believe will be sufficient to address our warranty obligations; however, our actual liability for product returns may significantly exceed the amount of our reserves. If we underestimate our potential liability for future product returns, or if unanticipated events result in returns that exceed our historical experience, our financial condition and operating results could be materially and adversely affected.

Our business operations, financial performance and results of operations ~~have been adversely affected and~~ could ~~in the future~~ be materially adversely affected by ~~the~~ pandemics, epidemics or other public health crises, such as COVID-19.

The occurrence of pandemics, epidemics or other public health crises could materially affect our business, financial condition, results of operations and cash flows, including due to negative impacts to the global economy, disruptions to global supply chains and workforce participation, and volatility and disruption of financial markets. For example, ~~since~~following COVID-19’s initial outbreak, governments and businesses took unprecedented measures in response, including restrictions on travel and business operations, temporary closures of businesses, and quarantine and shelter-in-place orders. Such response significantly curtailed global economic activity and caused significant volatility and disruption in global financial markets., ~~The~~which ~~COVID-19 pandemic and the measures taken by many countries in response have~~ adversely affected ~~and could in the future materially adversely impact~~ our business operations, financial performance and results of operations. During the course of the COVID-19 pandemic, certain of our facilities ~~have~~ experienced disruptions, such as our MVE Biological Solutions manufacturing facility in Chengdu, China that was temporarily impacted by COVID-19 lockdowns in China during the third quarter of 2022, and similar disruptions could occur in the future.

The extent to which pandemics, epidemics or other public health crises may impact our business operations, financial performance and results of operations is uncertain and will depend on many factors outside our control, including the timing, extent, trajectory and duration of the pandemic, epidedemic or other public health crises, the emergence of new variants, the development, availability, distribution and effectiveness of vaccines and treatments, and the imposition of protective public safety measures. Other potential impacts on us resulting from pandemics, epidemics or other public health crises may include, but not limited to, material adverse effects on our manufacturing, supply chain and distribution channels, our ability to execute our strategic plans, and our profitability. The potential effects of pandemics, epidemics or other public health crises may also impact and potentially heighten many of our other risk factors discussed in this “Risk Factors” section.16

Table of Contents

The extent to which pandemics, epidemics or other public health crises may impact our business operations, financial performance and results of operations is uncertain and will depend on many factors outside our control, including the timing, extent, trajectory and duration of the pandemic, epidemic or other public health crises, the emergence of new variants, the development, availability, distribution and effectiveness of vaccines and treatments, and the imposition of protective public safety measures. Other potential impacts on us resulting from pandemics, epidemics or other public health crises may include, but not limited to, material adverse effects on our manufacturing, supply chain and distribution channels, our ability to execute our strategic plans, and our profitability. The potential effects of pandemics, epidemics or other public health crises may also impact and potentially heighten many of our other risk factors discussed in this “Risk Factors” section.

We will have difficulty increasing our revenues if we experience delays, difficulties or unanticipated costs in establishing the sales, marketing and distribution capabilities necessary to successfully commercialize our solutions.

We plan to further enhance our sales, marketing and distribution capabilities in the Americas, EMEA, and APAC. It will be expensive and time-consuming for us to develop and integrate our global marketing and sales network and thus we intend to further broaden our strategic alliances with domestic and international providers of shipping services and other solutions providers to the life sciences industry to incorporate use of our platform of solutions in their service offerings. We may not be able to provide adequate incentive to our sales force or to establish and maintain favorable distribution and marketing collaborations with others to promote our solutions. In addition, any third party with whom we have established a marketing and distribution relationship may not devote sufficient time to the marketing and sales of our solutions, thereby exposing us to potential expenses in exiting such distribution agreements. We, and any of our alliance partners, must also market our services in compliance with federal, state, local and international laws relating to the provision of incentives and inducements. Violation of these laws can result in substantial penalties. Therefore, if we are unable to successfully motivate and expand our marketing and sales force and further develop our sales and marketing capabilities, or if our alliance partners fail to promote our solutions, we will have difficulty increasing our revenues and the revenue may not offset the additional expense of expansion.

We expect to base our equipment and inventory purchasing decisions on our forecasts of customers’ demand, and if our forecasts are inaccurate, our operating results could be materially harmed.

As our customer base increases, we expect the need to purchase additional equipment and inventory. Our forecasts will be based on multiple assumptions, each of which may cause our estimates to be inaccurate, affecting our ability to provide products to our customers. When demand for our products increases significantly, we may not be able to meet demand on a timely basis, and we may need to expend a significant amount of time working with our customers to allocate limited supply and maintain positive customer relations, or we may incur additional costs in order to rush the manufacture and delivery of additional products. If we underestimate customers’ demand, we may forego revenue opportunities, lose market share and damage our customer relationships. Conversely, if we overestimate customer demand, we may purchase more equipment and inventory than we are able to use or sell at any given time or at all. As a result of our failure to properly estimate demand for our products, we could have excess or obsolete equipment and/or inventory, resulting in a decline in the value of our equipment and/or inventory, which would increase our costs of revenues and reduce our liquidity. Our failure to accurately manage our equipment purchases and inventory relative to demand would adversely affect our operating results.

Table of Contents

customers. When demand for our products increases significantly, we may not be able to meet demand on a timely basis, and we may need to expend a significant amount of time working with our customers to allocate limited supply and maintain positive customer relations, or we may incur additional costs in order to rush the manufacture and delivery of additional products. If we underestimate customers’ demand, we may forego revenue opportunities, lose market share and damage our customer relationships. Conversely, if we overestimate customer demand, we may purchase more equipment and inventory than we are able to use or sell at any given time or at all. As a result of our failure to properly estimate demand for our products, we could have excess or obsolete equipment and/or inventory, resulting in a decline in the value of our equipment and/or inventory, which would increase our costs of revenues and reduce our liquidity. Our failure to accurately manage our equipment purchases and inventory relative to demand would adversely affect our operating results.

If we suffer a disruption or loss to our factories, facilities or distribution system due to factors outside of our control, our operations could be seriously harmed.

We rely on our distribution system including third-party shipment and carrier services to transport our shippers containing biological material. These third-party operations could be subject to natural disasters, adverse weather conditions, other business disruptions, and carrier error, which could cause delays in the delivery of our shippers, which in turn could cause serious harm to the biological material being shipped. As a result, any prolonged delay in shipment, whether due to technical difficulties, power failures, break-ins, destruction or damage to carrier facilities as a result of a natural disaster, fire, or any other reason, could result in damage to the contents of the shipper.

Additionally, our factories and facilities may be subject to catastrophic loss due to fire, flood, terrorism, increasing severity or frequency of extreme weather events, or other natural or man-made disasters, as well as disruptions due to a widespread outbreak of an illness or any other public health crisis, such as the COVID-19 pandemic. In particular, certain components of our key products are manufactured in China, which may be more likely than other locations to have disruptions caused by the response to a public health crisis, such as COVID-19. For example, our MVE Biological Solutions manufacturing facility in Chengdu, China was temporarily impacted by COVID-19 lockdowns in China during the third quarter of 2022, and similar disruptions could occur in the future.

Further, we operate facilities that specialize in the secure storage of biological specimens, materials and samples. If natural disasters or similar events, like hurricanes, fires or explosions or large-scale accidents or power outages, were to occur that prevented us from using all or a significant portion of these facilities, damaged critical infrastructure or our customers’ biological samples, or otherwise disrupted operations at such facilities, this could affect our ability to maintain ongoing operations and cause us to incur significant expenses. Insurance coverage may not be adequate to fully cover losses in any particular case.

For example, in January 2022, a fire occurred at the MVE Biological Solutions manufacturing facility located in New Prague, Minnesota, which manufactures aluminum dewars and is one of MVE Biological Solutions’ three global manufacturing facilities. As a consequence of the fire damage, the New Prague manufacturing operations were curtailed on an interim basis until the necessary repairs were completed, which adversely impacted our revenue in the first quarter of 2022. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations—MVE Biological Solutions Fire” for additional information.17

Table of Contents

us from using all or a significant portion of these facilities, damaged critical infrastructure or our customers’ biological samples, or otherwise disrupted operations at such facilities, this could affect our ability to maintain ongoing operations and cause us to incur significant expenses. Insurance coverage may not be adequate to fully cover losses in any particular case.

Our products and services may expose us to liability in excess of our current insurance coverage.

Our platform of products and services involve significant risks of liability, which may substantially exceed the revenues we derive from them. We cannot predict the magnitude of these potential liabilities. We currently maintain general liability insurance and product liability insurance. Claims may be made against us that exceed the limits of these policies.

Our liability policy is an “occurrence” based policy. Thus, our policy is complete when we purchased it and following cancellation of the policy it continues to provide coverage for future claims based on conduct that took place during the policy term. Our insurance coverage, however, may not protect us against all liability because our policies typically have various exceptions to the claims covered and also require us to assume some costs of the claim even though a portion of the claim may be covered. In addition, if we expand into new markets, we may not be aware of the need for, or be able to obtain insurance coverage for such activities or, if insurance is obtained, the dollar amount of any liabilities incurred could exceed our insurance coverage. A partially or completely uninsured claim, if successful and of significant magnitude, could have a material adverse effect on our business, financial condition and results of operations.

Table of Contents

If we use biological and hazardous materials in a manner that causes injury, we could be liable for damages.

Our customers may ship potentially harmful biological materials in our dewars. We cannot eliminate the risk of accidental contamination or injury to employees or third parties from the use, storage, handling or disposal of these materials. In the event of contamination or injury, we could be held liable for any resulting damages, and any liability could exceed our resources or any applicable insurance coverage we may have. Additionally, we are subject to, on an ongoing basis, federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. In the event of an accident, we could be held liable for damages.

We operate in a competitive industry and if we cannot compete effectively, we will lose business.

We expect to continue to experience significant and increasing levels of competition in the future. While there are technological and marketing barriers to entry, we cannot guarantee that these barriers will be sufficient to defend our market share against current and future competitors. Our principal competitive considerations in our market include:

●

financial resources to allocate to proper marketing and an appropriate sales effort;

●

acceptance of our solutions model;

●

acceptance of our solutions including per use fee structures and other charges for services;

●

keeping up technologically with ongoing development of enhanced features and benefits;

●

the ability to develop and maintain and expand strategic alliances;

●

establishing our brand name;

●

our ability to deliver our solutions to our customers when requested; and

●

our timing of introductions of new solutions and services.

Our future revenue stream depends to a large degree on our ability to bring new solutions and services to market on a timely basis. We generally sell our products and services in industries that are characterized by increased competition through frequent innovation, rapid technological changes and changing industry standards. Without the timely introduction of new products, services and enhancements, our products and services may become obsolete over time, in which case our revenue and operating results could suffer.

There may also be other companies which are currently developing competitive products and services or which may in the future develop technologies and products that are comparable, superior or less costly than our own. For example, some specialty couriers and packaging manufacturers with greater resources currently provide temperature-controlled packaging solutions and may develop other products or solutions in the future, both of which compete with our products. A competitor that has greater resources than us may be able to develop and expand their networks and product offerings more quickly, devote greater resources to the marketing and sale of ~~their solutions and adopt more aggressive pricing policies. We may not be able to successfully compete with a competitor that has greater resources, which may adversely affect our business.~~

Table of Contents

their solutions and adopt more aggressive pricing policies. We may not be able to successfully compete with a competitor that has greater resources, which may adversely affect our business.

If we successfully develop products and/or services, but those products and/or services do not achieve and maintain market acceptance, our business will not be profitable.

The degree of acceptance of our platform of existing products and services or any future products or services by our current target markets, and any other markets to which we attempt to sell our products and services, as well as our profitability and growth, will depend on a number of factors including, among others, our shippers’ ability to perform and preserve the integrity of the materials shipped, relative convenience and ease of use of our shippers and/or Cryoportal®, reliability and effectiveness of our bioservices, biostorage and cryopreservation services, availability of alternative products or new technologies that make our solutions ~~and services~~ less desirable or competitive, pricing and cost effectiveness, effectiveness of our or our collaborators’ sales and marketing strategy and the adoption cycles of our targeted customers.

In addition, even if our products and services achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or services are introduced that are more favorably received than our products and services, are more cost effective, or render our products obsolete. Further, there can be no assurance that future developments in technology will not make our technology non-competitive or obsolete, or significantly reduce our operating margins or the demand for our offerings, or otherwise negatively impact our ability to be profitable.

Table of Contents

The integration and operation of acquired businesses may disrupt our business and create additional expenses, and we may not achieve the anticipated benefits of the acquisitions.

Integration of an acquired business involves numerous risks, including assimilation of operations of the acquired business and difficulties in the convergence of systems and processes, the diversion of management’s attention from other business concerns, risks of entering markets in which we have had no or only limited direct experience, assumption of unknown or unquantifiable liabilities, difficulties in completing strategic initiatives already underway in the acquired company, and unfamiliarity with partners of the acquired company, each of which could have a material adverse effect on our business, results of operations and financial condition. We cannot assure that these risks or other unforeseen factors will not offset the intended benefits of the acquisitions, in whole or in part.

Additionally, potential acquisition opportunities become available to us from time to time, and we periodically engage in discussions or negotiations relating to potential acquisitions, including acquisitions that may be material in size or scope to our business. Any acquisition may or may not occur and, if an acquisition does occur, it may not be successful in enhancing our business for one or more of the following reasons:

●

any business acquired may not be integrated successfully and may not prove profitable;

●

the price we pay for any business acquired may overstate the value of that business or otherwise be too high;

●

liabilities we take on through the acquisition may prove to be higher than we expected;

●

we may fail to achieve acquisition synergies; or

●

the focus on the integration of operations of acquired entities may divert management’s attention from the day-to-day operation of our businesses.

Acquisitions and strategic investments and alliances may also require us to integrate and collaborate with a different company culture, management team, business model, business infrastructure and sales and distribution methodology, and assimilate and retain geographically dispersed, decentralized operations and personnel. Depending on the size and complexity of an acquisition, our successful integration of the entity depends on a variety of factors, including introducing new products and meeting revenue targets as expected, the retention of key employees and key customers, increased exposure to certain governmental regulations and compliance requirements and increased costs and use of resources. Further, the integration of acquired businesses is likely to result in our systems and internal controls becoming increasingly complex and more difficult to manage. Any difficulties in the assimilation of acquired businesses into our control system could harm our operating results or cause us to fail to meet our financial reporting obligations.

Even if we are able to successfully integrate acquired businesses, we may not be able to realize the revenue and other synergies and growth that we anticipated from the acquisition in the time frame that we expected, and the costs of achieving these benefits may be higher than what we expected. As a result, the acquisition and integration of acquired businesses may not contribute to our earnings as expected and we may not achieve the other anticipated strategic and financial benefits of such transactions.

Table of Contents

Impairment of our goodwill and other intangible assets has had, and in the future could have, a material non-cash adverse impact on our results of operations.

As of December 31, ~~2024~~ 2025, we had $5122.74 million of goodwill and $~~170~~138.51 million of other intangible assets on our balance sheets. We assess intangible assets for impairment on an annual basis in the fourth quarter or more frequently if we believe indicators of impairment exist. In addition, intangible assets and their related useful lives are reviewed at least annually to determine whether there are any adverse conditions that would indicate the carrying value of these assets may not be recoverable. Our valuation methodology for assessing impairment requires management to make judgments and assumptions based on experience and to rely heavily on projections of future operating performance. Because we operate in highly competitive environments, projections of our future operating results and cash flows may vary significantly from our actual results. We may be required to record non-cash impairment charges with respect to our goodwill or other intangible assets during any period we determine these assets are impaired, which has had, and in the future could have, a material adverse impact on our results of operations. For example, for the year ended December 31, 2024, we recorded non-cash impairment charges of $54.6 million related to the full impairment of the goodwill associated with our MVE reporting unit and $9.2 million related to the impairment of certain trademarks and tradenames.

Table of Contents

Risks Related to Our Technology and Intellectual Property

We rely upon certain critical information systems, including our Cryoportal^® software platform, for the operation of our business; the failure of any critical information system could adversely impact our reputation and future revenues, and we may be required to increase our spending on data and system security.

We rely upon certain critical information systems, including our Cryoportal^® software platform which is used by our customers and business partners to automate the entry of orders, prepare customs documentation and facilitate status and location monitoring of shipped orders while in transit. In addition, the provision of services to our customers and the operation of our networks and systems involve the storage and transmission of significant amounts of proprietary information and sensitive or confidential data, including personal information of customers, employees and others. Our technology infrastructure and critical information systems are subject to damage or interruption from a number of potential sources, including unauthorized intrusions, cyberattacks, software viruses or other malware, natural disasters, power failures, employee error or malfeasances and other events. Despite our best efforts, no cybersecurity or emergency recovery process is failsafe, and if our safeguards fail or our technology infrastructure or critical information systems are compromised, the safety and efficiency of our operations could be materially harmed, our reputation could suffer, and we could face additional costs, liabilities, costly legal challenges.

Cyberattacks, data incidents and breaches in the security of our information systems and networks and of the electronic and confidential information in our possession could materially adversely impact our business, financial condition and results of operations, in addition to our reputation and relationships with our employees, customers, suppliers and business partners.

As part of our normal business activities, we collect and store or have access to certain proprietary confidential, and personal information, including information about our employees, customers, suppliers and business partners, which may be entitled to protection under a number of regulatory regimes. The protection and security of our network systems and our own information, as well as information relating to our employees, customers, suppliers, business partners and others, is vitally important to us. Any failure of us to maintain the security of our network systems and the proprietary, confidential, and personal data in our possession, including via the penetration of our network security and the misappropriation of proprietary, confidential and personal information, could result in costly investigations and remediation, business disruption, damage to our reputation, financial obligations to third parties, fines, penalties, regulatory proceedings and private litigation with potentially large costs, and also result in deterioration in our employees’, customers’, suppliers’ and business partners’ confidence in us and other competitive disadvantages, and thus could have a material adverse effect on our business, financial condition and results of operations.

The frequency, intensity, and sophistication of cyberattacks and data security incidents has significantly increased in recent years and is constant. As with many other businesses, we are continually subject to cyberattacks and the risk of data security incidents. Due to the increased risk of these types of attacks and incidents, we have implemented information technology and data security tools, measures, and processes designed to protect our networks systems, services, and the personal, confidential or proprietary information in our possession, and to ensure an effective response to any cyberattack or data security incident. We also have privacy and data security policies in place that are designed to detect, prevent, and/or mitigate cyberattacks and data security incidents. Whether or not these policies, tools, and measures are ultimately successful, the expenditures could have an adverse impact on our financial condition and results of operations, and divert management’s attention from pursuing our strategic objectives. As newer technologies evolve, we could ~~be exposed to increased risks from cyberattacks, data security events, and data breaches, including those from human error, negligence or mismanagement or from illegal or fraudulent acts.~~

Although we take the security of our network systems and information seriously, there can be no assurance that the security measures we employ will effectively prevent unauthorized persons from obtaining unauthorized access to our systems and information due to the evolving nature and intensity of cyberattacks and threats to data security, in light of new and sophisticated tools and methods used by criminals and cyberterrorists to penetrate and compromise systems, including computer viruses, malware, ransomware, phishing, misrepresentation, social engineering and forgery, which make it increasingly challenging to anticipate, harder to detect, and more difficult to adequately mitigate these risks. While we have cyber security insurance, we may incur significant costs in the event of a successful cyber incident against us or in responding to and recovering from a cyber incident that are not covered by, or exceed the limits of, such insurance. Additionally, the cost and operational consequences of implementing, maintaining and enhancing further data or system protection measures could increase significantly to overcome increasingly intense, complex and sophisticated global cyber threats.20

Table of Contents

be exposed to increased risks from cyberattacks, data security events, and data breaches, including those from human error, negligence or mismanagement or from illegal or fraudulent acts.

Our success depends, in part, on our ability to obtain patent protection for our solutions, preserve our trade secrets, and operate without infringing the proprietary rights of others.

Our policy is to seek to protect our proprietary position by, among other methods, filing United States patent applications related to our technology, inventions and improvements that are important to the development of our business. Our patents or patent applications may be challenged, invalidated or circumvented in the future or the rights granted may not provide a competitive advantage. We intend to vigorously protect and defend our intellectual property. Costly and time-consuming litigation brought by us may be necessary to enforce our patents and to protect our trade secrets and know-how, or to determine the enforceability, scope and validity of the proprietary rights of others.

We also rely upon trade secrets, technical know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect these trade secrets, in part, by entering into confidentiality agreements and inventions assignment and work for hire agreements in connection with employment, consulting, or advisory relationships. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Additionally, our competitors may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our proprietary technology, or we may not be able to meaningfully protect our rights in unpatented proprietary technology.

Our current and potential competitors and other third parties may have or obtain patents or additional proprietary rights that would prevent, limit or interfere with our ability to make, use or sell our solutions either in the United States or internationally. Additionally, we may face assertions of claims by holders of patents alleging that we are infringing upon their patent rights, which claims may be without merit, but may nonetheless result in our incurring substantial costs of defense.

Risks Related to Regulatory and Legal Matters

Complying with certain regulations that apply to shipments using our solutions can limit our activities and increase our cost of operations.

Shipments using our solutions and services are subject to various regulations in the various countries in which we operate. For example, shipments using our solutions may be required to comply with the shipping requirements promulgated by the CDC, the Occupational Safety and Health Organization (“OSHA”), the DOT as well as rules established by the IATA and the ICAO. Additionally, our data logger may be subject to regulation and certification by the FDA, the FCC, and the FAA. We will need to ensure that our solutions and services comply with relevant rules and regulations to make our solutions and services marketable, and in some cases, compliance is difficult to determine. Significant changes in such regulations could require costly changes to our solutions and services or prevent use of our shippers for an extended period of time while we seek to comply with changed regulations. If we are unable to comply with any of these rules or regulations or fail to obtain any required approvals, our ability to market our solutions and services may be adversely affected. In addition, even if we are able to comply with these rules and regulations, compliance can result in increased costs. In either event, our financial results and condition may be adversely affected. We depend on our business partners and unrelated and frequently unknown third-party agents in foreign countries to act on our behalf to complete the importation process and to make delivery of our shippers to the final user. The failure of these third parties to perform their duties could result in damage to the contents of the shipper resulting in customer dissatisfaction or liability to us, even if we are not at fault.

~~Changes in trade policy, tariff and import/export regulations may have a material adverse effect on our business, financial condition and results of operations.~~21

Our international operations and transactions depend upon favorable trade relations between the United States and the foreign countries in which our customers and suppliers have operations. For example, the Trump administration instituted changes in trade policies that included the imposition of higher tariffs on imports into the U.S. and other government regulations affecting trade between the U.S. and other countries where we conduct our business. It may be time consuming and expensive for us to adapt to any changes in U.S. or international social, political, regulatory and economic conditions or in laws and policies governing foreign trade, manufacturing, development and investment in the territories or countries where we currently sell our products or conduct our business. If such changes occur, including as a result of these recent changes, this could adversely affect our business.

Table of Contents

Changes in trade policy, tariff and import/export regulations may have a material adverse effect on our business, financial condition and results of operations.

Our international operations and transactions depend upon favorable trade relations between the United States and the foreign countries in which our customers and suppliers have operations. It may be time consuming and expensive for us to adapt to any changes in U.S. or international social, political, regulatory and economic conditions or in laws and policies governing foreign trade, manufacturing, development and investment in the territories or countries where we currently sell our products or conduct our business. If such changes occur, this could adversely affect our business and results of operations.

For example, beginning in 2025, the current Trump administration instituted changes in trade policies that included the imposition of higher tariffs on imports into the U.S. and other government regulations affecting trade between the U.S. and other countries where we conduct our business, such as China and the European Union (EU), among others. In response, several countries have imposed, or threatened to impose, reciprocal tariffs on imports from the U.S. and other retaliatory measures. Various modifications to the U.S. tariffs have been announced and further changes could be made in the future, which may include additional sector-based tariffs or other measures. The ultimate impact remains uncertain and will depend on several factors, including whether additional or incremental U.S. tariffs or other measures are announced or imposed, to what extent other countries implement tariffs or other retaliatory measures in response, and the overall magnitude and duration of these measures. If disputes and conflicts further escalate, actions by governments in response could be significantly more severe and restrictive.

We, along with our customers, are subject to various international governmental regulations. Compliance with or changes in such regulations may cause us to incur significant expenses, and if we fail to maintain satisfactory compliance with certain regulations, we may be forced to recall products and cease their manufacture and distribution, and we could be subject to civil or criminal penalties.

We, along with our customers, are subject to various significant international, federal, state and local regulations, including but not limited to regulations in the areas of health and safety, packaging, product content, employment, labor and immigration, import/export controls, trade restrictions and anti-competition. In addition, as a global organization, we are subject to data privacy and security laws, regulations, and customer-imposed controls in numerous jurisdictions as a result of having access to and processing confidential, personal, sensitive and/or patient health data in the course of our business. The EU’s General Data Protection Regulation (“GDPR”), which became effective in May 2018, applies to our activities related to products and services that we offer to EU customers and workers. The GDPR established new requirements regarding the handling of personal data and includes significant penalties for non-compliance (including possible fines of up to 4 percent of total company revenue). Other governmental authorities around the world have passed or are considering similar types of legislative and regulatory proposals concerning data protection. Each of these privacy, security and data protection laws and regulations could impose significant limitations and increase our cost of providing our products and services where we process end user personal data and could harm our results of operations and expose us to significant fines, penalties and other damages.

We must also comply with complex foreign and U.S. laws and regulations, such as the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act, and other local laws prohibiting corrupt payments to governmental officials, anti-competition regulations and sanctions imposed by the U.S. Office of Foreign Assets Control and other similar laws and regulations. Violations of these laws and regulations could result in fines and penalties, criminal sanctions, restrictions on our business conduct and on our ability to offer our products in one or more countries, and could also materially affect our brand, our ability to attract and retain employees, our international operations, our business and our operating results. Although we have implemented policies and procedures designed to ensure compliance with these laws and regulations, there can be no assurance that our employees, contractors, or agents will not violate our policies.

These regulations are complex, change frequently and have tended to become more stringent over time. We may be required to incur significant expenses to comply with these regulations or to remedy any violations of these regulations. Any failure by us to comply with applicable government regulations could also result in the cessation of our operations or portions of our operations, product recalls or impositions of fines and restrictions on our ability to carry on or expand our operations. In addition, because many of our products are regulated or sold into regulated industries, we must comply with additional regulations in marketing our products. Any significant change in these regulations could reduce demand for our products, force us to modify our products to comply with new regulations or increase our costs of producing these products. If demand for our products is adversely affected or our costs increase, our operating results and business would suffer.

Table of Contents

We are subject to regulation by the FDA or certain similar foreign regulatory agencies, and failure to comply with such regulations could harm our reputation, business, financial condition and results of operations.

Certain of our operations are subject to regulation by the FDA or similar foreign regulatory agencies. In addition, we may in the future develop products that are subject to regulation as medical devices by the FDA and similar foreign regulatory agencies. For example, we are aware that China’s National Medical Products Administration has had discussions that may require certain of our products to be registered as Class II medical devices. The regulations enforced by the FDA and similar foreign regulatory agencies govern a wide variety of product-related activities, including the research, development, testing, manufacture, quality control, approval, clearance, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing, post-approval monitoring and reporting, pricing, and export and import of pharmaceutical products. If we or any of our customers, suppliers or distributors fail to comply with FDA and other applicable foreign regulatory requirements or are perceived to potentially have failed to comply, we may face, among other things, warning letters; adverse publicity affecting both us and our customers; investigations or notices of non-compliance, fines, injunctions, and civil penalties; import or export restrictions; partial suspensions or total shutdown of production facilities or the imposition of operating restrictions; increased difficulty in obtaining required FDA clearances or approvals or foreign equivalents; seizures or recalls of our products or those of our customers; or the inability to sell our products and services. Any such FDA or other foreign regulatory agency actions could disrupt our business and operations, lead to significant remedial costs and have a material adverse impact on our financial position and results of operations.

Table of Contents

Risks Related to Our Financial Condition

Historically, we have incurred significant losses and we may continue to incur losses in the future.

WeAlthough ~~incurred~~we agenerated net ~~loss~~income of $78.3 million for the year ended December 31, 2025, we have historically incurred significant losses, including losses of $114.8 million and $99.6 million million for the years ended December 31, 2024 and 2023, ~~respectively~~resepectively. As of December 31, ~~2024~~2025, we had an accumulated deficit of $~~757~~688.29 million. In order to achieve and sustain revenue growth in the future, we must expand our market presence and revenues from existing and new customers. We may continue to incur losses in the future and may never generate revenues sufficient to become profitable or to sustain profitability. Continuing losses may impair our ability to raise the additional capital required to continue and expand our operations.

Our indebtedness and liabilities could limit the cash flow available for our operations and expose us to risks that could adversely affect our business, financial condition and results of operations.

We have a substantial amount of indebtedness. As of December 31, ~~2024~~2025, we had approximately $~~301~~262.64 million of indebtedness and other liabilities, including trade payables, on a consolidated basis. We may also incur additional indebtedness to meet future financing needs. Our indebtedness could have significant negative consequences for our security holders and our business, results of operations and financial condition by, among other things:

●

increasing our vulnerability to adverse economic and industry conditions;

●

limiting our ability to obtain additional financing;

●

requiring the dedication of a substantial portion of our cash flow from operations to service our indebtedness, which will reduce the amount of cash available for other purposes;

●

limiting our flexibility to plan for, or react to, changes in our business;

●

diluting the interests of our existing stockholders as a result of issuing shares of our common stock upon conversion of any convertible indebtedness; and

●

placing us at a possible competitive disadvantage with competitors that are less leveraged than us or have better access to capital.

Our business may not generate sufficient funds, and we may otherwise be unable to maintain sufficient cash reserves, to pay amounts due under our indebtedness, including our outstanding ~~convertible senior notes (collectively, the “Convertible Senior Notes”) consisting of our 3.00% convertible senior notes due 2025 (the “2025 Convertible Senior Notes”) and our~~ 0.75% convertible senior notes due 2026 (the “2026 Convertible Senior Notes”), and our cash needs may increase in the future. In addition, any future indebtedness that we may incur may contain financial and other restrictive covenants that limit our ability to operate our business, raise capital or make payments under our other indebtedness. If we fail to comply with these covenants or to make payments under our indebtedness when due, then we would be in default under that indebtedness, which could, in turn, result in that and our other indebtedness becoming immediately payable in full.

Table of Contents

Risks Related to Our Preferred Stock

The issuance of shares of our Series C Preferred Stock reduces the relative voting power of holders of our common stock, dilutes the ownership of such holders, and may adversely affect the market price of our common stock.

In connection with financing our acquisition of MVE Biological Solutions, on October 1, 2020, we completed the sale of 250,000 shares of a newly designated Series C Convertible Preferred Stock, par value $0.001 (“Series C Preferred Stock”), at a price of $1,000 per share, the original purchase price, to funds affiliated with The Blackstone Group Inc., or Blackstone. The holders of our Series C Preferred Stock are entitled to dividends at a rate of 4.0% per annum, paid-in-kind, accruing daily and paid quarterly in arrears and are also entitled to participate in dividends declared or paid on the common stock on an as-converted basis.

Each holder of our Series C Preferred Stock (collectively, the “Series C Preferred Stockholders”) has the right, at its option, to convert its Series C Preferred Stock, in whole or in part, into common stock at a conversion price equal to $38.6152 per share subject to certain customary adjustments. Subject to certain conditions, we may, at our option, require conversion of all of the outstanding shares of Series C Preferred Stock to common stock if, for at least 20 trading days during the 30 consecutive trading days immediately preceding the date we notify the Series C Preferred Stockholders of the election to convert, the closing price of our common stock is at least 150% of the conversion price. On February 5, 2021, the Company received a waiver and conversion notice from Blackstone Freeze Parent L.P. and Blackstone Tactical Opportunities Fund – FD L.P. and converted an aggregate of 50,000 shares of the Series C Preferred Stock, resulting in the issuance of an aggregate of 1,312,860 shares of common stock.

Table of Contents

L.P. and Blackstone Tactical Opportunities Fund – FD L.P. and converted an aggregate of 50,000 shares of the Series C Preferred Stock, resulting in the issuance of an aggregate of 1,312,860 shares of common stock.

Any subsequent conversion of shares of the Series C Preferred Stock to shares of our common stock would further dilute the ownership interest of existing holders of our common stock, and any sale in the public market of shares of our common stock issuable upon conversion of the Series C Preferred Stock could adversely affect prevailing market prices of our common stock. Additionally, we granted the Series C Preferred Stockholders customary registration rights in respect of their securities. These registration rights facilitate the resale of our common stock issuable upon conversion of such securities into the public market, and any such resale would increase the number of shares of our common stock available for public trading.

The Series C Preferred Stockholders may exercise influence over us, including through their right to nominate for election one member to our board of directors.

The Series C Preferred Stockholders are generally entitled to vote with the holders of the shares of common stock on all matters submitted for a vote of holders of shares of Common Stock (voting together with the holders of shares of common stock as one class) on an as-converted basis, subject to certain NASDAQ voting limitations, if applicable. Additionally, the consent of the holders of a majority of the outstanding shares of Series C Preferred Stock is required for so long as any shares of the Series C Preferred Stock remain outstanding for (i) amendments to the Company’s organizational documents that have an adverse effect on the holders of Series C Preferred Stock and (ii) issuances by the Company of securities that are senior to, or equal in priority with, the Series C Preferred Stock, including any shares of the Company’s Class A Preferred Stock or Class B Preferred Stock. In addition, for so long as 75% of the Series C Preferred Stock issued in connection with the related securities purchase agreement remains outstanding, the consent of the holders of a majority of the outstanding shares of Series C Preferred Stock will be required for (i) any voluntary dissolution, liquidation, bankruptcy, winding up or deregistration or delisting and (ii) incurrence by Cryoport of any indebtedness unless our ratio of debt to LTM EBITDA (as defined in the Certificate of Designation of the Series C Preferred Stock) would be less than a ratio of 5-to-1 on a pro forma basis giving effect to such incurrence and the use of proceeds therefrom.

Additionally, an affiliate of Blackstone has the right to nominate for election one member to our board of directors for so long as certain parties hold 66.67% of the Series C Preferred Stock issued in the Blackstone financing transaction. If elected, the director designated by Blackstone is entitled to serve on committees of our board of directors, subject to applicable law and NASDAQ rules. Notwithstanding the fact that all directors will be subject to fiduciary duties to us and to applicable law, the interests of the director designated by Blackstone may differ from the interests of our security holders as a whole or of our other directors.

As a result, the Series C Preferred Stockholders have the ability to influence the outcome of certain matters affecting our governance and capitalization. The sponsors of the Series C Preferred Stockholders are in the business of making or advising on investments in companies, including businesses that may directly or indirectly compete with certain portions of our business, and they may have interests that diverge from, or even conflict with, those of our other shareholders. They may also pursue acquisition opportunities that may be complementary to our business, and, as a result, those acquisition opportunities may not be available to us. Our obligations to the Series C Preferred Stockholders could also limit our ability to obtain additional financing or increase our borrowing costs, which could have an adverse effect on our financial condition.

Table of Contents

Our obligations to the Series C Preferred Stockholders could also limit our ability to obtain additional financing or increase our borrowing costs, which could have an adverse effect on our financial condition.

Our Series C Preferred Stock has rights, preferences, and privileges that are not held by, and are preferential to, the rights of holders of our common stock, which could adversely affect our liquidity and financial condition.

The Series C Preferred Stockholders have the right under the Certificate of Designation of the Series C Preferred Stock to receive a liquidation preference entitling them to be paid an amount per share equal to the greater of (i) the original purchase price, plus all accrued and unpaid dividends and (ii) the amount that the holder would have been entitled to receive at such time if the Series C Preferred Stock were converted into common stock. In addition, the Series C Preferred Stockholders are entitled to dividends at a rate of 4.0% per annum, paid-in-kind, accruing daily and paid quarterly in arrears. The Series C Preferred Stockholders are also entitled to participate in dividends declared or paid on the common stock on an as-converted basis.

Table of Contents

Risks Related to Ownership of Our Common Stock

Certain of our existing stockholders own and have the right to acquire a substantial number of shares of common stock.

As of February 2827, ~~2025~~2026, our directors, executive officers and beneficial owners of 510% or more of our outstanding common stock beneficially owned 3812,~~410~~203,~~042~~384 shares of common stock assuming their conversion of all outstanding Series C Preferred Stock and their exercise of all outstanding options held by them that are exercisable within 60 days of February 2827, ~~2025~~2026, which represented approximately 7123.10% of our outstanding common stock. As such, the concentration of beneficial ownership of our common stock may have the effect of delaying or preventing a change in control of Cryoport and may adversely affect the voting or other rights of other holders of our common stock.

Future sales of shares of our common stock may depress the price of our shares and be dilutive to our existing stockholders.

Future issuances of shares of our common stock or the availability of shares for resale in the open market may decrease the market price per share of our common stock. As of February 2827, ~~2025~~2026, there were 49,~~910~~856,~~391~~135 shares of our common stock outstanding. Substantially all of these shares of common stock are eligible for trading in the public market. The market price of our common stock may decline if our stockholders sell a large number of shares of our common stock in the public market, or the market perceives that such sales may occur.

As of December 31, ~~2024~~2025, we could also issue up to an additional 76,~~841~~782,~~565~~638 shares of our common stock upon exercise of outstanding options and vesting of restricted stock units and 2,~~896~~437,~~124~~831 shares of our common stock reserved for future issuance under our stock incentive plans. In addition, we reserved ~~599,953 shares of our common stock issuable upon conversion of the 2025 Convertible Senior Notes,~~ 1,583,280 shares of our common stock issuable upon conversion of the 2026 Convertible Senior Notes, and 6,~~133~~382,~~876~~937 shares of our common stock issuable upon conversion of our Series C Preferred Stock. The exercise of any options or vesting of restricted stock units, as well as the issuance of our common stock upon conversion of the 2026 Convertible Senior Notes, the Series C Preferred Stock, or in connection with acquisitions and other issuances of our common stock, could have an adverse effect on the market price of the shares of our common stock and dilute our existing stockholders.

To the extent that we raise additional funds through the sale of equity or convertible debt securities, the issuance of such securities will result in dilution to our stockholders. Further, investors purchasing shares or other securities in the future could have rights superior to existing stockholders.

Our stock price has been and will likely continue to be volatile.

The market price of our common stock has been highly volatile and could fluctuate widely in price in response to various factors, many of which are beyond our control, including, but not limited to technological innovations or new solutions and services by us or our competitors, additions or departures of key personnel, sales of our common stock, our ability to execute our business plan, our operating results being below expectations, loss of any strategic relationship, industry developments, economic and other external factors and period-to-period fluctuations in our financial results.

In addition, the securities markets have from time-to-time experienced significant price and volume fluctuations that are unrelated to the operating performance of companies. These market fluctuations may also materially and adversely affect the market price of our common stock.

Table of Contents

We have not paid dividends on our common stock in the past and do not expect to pay dividends in the foreseeable future. Any return on investment may be limited to the value of our common stock.

We have never paid cash dividends on our common stock and do not anticipate paying cash dividends in the foreseeable future. Any future determination to pay dividends will be at the discretion of our board of directors, subject to compliance with covenants in current and future agreements governing our indebtedness, and will depend on our results of operations, financial condition, capital requirements, contractual arrangements and other factors that our board of directors deems relevant. If we do not pay dividends, our common stock may be less valuable because a return on your investment will only occur if the price of our common stock appreciates.

Table of Contents

Our Articles of Incorporation allows our board of directors to issue up to 2,500,000 shares of “blank check” preferred stock.

Our Articles of Incorporation allows our board of directors to issue up to 2,500,000 shares of “blank check” preferred stock, without action by our stockholders. We have designated 800,000 shares as Class A Preferred Stock, 585,000 shares as Class B Preferred Stock and 250,000 shares of Series C Preferred Stock, of which 200,000 shares of Series C Preferred Stock are issued and outstanding at February 2327, ~~2024~~2026. See “—Risks Related to Our Preferred Stock” for additional information regarding our outstanding Series C Preferred Stock. Without limiting the foregoing, (i) such shares of preferred stock could have liquidation rights that are senior to the liquidation preference applicable to our common stock and Preferred Stock, (ii) such shares of preferred stock could have voting or conversion rights, which could adversely affect the voting power of the holders of our common stock and preferred stock and (iii) the ownership interest of holders of our common stock will be diluted following the issuance of any such shares of preferred stock. In addition, the issuance of such shares of blank check preferred stock could have the effect of discouraging, delaying or preventing a change of control of our Company.

Provisions in our bylaws and Nevada law might discourage, delay or prevent a change of control of our Company or changes in our management and, as a result, may depress the trading price of our common stock.

Provisions of our bylaws and Nevada law may discourage, delay or prevent a merger, acquisition or other change in control that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares of our common stock. The relevant bylaw provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management. These provisions include advance notice requirements for stockholder proposals and nominations, and the ability of our board of directors to make, alter or repeal our bylaws.

In addition, Section 78.411, et seq. of the Nevada Revised Statutes prohibits a publicly-held Nevada corporation from engaging in a business combination with an interested stockholder (generally defined as a person which together with its affiliates owns, or within the last two years has owned, 10% of our voting stock) for a period of two years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.

The existence of the foregoing provisions and other potential anti-takeover measures could limit the price that investors might be willing to pay in the future for shares of our common stock. They could also deter potential acquirers of our Company, thereby reducing the likelihood that you could receive a premium for your common stock in an acquisition.

General Risk Factors

Our ability to grow and compete in our industry will be hampered if we are unable to retain the continued service of our key professionals or to identify, hire and retain additional qualified professionals.

Our success in implementing our business strategy depends largely on the skills, experience and performance of key members of our executive management team and others in key management positions. The collective efforts of each of these persons working as a team will be critical to us as we continue to develop our technologies, tests and engineering and development and sales programs. As a result of the difficulty in locating qualified new management, the loss or incapacity of existing members of our executive management team could adversely affect our operations. If we were to lose one or more of these key employees, we could experience difficulties in finding qualified successors, competing effectively, developing our technologies and implementing our business strategy. We do not maintain “key person” insurance on any of our employees.

In addition, a critical factor to our business is our ability to attract and retain qualified professionals including key employees and consultants. We are continually at risk of losing current professionals or being unable to hire additional professionals as needed. If we are unable to attract new qualified employees, our ability to grow will be adversely affected. If we are unable to retain current employees or strategic consultants, our financial condition and ability to maintain operations may be adversely affected.

3426

Table of Contents

we are unable to attract new qualified employees, our ability to grow will be adversely affected. If we are unable to retain current employees or strategic consultants, our financial condition and ability to maintain operations may be adversely affected.

If equity research analysts do not publish research or reports about our business or if they issue unfavorable commentary or downgrade our common stock, the price of our common stock could decline.

The trading market for our common stock relies in part on the research and reports that equity research analysts publish about us and our business. We do not control these analysts. The price of our common stock could decline if one or more equity analyst downgrades our stock or if analysts downgrade our stock or issue other unfavorable commentary or cease publishing reports about us or our business.

ITEM 1B. Unresolved Staff Comments

Not applicable.

ITEM 1C. Cybersecurity

Risk Management and Strategy

We identify and assess material risks from cybersecurity threats to our information systems and the information residing in our information systems by monitoring and evaluating our threat environment on an ongoing basis using various methods including, for example, using manual and automated tools, subscribing to reports and services that identify cybersecurity threats, analyzing reports of threats and threat actors, conducting scans of the threat environment, and conducting risk assessments.

We manage material risks from cybersecurity threats to our information systems and the information residing in our information systems through various processes and procedures, including, depending on the environment, risk assessments, incident detection and response, vulnerability management, disaster recovery and business continuity plans, internal controls within our accounting and financial reporting functions, encryption of data, network security controls, access controls, physical security, asset management, systems monitoring, and employee training. We engage third-party service providers to provide some of the resources used in our information systems and some third-party service providers have access to information residing in our information systems. With respect to such third parties, we seek to engage reliable, reputable service providers that maintain cybersecurity programs. Depending on the nature and extent of the services provided, the sensitivity and quantity of information processed, and the identity of the service provider, our processes may include conducting due diligence on the cybersecurity practices of such provider and contractually imposing cybersecurity related obligations on the provider.

We also engage third parties to assist with cybersecurity risk assessments, incident detection and response, vulnerability management, systems monitoring, and employee training.

We are not aware of any risks from cybersecurity threats, including as a result of any cybersecurity incidents, which have materially affected or are reasonably likely to materially affect Cryoport, including our business strategy, results of operations, or financial condition. Refer to “Part I, Item 1A—Risk Factors—Risks Related to Our Technology and Intellectual Property—Cyberattacks, data incidents and breaches in the security of our information systems and networks and of the electronic and confidential information in our possession could materially adversely impact our business, financial condition and results of operations, in addition to our reputation and relationships with our employees, customers, suppliers and business partners” in this Form 10-K for additional discussion about cybersecurity-related risks.

Governance

Our board of directors holds oversight responsibility over Cryoport’s risk management and strategy, including material risks related to cybersecurity threats. This oversight is executed directly by our board of directors and through its audit committee. Our audit committee oversees the management of Cryoport’s major financial risk exposures, the steps management has taken to monitor and control such exposures, and the process by which risk assessment and management is undertaken and handled, which would include cybersecurity risks, in accordance with its charter. The audit committee holds quarterly meetings and receives periodic reports from management regarding risk management, including major financial risk exposures from cybersecurity threats or incidents.

Within management, our Chief Information Security Officer is primarily responsible for assessing and managing our material risks from cybersecurity threats and ~~keep~~keeping the senior executive officers informed on a regular basis of the identification, assessment, and management of cybersecurity risks and of any cybersecurity incidents. Our Chief Information Security Officer is supported by the Chief Information Officer or Information Technology Director, as applicable, of our business units with respect to the assessment and management of our material risks from cybersecurity risks on a day-to-day basis. Such management personnel have prior experience and training in managing information systems and cybersecurity matters and participate in ongoing training programs.

3527

Table of Contents

Chief Information Officer or Information Technology Director, as applicable, of our business units with respect to the assessment and management of our material risks from cybersecurity risks on a day-to-day basis. Such management personnel have prior experience and training in managing information systems and cybersecurity matters and participate in ongoing training programs.

ITEM 2. Properties

Our principal executive office is located in Brentwood, Tennessee. We lease or own various corporate, global logistics and supply chain centers, biostorage, manufacturing, and research and development facilities at ~~over~~20 50 sites across the Americas, EMEA and APAC regions.

The following table summarizes our principal facilities and other materially important physical properties as of December 31, ~~2024~~2025:

Location Ownership Use Brentwood, Tennessee Leased Principal Executive Office Irvine, California Leased Administrative, Global Supply Chain Center, and Research and Development Center Morris Plains, New Jersey Leased Global Supply Chain Center, ~~Administrative,~~ and ~~Logistics~~Administrative ~~Center~~ Houston, Texas Leased Administrative, Global Supply Chain Center and Biostorage Center ~~Hoofddorp,~~Louvres ~~the~~(Paris ~~Netherlands~~Area), France Leased Global Supply Chain Center ~~Ball Ground~~Liège, ~~Georgia~~Belgium Leased ~~Administrative~~Bioservices, ~~Manufacturing~~Cryopreservation, and Research and Development Center ~~New Prague~~Hoofddorp, ~~Minnesota~~the Netherlands ~~Owned~~Leased ~~Manufacturing~~Global ~~Chengdu~~Logistics Center Ball Ground, ~~China~~Georgia ~~Owned~~Leased Administrative, ~~and~~ Manufacturing ~~Clermont-Ferrand~~, ~~France~~and Research ~~Owned~~and Development ~~Administrative~~Center ~~and~~New ~~Global~~Prague, ~~Supply~~Minnesota ~~Chain~~ ~~Center~~Owned ~~Lisbon~~ Manufacturing Chengdu, ~~Portugal~~China ~~Leased~~Owned Administrative ~~Tremblay~~and enManufacturing ~~France~~Clermont-Ferrand, France ~~Leased~~Owned Administrative and ~~Global Logistics Center~~Bioservices

We believe that these facilities are adequate, suitable and of sufficient capacity to support our immediate needs.

ITEM 3. Legal Proceedings

In the ordinary course of business, we are at times subject to various legal proceedings and disputes, including product liability claims. We currently are not aware of any such legal proceedings or claim that we believe will have, individually or in the aggregate, a material adverse effect on our business, operating results or cash flows. It is our practice to accrue for open claims based on our historical experience and available insurance coverage.

ITEM 4. Mine Safety Disclosures

Not applicable

Table of Contents

PART II

ITEM 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Common Stock

As of February 2827, ~~2025~~2026, there were 49,~~910~~856,~~391~~135 shares of common stock outstanding and ~~153~~149 stockholders of record. Because many shares of our common stock are held by brokers and other institutions on behalf of stockholders, we are unable to estimate the total number of stockholders represented by these stockholders of record.

Market Information

The Company’s common stock is currently listed on the NASDAQ Capital Market and is traded under the symbol “CYRX.”

Table of Contents

Stock Performance Graph (1)

The graph below compares Cryoport’s cumulative 5-year total shareholder return on common stock with the cumulative total returns of the Russell 3000 Index and S&P 1500 Life Sciences Tools & Services Industry Index. The graph tracks the performance of a $100 investment in our common stock and in each index from December 31, ~~2019~~2020 to December 31, 2025 ~~2024~~ and assumes that, as to such indices, dividends were reinvested. We have never paid cash dividends on our common stock. The stock price performance on the following graph is not necessarily indicative of future stock price performance.

COMPARISON OF 5 YEAR CUMULATIVE TOTAL RETURN*

Among Cryoport, Inc., the Russell 3000 Index and the S&P 1500 Life Sciences Tools & Services Industry Index

*$100 invested on 12/31/1920 in Cryoport common stock or applicable index. Fiscal year ending December 31.

(1)

The information contained in the performance graph shall not be deemed to be “soliciting material” or to be “filed” with the SEC, and such information shall not be incorporated by reference into any future filing under the Securities Act or the Exchange Act, except to the extent that Cryoport specifically incorporates it by reference into such filing.

Table of Contents

Dividends

No dividends on common stock have been declared or paid by the Company. The Company intends to employ all available funds for the development of its business and, accordingly, does not intend to pay any cash dividends in the foreseeable future. Any future determination to pay dividends will be at the discretion of our board of directors, subject to compliance with covenants in current and future agreements governing our indebtedness, and will depend on our results of operations, financial condition, capital requirements, contractual arrangements and other factors that our board of directors deems relevant.

Recent Sale of Unregistered Securities

None.

Table of Contents

Issuer Purchases of Equity Securities

None.


					Maximum
					Number (or
				Total Number of	Approximate
				Shares (or Units)	Dollar Value) of
				Purchased as	Shares (or Units)
				Part of Publicly	that May Yet Be
	Total Number of	Average Price		Announced	Purchased
	Shares (or Units)	Paid per Share		Plans or	Under the Plans
Period	Purchased ⁽¹⁾	(or Unit)		Programs ⁽²⁾	or Programs
October 1, 2025 through October 31, 2025	—		—	—	$	65,936,710
November 1, 2025 through November 30, 2025	228,994	$	8.73	228,994	$	63,936,770
December 1, 2025 through December 31, 2025	—		—	—	$	63,936,770
Total	228,994			228,994

(1) These shares were returned to the status of authorized but unissued shares of common stock.

(2) On March 11, 2022, the Company announced that its Board of Directors authorized a repurchase program through December 31, 2025, authorizing the repurchase of common stock and/or convertible senior notes in the amount of up to $100.0 million from time to time, on the open market or otherwise, in such quantities, at such prices, and in such manner as determined by the Company’s management at its discretion (the “2022 Repurchase Program”). The 2022 Repurchase Program expired on December 31, 2025 pursuant to its terms.

On August 6, 2024, the Company announced that its Board of Directors authorized a repurchase program through December 31, 2027, authorizing the repurchase of common stock and/or convertible senior notes in the amount of up to $200.0 million from time to time, on the open market or otherwise, in such quantities, at such prices, and in such manner as determined by the Company’s management at its discretion (the “2024 Repurchase Program” and together with the 2022 Repurchase Program, the “Repurchase Programs”). The authorized amount under the 2024 Repurchase Program was in addition to the 2022 Repurchase Program and did not modify the 2022 Repurchase Program. The size and timing of any repurchases under the 2024 Repurchase Program will depend on a number of factors, including the market price of the Company’s common stock, general market and economic conditions, and applicable legal requirements.

ITEM 6. [Reserved]

ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of our operations should be read in conjunction with our consolidated financial statements and related notes included elsewhere in this Form 10-K. Our actual results could differ materially from those contained in forward-looking statements due to a number of factors. See “Forward-Looking Statements” in this Form 10-K.

For further discussion and analysis regarding our financial condition and results of operations for the year ended December 31, ~~2023~~2024 as compared to the year ended December 31, ~~2022~~2023, refer to “Part II, Item 7 - Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2023~~2024 filed with the SEC on March 137, ~~2024~~2025.

Table of Contents

General Overview

~~Cryoport~~We isare a leading global provider of ~~innovative~~integrated, ~~products~~temperature-controlled ~~and~~supply ~~services~~chain ~~supporting~~solutions for the life sciences, inwith ~~the~~a ~~biopharma/pharma,~~strong ~~animal~~focus ~~health,~~on ~~and~~supporting ~~reproductive~~the ~~medicine~~rapidly ~~markets.~~growing ~~Our~~cell ~~mission~~and isgene totherapy ~~enable~~(“CGT”) ~~the~~market. ~~future~~Our ofsolutions ~~medicine~~are ~~for~~purpose-built to support a ~~new~~broad ~~era~~range of global life sciences. ~~With~~markets, ~~over~~including 50biopharmaceutical ~~strategic~~and ~~locations~~pharmaceutical ~~covering~~companies, the ~~Americas,~~animal ~~EMEA~~health ~~(Europe~~markets, ~~the~~reproductive ~~Middle East and Africa) and APAC (Asia Pacific)~~medicine, ~~Cryoport's~~academic ~~global platform provides mission-critical bio-logistics~~institutions, ~~bio-storage~~research, ~~bio-processing,~~ and ~~cryogenic~~government ~~systems to over 3,000 customers worldwide~~agencies. Our ~~platform of~~ solutions ~~and~~help ~~services, together with~~ our ~~global~~customers ~~team~~ensure ofthe ~~over 1~~safe,~~100~~ ~~dedicated~~compliant ~~colleagues~~storage, ~~delivers~~handling, aand ~~unique~~delivery ~~combination~~ of ~~innovative~~high ~~supply~~value, ~~chain~~temperature ~~technologies~~sensitive ~~and~~biological ~~services through our industry-leading brands~~materials, including ~~Cryoport~~cell ~~Systems,~~and ~~MVE~~gene ~~Biological~~therapies ~~Solutions, CRYOPDP,~~ and ~~CRYOGENE~~immunotherapies.

Our corporate headquarters, located in Nashville, Tennessee, is complemented by global sites in the Americas, EMEA (Europe, the Middle East, and Africa), and APAC (Asia-Pacific), including locations in the United States, United Kingdom, France, the Netherlands, Belgium, Germany, Japan, and China.

See the “Business” section in Part I, Item 1 of this Form 10-K for additional information.

Impact of Inflation

Inflation generally impacts us by increasing our costs of labor, material, transportation and pricing from third party manufacturers. ~~While~~The ~~the~~ rates of inflation have not had a material impact on our financial statements in the past~~, we have seen some impact on gross margins in 2023 and 2022~~. Based on the current economic outlook, inflationary pressures could affect our financial performance in the future if cost increases cannot be offset by net realized annual price increases and productivity gains.

Segment Reporting

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker (“CODM”) in making decisions regarding resource allocation and assessing performance. The CODM is the Company’s Chief Executive Officer.

We have two reportable segments: Life Sciences Services and Life Sciences Products. The Company’s Life Sciences Services reportable segment, which aggregates two operating segments (BioLogistics and BioStorage/BioServices), provides temperature-controlled logistics, biostorage and bioservices within the life science industry through direct sales. Cryopreservation services are included in the BioLogistics operating segment. Revenue from the Life Sciences Services reportable segment is primarily comprised of Life Sciences Services revenue, but also includes certain immaterial revenue from the sale of accessories that constitute Life Sciences Products revenue. The Company’s Life Sciences Products reportable segment manufactures and sells cryogenic systems, such as freezers and cryogenic dewars and related ancillary accessories used in the storage and transport of life science commodities through direct sales or a distribution network. Revenue from this reportable segment is exclusively Life Sciences Products revenue. See Note 19 – Segment Reporting to our consolidated financial statements included under Part II, Item 8 “Financial Statements and Supplementary Data” for additional information about our segments.

Critical Accounting Policies and Estimates

Our discussion and analysis of our consolidated financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in conformity with accounting principles generally accepted in the U.S., or U.S. GAAP. While our significant accounting policies are more fully described in the notes to our consolidated financial statements, we have identified the policies and estimates below as being critical to our business operations and the understanding of our results of operations. These policies require management’s most difficult, subjective or complex judgements, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. The impact of and any associated risks related to these policies on our business operations are discussed throughout “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” including in the “Results of Operations” section, where such policies affect our reported and expected financial results. Although we believe that our estimates, assumptions, and judgements are reasonable, they are based upon information presently available. Actual results may differ significantly from these estimates under different assumptions, judgments, or conditions.

38The SEC defines critical accounting policies as those that are, in management’s view, most important to the portrayal of our financial condition and results of operations and most demanding of our judgment. We consider the following policies and estimates to be critical to an understanding of our consolidated financial statements and the uncertainties associated with the complex judgments made by us that could impact our results of operations, financial position and cash flows: Revenue Recognition, Discontinued

Table of Contents

~~While our significant accounting policies are more fully described in the notes to our consolidated financial statements~~Operations, weIntangible ~~have~~Assets ~~identified the policies~~ and ~~estimates~~Goodwill, ~~below~~Convertible asSenior ~~being~~Notes, ~~critical~~Stock-based toCompensation, ~~our business operations~~ and ~~the~~Income ~~understanding of our results of operations~~Taxes. ~~These~~See ~~policies~~Note ~~require~~2 ~~management’s~~– ~~most~~Summary ~~difficult, subjective or complex judgements, often as a result~~ of ~~the~~Significant ~~need~~Accounting Policies to ~~make~~our ~~estimates~~accompanying ~~about~~consolidated ~~the~~financial ~~effect~~statements ofincluded ~~matters~~under ~~that~~Part ~~are~~II, ~~inherently~~Item ~~uncertain.~~8 ~~The impact of and any associated risks related to these policies on our business operations are discussed throughout~~ “~~Management’s~~Financial ~~Discussion~~Statements and ~~Analysis~~Supplementary ~~of Financial Condition,~~Data” ~~including~~for ina ~~the~~description ~~“Results~~ of ~~Operations”~~our ~~section,~~critical ~~where~~accounting ~~such~~ policies ~~affect our reported~~ and ~~expected financial results. Although we believe that our~~ estimates~~, assumptions, and judgements are reasonable, they are based upon information presently available~~. ~~Actual results may differ significantly from these estimates under different assumptions, judgments, or conditions.~~

The SEC defines critical accounting policies as those that are, in management’s view, most important to the portrayal of our financial condition and results of operations and most demanding of our judgment. We consider the following policies and estimates to be critical to an understanding of our consolidated financial statements and the uncertainties associated with the complex judgments made by us that could impact our results of operations, financial position and cash flows: Revenue Recognition, Business Combinations, Intangible Assets and Goodwill, Convertible Senior Notes, Stock-based Compensation, and Income Taxes. See Note 2: “Summary of Significant Accounting Policies” of our accompanying consolidated financial statements for a description of our critical accounting policies and estimates.

Revenue Recognition

Revenues are recognized when control is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods and services. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied.

Performance Obligations

At contract inception, an assessment of the goods and services promised in the contracts with customers is performed and a performance obligation is identified for each distinct promise to transfer to the customer a good or service (or bundle of goods or services). To identify the performance obligations, the Company considers all of the goods or services promised in the contract regardless of whether they are explicitly stated or are implied by customary business practices. Revenue is recognized when our performance obligation has been met. The Company considers control to have transferred upon delivery because the Company has a present right to payment at that time since the Company has satisfied its performance obligations related to the successful delivery. In instances where the customer has elected to use their own ~~freight~~courier services, revenue is recognized upon delivery of the shipper to the customer.

For arrangements under which the Company provides biological specimen storage services and logistics support and management to the customer, the Company satisfies its performance obligations as those services are performed whereby the customer simultaneously receives and consumes the benefits of such services under the agreement.

Revenue generated from short-term logistics and engineering consulting services provided to customers is recognized when the Company satisfies the contractually defined performance obligations. When a contract includes multiple performance obligations, the contract price is allocated among the performance obligations based upon the stand-alone selling prices. Approved contract modifications are accounted for as either a separate contract or as part of the existing contract depending on the nature of the modification.

Our performance obligations on our orders and under the terms of agreements with customers are generally satisfied within one year from a given reporting date and, therefore, we omit disclosure of the transaction price allocated to remaining performance obligations on open orders.

Shipping and handling activities related to contracts with customers are accounted for as costs to fulfill our promise to transfer the associated products pursuant to the accounting policy election allowed under Topic 606 and are not considered a separate performance obligation to our customers. Accordingly, the Company records amounts billed for shipping and handling as a component of revenue. Shipping and handling fees and costs are included in cost of revenues in the accompanying ~~condensed~~ consolidated statements of operations.

Table of Contents

Revenues are recognized net of any taxes collected from customers, which are subsequently remitted to governmental agencies.

~~Business~~Discontinued ~~Combinations~~Operations

~~Amounts~~We ~~paid~~review ~~for acquisitions are allocated to~~ the ~~tangible~~presentation ~~and~~of ~~intangible~~planned ~~assets~~business ~~acquired~~dispositions ~~and~~in ~~liabilities~~the ~~assumed,~~consolidated iffinancial ~~any,~~statements based on ~~their fair values at~~ the ~~dates~~available ofinformation ~~acquisition. This purchase price allocation process requires management to make significant estimates~~ and ~~assumptions~~events ~~with~~that ~~respect~~have ~~to intangible assets~~occurred. The ~~fair~~review ~~value~~consists of ~~identifiable~~evaluating ~~intangible~~whether ~~assets~~the isbusiness ~~based~~meets onthe ~~detailed~~definition ~~valuations~~of ~~that~~a ~~use~~component ~~information~~for ~~and~~which ~~assumptions~~the ~~determined~~operations byand ~~management.~~cash ~~Any~~flows ~~excess~~are ofclearly ~~purchase~~distinguishable ~~price~~from ~~over~~ the ~~fair~~other ~~value~~components of the ~~net~~business, ~~tangible~~ and ~~intangible~~if ~~assets~~so, ~~acquired~~whether it is ~~allocated~~anticipated tothat ~~goodwill.~~after ~~While~~the wedisposal ~~use~~the ~~our~~cash ~~best~~flows ~~estimates~~of ~~and~~the ~~assumptions~~component towould ~~accurately~~be ~~value~~eliminated ~~assets~~from ~~acquired~~continuing operations and ~~liabilities~~whether ~~assumed at~~ the ~~acquisition~~disposition ~~date~~represents asa ~~well~~strategic asshift ~~any~~that ~~contingent~~has ~~consideration,~~a ~~where~~major ~~applicable,~~effect ~~our~~on ~~estimates~~operations ~~are inherently uncertain~~ and ~~subject~~financial ~~to refinement~~results. AsIn ~~a result~~addition, ~~during~~we ~~the~~evaluate ~~measurement~~whether ~~period,~~the ~~which~~business ~~may~~has bemet ~~up to one year from~~ the ~~acquisition~~criteria ~~date,~~as wea ~~record~~business ~~adjustments~~held tofor ~~the~~sale. ~~assets~~In ~~acquired~~order ~~and~~for ~~liabilities~~a ~~assumed~~planned ~~with~~disposition ~~the~~to ~~corresponding~~be ~~offset~~classified toas ~~goodwill.~~a ~~Upon~~business ~~conclusion~~held offor sale, the ~~measurement~~established ~~period~~criteria ormust ~~final~~be ~~determination~~met as of the ~~values~~reporting ofdate, ~~assets~~including ~~acquired~~an oractive ~~liabilities~~program ~~assumed,~~to ~~whichever~~market ~~comes~~the ~~first,~~business ~~any~~and ~~subsequent~~the ~~adjustments~~expected ~~are~~disposition ~~recorded~~of tothe ~~our~~business ~~consolidated~~within ~~statements~~one ~~of operations~~year.

We use the income approach to determine the fair value of certain identifiable intangible assets such as customer relationships. This approach determines fair value by estimating after-tax cash flows attributable to these assets over their respective useful lives and then discounting these after-tax cash flows back to a present value. We base our assumptions on estimates of future cash flows, expected growth rates, expected trends in technology, etc. We base the discount rates used to arrive at a present value as of the date of acquisition on the time value of money and certain industry-specific risk factors. We believe the estimated purchased customer relationships, agent networks, software, developed technologies, and trademarks/tradenames so determined represent the fair value at the date of acquisition and do not exceed the amount a third party would pay for the assets.32

Table of Contents

Planned business dispositions are presented as discontinued operations when all the criteria described above are met. For those divestitures that qualify as discontinued operations, all comparative periods presented are reclassified as held for sale in the consolidated balance sheets. Additionally, the results of operations of a discontinued operation are reclassified to income or loss from discontinued operations, net of tax, for all periods presented in the consolidated statements of operations. Results of discontinued operations include all revenues and expenses directly derived from such businesses; general corporate overhead is not allocated to discontinued operations. These reclassifications have no impact on the Company’s previously reported consolidated net income (loss).

Intangible Assets and Goodwill

Intangible assets

~~Intangible assets with a definite life are amortized over their useful lives using the straight~~Indefinite-~~line~~lived ~~method,~~intangible ~~which~~assets ~~is the best estimate of the value we~~ are ~~receiving~~comprised ~~over the useful life~~ of ~~the~~trade ~~intangible~~name/trademarks ~~asset~~acquired ~~and another systematic method was not deemed more appropriate. The amortization expense is recorded within selling, general and administrative expense~~ in the ~~consolidated~~Company’s ~~statements~~acquisitions, ~~of operations. Intangible assets~~ and ~~their related useful lives~~ are ~~reviewed~~tested atfor ~~least~~impairment annually tousing ~~determine~~a ifrelief ~~any~~from ~~adverse~~royalty ~~conditions~~method ~~exist~~ that ~~would~~relies ~~indicate~~on ~~the~~estimates ~~carrying value~~ of ~~these~~future ~~assets may not be recoverable. More frequent impairment assessments are conducted if certain conditions exist~~revenues, ~~including~~royalty ~~a change in the competitive landscape~~rates, ~~any~~and ~~internal~~discount decisions to pursue new or different technology strategies, a loss of a significant customer, or a significant change in the marketplace, including changes in the prices paid for the Company’s products or changes in the size of the market for the Company’s productsrates. If ~~impairment indicators are present,~~ the ~~Company determines whether the underlying intangible~~ asset is ~~recoverable through estimated future undiscounted cash flows. If the asset is~~ not found to be recoverable, it is written down to the estimated fair value. ofAs ~~the~~a ~~asset~~result ~~based~~of onan ~~the~~interim ~~sum~~impairment ofassessment ~~the~~performed ~~future~~as ~~discounted~~of ~~cash~~June ~~flows~~30, ~~expected~~2024, towe ~~result~~recorded ~~from~~a ~~the~~$9.0 ~~use~~million ~~and~~impairment ~~disposition~~charge ofrelated ~~the~~to ~~asset.~~trademarks Iffor ~~the~~our ~~estimate~~MVE ofreporting anunit, ~~intangible~~and ~~asset’s~~a ~~remaining~~$0.3 ~~useful~~million ~~life~~impairment ischarge ~~changed,~~related to the ~~remaining~~write-off ~~carrying amount~~ of ~~the~~Cell&Co’s ~~intangible~~trade ~~asset~~name that is ~~amortized~~no ~~prospectively~~longer ~~over~~in ~~the~~use ~~revised~~as ~~remaining~~a ~~useful~~result ~~life.~~of ~~The~~the Company’s ~~continues~~global torebranding ~~believe~~initiative, ~~that~~see ~~its~~Note ~~definite-lived~~10 ~~intangible~~– ~~assets~~Goodwill ~~are~~and ~~recoverable~~Intangible atAssets ~~December 31, 2024~~for additional information. The Company has performed ana ~~interim~~quantitative impairment assessment asin ofthe ~~June~~fourth ~~30,~~quarter ~~2024,~~of 2025 and concluded that there has been no impairment of our indefinite-lived intangible assets for the periods presented.

~~Indefinite-lived~~Intangible ~~intangible~~ assets with a definite life are comprised of ~~trade~~patents, ~~name/~~trademarks, software development costs and the intangible assets acquired in the Company’s ~~recent~~ acquisitions, ~~and~~which ~~are~~include ~~tested~~a ~~for~~non-compete ~~impairment~~agreement, ~~annually~~technology, ~~using~~customer arelationships, ~~relief~~trade ~~from~~name/trademark, ~~royalty~~agent ~~method~~network, ~~that~~order ~~relies~~backlog, ondeveloped ~~estimates~~technology ofand ~~future~~land ~~revenues,~~use ~~royalty~~rights. ~~rates,~~Intangible ~~and~~assets ~~discount~~with ~~rates.~~a Ifdefinite life are amortized using the ~~asset~~straight-line ismethod ~~not~~over ~~found~~the toestimated beuseful ~~recoverable~~lives, itsee isNote ~~written~~10 ~~down~~– toGoodwill ~~the~~and ~~estimated~~Intangible ~~fair~~Assets ~~value.~~for Asadditional ainformation. ~~result~~The ofCompany anuses ~~interim~~the ~~impairment~~following ~~assessment~~valuation ~~performed~~methodologies asto ofvalue ~~June~~the ~~30,~~significant ~~2024,~~intangible weassets ~~recorded~~with a ~~$9.0~~definite ~~million~~life ~~impairment~~acquired: ~~charge~~income ~~related~~approach tofor ~~trademarks~~customer relationships, replacement cost for ~~our~~agent ~~MVE~~network ~~reporting~~and ~~unit~~software, and arelief ~~$0.3~~from ~~million~~royalty ~~impairment~~for ~~charge~~trade ~~related~~name/trademarks toand ~~the~~developed ~~write-off~~technology. The Company capitalizes costs of ~~Cell&Co’s~~obtaining ~~trade~~patents ~~name~~and ~~that~~trademarks, iswhich noare ~~longer~~amortized, inusing ~~use~~the asstraight-line amethod ~~result~~over their estimated useful life of ~~the~~five ~~Company’s~~years ~~global~~once ~~rebranding~~the ~~initiative~~patent ~~(see~~or ~~Note~~trademark ~~10)~~has been issued.

The Company evaluates the recoverability of identifiable intangible assets with a definite life whenever events or changes in circumstances indicate that an intangible asset’s carrying amount may not be recoverable. Such circumstances could include, but are not limited to: (1) a significant decrease in the market value of an asset, (2) a significant adverse change in the extent or manner in which an asset is used, or (3) an accumulation of costs significantly in excess of the amount originally expected for the acquisition of an asset. The Company measures the carrying amount of the asset against the estimated undiscounted future cash flows associated with it. Should the sum of the expected undiscounted future net cash flows be less than the carrying value of the asset being evaluated, an impairment loss would be recognized. The impairment loss would be calculated as the amount by which the carrying value of the asset exceeds its fair value. The estimate of fair value is based on various valuation techniques, including the discounted value of estimated future cash flows. The evaluation of asset impairment requires the Company to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may differ from assumed and estimated amounts. The Company has performed a quantitative impairment assessment in the fourth quarter of 2025 and concluded that there has been no impairment of our intangible assets with a definite life for the periods presented.

Goodwill

WeThe ~~test~~Company evaluates goodwill ~~for impairment~~ on an annual basis in the fourth quarter or more frequently if management believes indicators of impairment exist. ~~Events~~Such ~~that~~indicators ~~would~~could ~~indicate~~include, ~~impairment~~but ~~and~~are ~~trigger~~not limited to: (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an ~~interim~~adverse ~~impairment~~action or assessment ~~include~~by a regulator. For each reporting unit being tested, ~~but~~the ~~are~~Company ~~not~~compares ~~limited~~the fair value of the reporting unit with its carrying amount and then recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value up to the total amount of goodwill allocated to the reporting unit. As a result of our 2023 quantitative assessment, ~~current~~we ~~economic~~concluded ~~and~~that ~~market~~goodwill ~~conditions~~related to the MVE reporting unit was impaired as of December 31, 2023, ~~including~~and arecorded ~~decline~~an impairment charge of $49.6 million in ~~market~~the ~~capitalization~~consolidated statement of operations for the year ended December 31, 2023. As a ~~significant~~result ~~adverse~~of ~~change~~an interim impairment assessment performed as of June 30, 2024, we concluded that the goodwill related to the MVE reporting unit was further impaired, and recorded an impairment charge of $54.6 million related to full impairment of the goodwill related to the MVE reporting unit in ~~legal~~the ~~factors~~consolidated statement of operations for the year ended December 31, 2024, see

4033

Table of Contents

~~business~~Note ~~climate~~10 or– ~~operational~~Goodwill ~~performance of the business,~~ and anIntangible ~~adverse~~Assets ~~action or assessment by a regulator. Accounting guidance also permits an optional qualitative assessment~~ for ~~goodwill~~additional ~~to determine whether it is more likely than not that the carrying value of a reporting unit exceeds its fair value~~information. If, after this qualitative assessment, we determine that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then no further quantitative testing would be necessary. A quantitative assessment is performed if the qualitative assessment results in a more likely than not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded to the extent the reporting unit’s carrying value exceeds its fair value. As a result of anour ~~interim~~2025 ~~impairment~~quantitative assessment ~~performed as of June 30~~, ~~2024,~~ we concluded that ~~there has been no impairment of the~~ goodwill ~~associated~~is ~~with the CRYOPDP reporting unit as its carrying value did~~ not ~~exceed its estimated fair value. We further concluded that goodwill related to the MVE reporting unit is~~ impaired, ~~and~~as ~~recorded an impairment charge~~ of ~~$54.6 million in the consolidated statement of operations for the year ended~~ December 31, ~~2024 (see Note 10)~~2025.

Management will continue to monitor the reporting units for changes in the business environment that could impact the recoverability in future periods. The recoverability of goodwill is dependent upon the continued growth of revenue and cash flows from the Company’s business activities. Examples of events or circumstances that could result in changes to the underlying key assumptions and judgments used in our goodwill impairment tests, and ultimately impact the estimated fair value of the Company’s reporting units include adverse macroeconomic or geopolitical conditions; and fluctuations in foreign currency exchange rates impacting the results of operations and the value of foreign assets and liabilities. While historical performance and current expectations have resulted in fair values of our reporting units in excess of carrying values, if our assumptions are not realized, it is possible that an impairment charge may need to be recorded in the future.

Convertible Senior Notes

The Convertible Senior Notes are accounted for in accordance with ASC 470-20, Debt with Conversion and Other Options (“ASC 470-20”) and ASC 815-40, Contracts in Entity’s Own Equity (“ASC 815-40”). Under ASC 815-40, to qualify for equity classification (or nonbifurcation, if embedded) the instrument (or embedded feature) must be both (1) indexed to the issuer’s stock and (2) meet the requirements of the equity classification guidance. Based upon the Company’s analysis, it was determined the Convertible Senior Notes do contain embedded features indexed to its own stock, but do not meet the requirements for bifurcation and recognition as derivatives, and therefore do not need to be separately recognized. Accordingly, the proceeds received from the issuance of the Convertible Senior Notes were recorded as a single liability measured at amortized cost on the consolidated balance sheets.

Stock-based Compensation

We use the Black-Scholes option pricing model to calculate the fair value of stock option awards on the grant date. The expected option life assumption is estimated based on the simplified method. Accordingly, the Company has utilized the average of the contractual term of the options and the weighted average vesting period for all options to calculate the expected option term. The risk-free interest rate assumption is based upon observed interest rates appropriate for the expected term of our employee stock options. The expected volatility is based on the average of the historical volatility and the implied volatility of our stock commensurate with the expected life of the stock-based award. We do not anticipate paying dividends on our common stock in the foreseeable future.

We recognize stock-based compensation cost on a straight-line basis over the vesting period. Stock-based compensation expense is recognized only for those awards that ultimately vest.

Income Taxes

Deferred taxes are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. Valuation allowances are provided, if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. We account for uncertain tax positions using a “more-likely-than-not” threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. We evaluate our tax position on a quarterly basis. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.

4134

Table of Contents

Results of Operations

Results of Operations for Year Ended December 31, ~~2024~~2025 Compared to the Year Ended December 31, ~~2023~~2024

The following table summarizes certain information derived from our consolidated statements of operations (in thousands):


	Year Ended December 31,
	~~2024~~2025		~~2023~~2024		$ Change		% Change
Life sciences services revenue	$	153,660	$	144,087	$	9,573	6.6%
Life Sciences Services revenue	$	96,497	$	82,044	$	14,453	17.6%
Life sciences products revenue		74,725		89,168		(14,443)	(16.2%)
Life Sciences Products revenue		79,680		74,725		4,955	6.6%
Total revenue		~~228~~176,~~385~~177		~~233~~156,~~255~~769		(419,~~870)~~408	(212.14%)

Cost of services revenue		(8549,~~206~~429)		(8143,~~820~~564)		(35,~~386~~865)	413.15%
Cost of products revenue		(43,~~548~~694)		(5243,~~103~~548)		~~8,555~~(146)	~~(16~~0.43%)
Total cost of revenue		(~~128~~93,~~754~~123)		(~~133~~87,~~923~~112)		5(6,~~169~~011)	(36.9%)

Gross margin		9983,~~631~~054		9969,~~332~~657		~~299~~13,397	019.32%
Selling, general and administrative		(148,978)		(146,880)		(2,098)	1.4%

Engineering and development		(17,710)		(18,040)		330	(1.8%)
Selling, general and administrative		(102,819)		(109,809)		6,990	(6.4%)
Impairment loss		(63,809)		(49,569)		(14,240)	28.7%
Engineering and development		(17,041)		(17,710)		669	(3.8%)
Investment income		9,895		10,577		(682)	(6.4%)
Impairment loss		—		(63,809)		63,809	(100.0%)
Interest expense		(4,108)		(5,503)		1,395	(25.3%)
Investment income		9,798		9,895		(97)	(1.0%)
Gain on extinguishment of debt, net		18,505		5,679		12,826	225.8%
Interest expense, net		(2,361)		(3,977)		1,616	(40.6%)
Other income (expense), net		(6,906)		5,056		(11,962)	(236.6%)
Gain on extinguishment of debt, net		—		18,505		(18,505)	(100.0%)
Provision for income taxes		(1,276)		(239)		(1,037)	434.1%
Other income (expense), net		(2,801)		(7,101)		4,300	(60.6%)

Provision for income taxes		(1,799)		(359)		(1,440)	401.1%
Net loss	$	(114,756)	$	(99,587)	$	(15,169)	15.2%

Loss from continuing operations		(33,969)		(104,708)		70,739	(67.6%)
Income (loss) from discontinued operations, net		112,270		(10,048)		122,318	(1217.3%)
Net income (loss)	$	78,301	$	(114,756)	$	193,057	(168.2%)
Paid-in-kind dividend on Series C convertible preferred stock		(8,000)		(8,000)		—	—
Net loss attributable to common stockholders	$	(122,756)	$	(107,587)	$	(15,169)	14.1%
Net income (loss) attributable to common stockholders	$	70,301	$	(122,756)	$	193,057	(157.3%)

Total revenue by ~~market~~type (in thousands)


	Year Ended December 31,
	~~2024~~2025		~~2023~~2024		$ Change		% Change
	($ in 000’s)
BioLogistics Solutions	$	78,137	$	67,019	$	11,118	16.6	%
BioLogistics Solutions	$	138,635	$	130,498	$	8,137	6.2	%
BioStorage/BioServices		18,360		15,025		3,335	22.2	%
BioStorage/BioServices		15,025		13,589		1,436	10.6	%
Life Sciences Services		96,497		82,044		14,453	17.6	%
Life Sciences Services		153,660		144,087		9,573	6.6	%
Life Sciences Products		79,680		74,725	$	4,955	6.6	%
Life Sciences Products		74,725		89,168	$	(14,443)	(16.2)	%
Total revenue	$	176,177	$	156,769		19,408	12.4	%
Total revenue	$	228,385	$	233,255		(4,870)	(2.1)

Revenue. Revenue ~~decreased~~increased by $419.94 million, or 212.14%, to $~~228~~176.42 million for the year ended December 31, ~~2024~~2025, as compared to $~~233~~156.38 million for the year ended December 31, ~~2023~~2024.

Revenue by type

Life Sciences Services revenue increased by $914.65 million, or 617.6%, from $~~144~~82.10 million to $~~153~~96.75 million for the year ended December 31, ~~2024~~2025, as compared to the same period in ~~2023~~2024. This increase was driven by year-over-year growth in ~~BioStorage/BioServices~~BioLogistics ~~and~~Solutions ~~Commercial~~revenue ~~Cell~~and &BioStorage/BioServices ~~Gene therapy~~ revenue of 1016.6% and 2022.12%, respectively, demonstrating strong demand for our services offerings. Revenue from the support of commercial cell and gene therapies included in BioLogistics Solutions revenue was $29.9 million for the year ended December 31, 2025, representing a 23.9% year-over-year increase from $24.1 million in the prior year. We also continued to gain clinical trial market share with Cryoport supporting a total of ~~701~~760 clinical trials globally at year end ~~2024~~2025, of which 8186 of these clinical trials were in phase 3, representing an overall increase of 2659 clinical trials from ~~675~~701 clinical trials at year end ~~2023~~2024. ~~Our company continues to lead the way in providing advanced temperature-controlled supply chain solutions designed to support the development of cell & gene therapies and our future growth.~~

4235

Table of Contents

~~Life~~We ~~Sciences~~continue ~~Products revenue decreased by $14.4 million, or 16.2%, from $89.2 million~~ to ~~$74.7~~lead ~~million for~~ the ~~year~~way ~~ended December 31, 2024, as compared to the same period~~ in ~~2023.~~providing ~~This~~advanced was primarily a result of decreased demand for cryogenic systems that commenced during the second quarter of 2023. Life Sciences Products revenue consists primarily of revenue from our portfolio of cryogenic stainlesstemperature-~~steel~~controlled ~~freezers,~~supply ~~aluminum~~chain ~~dewars~~solutions ~~and~~designed ~~related~~to ~~ancillary~~support ~~equipment used in~~ the ~~storage~~development ~~and transport~~ of ~~life~~cell ~~sciences commodities, which includes the rapidly growing Cell~~ and ~~Gene~~gene ~~Therapy~~therapies ~~market through a global network of distributors~~ and ~~direct~~our ~~client~~future ~~relationships~~growth.

~~Gross~~Life ~~margin~~Sciences ~~and~~Products ~~cost~~revenue ofincreased ~~revenue~~by $5.0 ~~Gross~~million, ~~margin~~or 6.6%, from $74.7 million to $79.7 million for the year ended December 31, ~~2024~~2025, ~~was~~as 43compared to the same period in 2024.6% ofLife ~~total~~Sciences Products revenue consists primarily of revenue from our portfolio of cryogenic stainless-steel freezers, asaluminum ~~compared~~dewars toand ~~42.6%~~related ancillary equipment used in the storage and transport of ~~total~~life sciences commodities, which includes the rapidly growing CGT market through a global network of distributors and direct client relationships. The increase in Life Sciences Products revenue ~~for~~was primarily driven by increased demand from customers in the ~~year~~EMEA ~~ended~~and ~~December 31, 2023~~APAC regions and strong demand from animal health customers in the Americas. ~~Cost~~Revenue from the support of ~~total~~commercial cell and gene therapies included in Life Sciences Products revenue ~~decreased~~was $53.25 million toand $~~128~~1.8 ~~million~~ for the ~~year~~years ended December 31, 2025 and 2024, ~~as compared to $133~~respectively.~~9 million in the same period in 2023.~~

Gross margin ~~for~~and ~~our~~cost ~~life~~of ~~sciences~~revenue. ~~services~~Gross ~~revenue~~margin for the year ended December 31, 2025 was 4447.51% of ~~services~~total revenue, as compared to 4344.24% of ~~services~~total revenue for the year ended December 31, ~~2023~~2024. ~~Our~~Cost ~~cost~~ of total revenue isincreased ~~primarily~~$6.0 ~~comprised~~million ~~of freight charges, payroll and associated expenses related~~ to ~~our~~$93.1 ~~global~~million ~~logistics~~for ~~and~~the ~~supply~~year ~~chain~~ended ~~centers~~December 31, 2025, ~~depreciation~~as ~~expenses~~compared ofto ~~our~~$87.1 ~~Cryoport~~million ~~Express®~~in ~~Shippers~~the ~~and~~same ~~supplies~~period ~~and~~in ~~consumables used for our solutions~~2024.

Gross margin ~~for~~of ~~our~~Life ~~life~~Sciences ~~sciences~~Services ~~products~~ revenue ~~remained~~increased ~~flat~~to at48.8% 41from 46.79% offor ~~products~~the ~~revenue~~year ended December 31, 2025, as compared to ~~41.6%~~the prior year, primarily as a result of ~~products~~a favorable revenue ~~for~~mix ~~the~~shift ~~year~~toward ~~ended~~higher-margin ~~December 31~~offerings, ~~2023.~~ ~~Life~~including ~~Sciences~~BioServices ~~Products~~and ~~revenue,~~BioStorage ~~related~~and the Company’s cost ofreduction ~~revenue~~initiatives ~~and~~implemented ~~resulting~~in ~~gross~~2024 ~~margins~~and ~~were~~refined ~~primarily~~throughout ~~driven~~2025 byas ~~our~~part ~~MVE~~of ~~Biological~~its ~~Solutions~~pathway ~~business~~to profitability strategy. Our cost of ~~products~~services revenue was primarily comprised of ~~materials, direct and indirect labor, inbound~~ freight charges, ~~purchasing~~facility ~~and receiving~~expenses, ~~inspection,~~payroll and ~~distribution~~associated ~~and~~expenses ~~warehousing~~related ofto ~~inventory.~~our Inglobal ~~addition,~~logistics ~~shop~~and ~~supplies,~~supply ~~facility~~chain ~~maintenance~~centers, ~~costs and~~ depreciation ~~expense~~expenses ~~for~~of ~~assets~~our ~~used~~Cryoport inExpress® ~~the~~Shippers ~~manufacturing~~and ~~process~~supplies ~~were~~and ~~included~~consumables inused ~~cost~~for ofour ~~products revenue~~solutions.

Gross margin of Life Sciences Products revenue increased to 45.2% from 41.7% for the year ended December 31, 2025, as compared to the prior year, primarily driven by manufacturing efficiency improvements within the MVE Biological Solutions operating segment. Our cost of products revenue was primarily comprised of materials, direct and indirect labor, inbound freight charges, purchasing and receiving, inspection, and distribution and warehousing of inventory. In addition, shop supplies, facility maintenance costs and depreciation expense for assets used in the manufacturing process were included in cost of products revenue.

Selling, general and administrative expenses. Selling, general and administrative (“SG&A”) expenses include the costs associated with selling our products and services and costs required to support our marketing efforts including legal, accounting, patent, shareholder services, amortization of intangible assets and other administrative functions.

For the year ended December 31, ~~2024~~2025, SG&A expenses ~~increased~~decreased by $27.10 million, or 16.4% as compared to the same period in ~~2023~~2024. This ~~increase~~decrease iswas primarily driven by ~~the~~decreases further build out of our competencies and infrastructure to support the continuing scaling of our business and demand for Cryoport’s systems and solutions and buildout of new competencies, such as IntegriCellTM platform, a standardized integrated apheresis cryopreservation and distribution solution for cell therapies. In October 2024, we announced the launch of our new state-of-the-art IntegriCellTM facility within our Houston campus. This offering addresses another critical aspect in ~~optimizing~~stock ~~the~~compensation ~~supply chain for the development and commercialization~~ of ~~cell-based therapies. Wages and associated employee costs increased~~ $8.5 ~~million from $67~~.4 million ~~in 2023 to $75.8 million in 2024. Depreciation and amortization increased $2.2 million~~, ~~primarily~~contingent ~~due~~consideration ~~to additional fixed assets purchased or acquired in our recent business acquisitions and the launch~~ of ~~Cryoportal® 2 Logistics Management Platform in May 2023, an increase of~~ $14.83 million, ~~as a result of cost alignment~~ and ~~reprioritization~~consulting ~~initiatives~~costs ~~and an increase~~ of $02.51 million ~~in public company related expenses (including legal, audit and internal control audit fees)~~. These ~~increases~~decreases were ~~partially~~ offset by aincreases ~~decrease~~facility ~~of $6.0 million in integration~~ and ~~acquisition~~other ~~costs~~overhead ~~primarily~~allocations ~~as a result~~ of ~~actively exploring a strategic business opportunity in 2023 that did not occur in 2024, a decrease of~~ $23.76 million, inand ~~stock~~wages ~~compensation expense,~~ and aassociated ~~decrease~~employee costs of $2.2 million ~~related to the change in contingent consideration~~.

Engineering and development expenses. Engineering and development expenses decreased by $0.37 million, or 13.8%, for the year ended December 31, ~~2024~~2025, as compared to the same period in ~~2023~~2024. The decrease was primarily due to a decrease of $01.51 million in ~~dues and subscription, a decrease of $0.5 million in~~ development costs, consulting and prototype expenses and a decrease of $0.36 million in stock compensation expense. These decreases were partially offset by an increase of $1.10 million in wages and associated employee costs to add software development and engineering resources. We continually strive to improve and expand the features of our ~~Cryoport Express®, Cryoport ELITE™ Solutions and~~ portfolio of temperature-controlled services and products~~, such as the recently introduced Cryoport Express® Cryogenic HV3 Shipping System~~. Our primary developments are directed towards facilitating the safe, reliable and efficient transport and storage of life science commodities through innovative and technology-based solutions. This includes significantly enhancing our Cryoportal® Digital Logistics Management Platform and related technology solutions as well as developments to expand our Cryoport Express® and shipper fleets. In addition, engineering and development efforts are also focused on MVE Biological Solutions’ portfolio of advanced cryogenic stainless-steel freezers, aluminum dewars and related ancillary equipment used in the storage and transport of life sciences commodities. We supplement our internal engineering and development resources with subject matter experts and consultants to enhance our capabilities and shorten development cycles.

Table of Contents

Impairment loss. As a result of the interim impairment assessment performed as of June 30, 2024, the Company recorded an impairment loss of $63.8 million, primarily related to full impairment charge of goodwill related to the MVE Biological Solutions reporting unit.

~~Investment Income. Investment income decreased by $0.7 million, for the year ended December 31, 2024, as compared to the prior year.~~36

~~Interest~~Table expense. Interest expense decreased by $1.4 million, from $5.5 million to $4.1 million for the year ended December 31, 2024, as compared to the prior year due to a decrease in interest on the convertible senior notes and amortization of ~~the related debt discount as a result of the repurchase of the 2026 Convertible Senior Notes in 2024.~~Contents

Investment Income. Investment income decreased by $0.1 million, for the year ended December 31, 2025, as compared to the prior year.

Interest expense. Interest expense decreased by $1.6 million, from $4.0 million to $2.4 million for the year ended December 31, 2025, as compared to the prior year due to a decrease in interest on the convertible senior notes and amortization of the related debt discount as a result of the repayment of the 2025 Convertible Senior Notes upon maturity in June 2025.

Gain on extinguishment of debt. During the year ended December 31, 2024, the Company repurchased $185.0 million in aggregate principal amount of the 2026 Convertible Senior Notes for a repurchase price of $163.1 million in cash, plus accrued and unpaid interest, resulting in a net gain of $18.5 million, which includes the write off of $2.7 million of unamortized debt issuance costs and $0.7 million of transaction costs.

Other income (expense), net. The ~~decrease~~increase in other income (expense), net for the year ended December 31, ~~2024~~2025, as compared to the prior year is primarily due to ana ~~increase~~decrease of $64.3 million in short-term investment net unrealized loss, a decrease of $2.71 million ~~for currency revaluation, a decrease~~ in ~~the~~current ~~gain~~period onforeign ~~insurance~~currency ~~claim~~loss, ofand $21.65 million inincrease ~~2023 related to the New Prague fire that did not occur~~ in ~~the~~non-recurring ~~current~~income, ~~year~~offset ~~and~~by a decrease of $02.5 million for ~~foreign~~ currency ~~due to current period losses~~revaluation.

Provision for income taxes. The provision for income taxes increased by $1.04 million for the year ended December 31, ~~2024~~2025, as compared to the same period in the prior year, resulting in effective tax rates of negative 15.16% and negative 0.23%, respectively. The increase in tax expense and the decrease in the effective tax rate for the year ended December 31, ~~2024~~ 2025, as compared to the prior year is due to changes in the valuation allowances on our foreign operations, a tax benefit from the reduction of the deferred tax liability on indefinite-lived intangible assets related to the impairment and an increase in our domestic losses which resulted in no additional tax benefit. The effective tax rate of negative 15.16% for the year ended December 31, ~~2024~~ 2025, differed from the U.S. federal statutory rate of 21% primarily due to changes in the valuation allowance that we maintain against our deferred tax assets, the ~~impairment~~expiration of ~~goodwill~~a portion of our US federal net operating loss carryforwards due to IRC Section 382 and the relative mix of income earned by certain foreign subsidiaries being taxed at different rates than the U.S. federal statuary rate.

Paid-in-kind dividend on Series C convertible preferred stock. The paid-in-kind dividend relates to the private placement of Series C Preferred Stock with Blackstone.

~~Business~~Discontinued ~~segment~~operations. ~~results~~Revenue from discontinued operations decreased by $39.4 million for the year ended December 31, 2025 as compared to the prior year. The Company recorded two quarters of revenue from discontinued operations in 2025, compared with a full year of revenue in 2024. Income (loss) from discontinued operations, net of income tax increased by $122.3 million for the year ended December 31, 2025, as compared to the same period in 2024, due to the divestiture of the CRYOPDP business in the second quarter of 2025.

Net income (loss). Net income (loss) increased by $193.1 million for the year ended December 31, 2025, as compared to the prior year. This increase was primarily due to the gain on divestiture of the CRYOPDP business of $117.0 million recorded in 2025, and the impairment loss of $63.8 million recorded in 2024, which did not reoccur in 2025.

~~Life~~Adjusted ~~Sciences~~EBITDA ~~Services~~from continuing operations. Adjusted EBITDA from continuing operations increased by $12.0 million from a negative $17.8 million to a negative $5.8 million for the year ended December 31, 2025, as compared to the prior year, primarily due to gross margin expansion and reduced operating expenses resulting from the Company’s cost reduction initiatives. Adjusted operating costs declined as a result of headcount reductions, lower contractor utilization, project reprioritization, and tighter expense management across the organization. These actions collectively contributed to a meaningful year-over-year improvement in adjusted EBITDA as the Company continued to align its cost structure with current industry conditions and position the business for sustainable profitability.

Life Sciences Services revenue increased from $149.9 million to $163.7 million for the year ended December 31, 2024, as compared to the same period in 2023. Adjusted EBITDA increased from ($14.6) million to ($10.4) million for the year ended December 31, 2024, as compared to the same period in 2023. Refer to the discussion of Life Sciences Services revenue in the Results of Operations section above for discussion of the key drivers of revenues from this segment. Segment expenses were higher due to increased cost of revenues from increased sales and an increase in employee related expenses of $10.7 million. These increases were partially offset by a decrease in other segment items of $2.7 million and a decrease in engineering and development expenses of $1.0 million.

Life Sciences Products

Life Sciences Products revenue decreased from $89.0 million to $72.0 million for the year ended December 31, 2024, as compared to the same period in 2023 as a result of decreased demand for cryogenic systems. Adjusted EBITDA decreased from $20.2 million to $12.7 million for the year ended December 31, 2024, as compared to the same period in 2023. Refer to the discussion of Life Sciences Products revenue in the Results of Operations section above for discussion of the key drivers of revenues from this segment which are exclusively Life Sciences Products. Segment expenses were lower due to decreased cost of revenues from decreased sales volume and lower employee related expenses of $1.9 million due to cost reduction measures. See Note 20 in the accompanying consolidated financial statements.

Table of Contents

Non-GAAP Financial Measures

We provide adjusted EBITDA ~~and~~from ~~revenue~~continuing ~~at constant currency~~operations, ~~both~~a non-GAAP financial ~~measures~~measure, as a supplemental ~~measures~~measure to U.S. GAAP measures regarding our operating performance. Non-GAAP financial measures are not calculated in accordance with U.S. GAAP, are not based on any comprehensive set of accounting rules or principles and may be different from non-GAAP financial measures presented by other companies. Non-GAAP financial measures, including adjusted EBITDA ~~and~~from ~~revenue~~continuing ~~at constant currency~~operations, should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with U.S. GAAP.

~~Adjusted EBITDA~~37

Adjusted EBITDA is defined as net loss adjusted for interest expense, income taxes, depreciation and amortization expense, stock-based compensation expense, acquisition and integration costs, cost reduction initiatives, investment income, unrealized gain or loss on investments, foreign currency gain or loss, net gain on insurance claim, gain on extinguishment of debt, impairment loss, changes in fair value of contingent consideration and charges or gains resulting from non-recurring events, as applicable.

Management believes adjusted EBITDA provides a useful measure of our operating results, a meaningful comparison with historical results and with the results of other companies, and insight into our ongoing operating performance. Further, management and our board of directors utilize adjusted EBITDA to gain a better understanding of our comparative operating performance from period-to-period and as a basis for planning and forecasting future periods. Adjusted EBITDA is also a significant performance measure used by us in connection with our incentive compensation programs. Management believes adjusted EBITDA, when read in conjunction with our U.S. GAAP financials, is useful to investors because it provides a basis for meaningful period-to-period comparisons of our ongoing operating results, including results of operations, against investor and analyst financial models, identifying trends in our underlying business and performing related trend analyses, and it provides a better understanding of how management plans and measures our underlying business.

A reconciliation of adjusted EBITDA to net loss, the most directly comparable U.S. GAAP financial measure, is presented below.

Cryoport, Inc. and Subsidiaries

Adjusted EBITDA Reconciliation

(Unaudited, in thousands)


	Three Months Ended				Year Ended
	December 31,				December 31,
	2024		2023		2024		2023
GAAP net loss	$	(18,677)	$	(62,389)	$	(114,756)	$	(99,587)
Non-GAAP adjustments to net loss:
Depreciation and amortization expense		7,894		7,449		30,757		27,487
Acquisition and integration costs		3		641		899		6,945
Cost reduction initiatives		768		—		1,884		—
Investment income		(1,427)		(2,615)		(9,895)		(10,577)
Unrealized (gain)/loss on investments		2,445		(3,542)		5,038		(1,242)
Gain on insurance claim		—		—		—		(2,642)
Foreign currency (gain)/loss		3,172		(1,078)		2,410		(964)
Interest expense, net		636		1,306		4,108		5,503
Stock-based compensation expense		4,413		5,848		19,704		22,808
Gain on extinguishment of debt, net		—		—		(18,505)		(5,679)
Impairment loss		—		49,569		63,809		49,569
Change in fair value of contingent consideration		(518)		(665)		(1,847)		(601)
Other non-recurring costs		—		187		—		437
Income taxes		29		(1,359)		1,276		239
Adjusted EBITDA		(1,262)		(6,648)		(15,118)		(8,304)

Table of Contents

~~Revenue~~Adjusted atEBITDA ~~Constant~~from ~~Currency~~continuing operations

WeAdjusted ~~believe~~EBITDA ~~that~~from ~~revenue~~continuing ~~growth~~operations is adefined ~~key~~as ~~indicator~~loss ~~of how our Company is progressing~~ from ~~period~~continuing tooperations ~~period~~adjusted ~~and~~for wenet ~~believe~~interest ~~that~~expense, ~~the~~income ~~non-GAAP~~taxes, ~~financial~~depreciation ~~measure~~and ~~“revenue~~amortization ~~at constant currency” is useful to investors in analyzing the underlying trends in revenue. Under U.S. GAAP~~expense, ~~revenue received in local (non~~stock-~~U.S.~~based ~~dollar)~~compensation ~~currency~~expense, isacquisition ~~translated~~and ~~into~~integration ~~U.S.~~costs, ~~dollars~~cost atreduction ~~the~~initiatives, ~~average~~investment ~~exchange~~income, ~~rate~~unrealized ~~for~~gain ~~the~~or ~~period~~loss ~~presented.~~on ~~As a result~~investments, ~~fluctuations in~~ foreign currency ~~exchange~~gain ~~rates~~or ~~affect~~loss, ~~the~~net ~~results~~gain ofon ~~our~~extinguishment ~~operations and the value~~ of ~~our~~debt, ~~foreign~~impairment ~~assets and liabilities~~loss, ~~which~~changes in ~~turn~~fair ~~may~~value ~~adversely affect results~~ of ~~operations~~contingent consideration and ~~cash~~charges ~~flows~~or ~~and~~gains ~~the~~resulting ~~comparability~~from ~~of period~~non-~~to-period~~recurring ~~results of operations. When we use the term “constant currency~~events,” itas ~~means that we have translated local currency revenue for the current reporting period into U~~applicable.S. dollars using the same average foreign currency exchange rates for the conversion of revenue into U.S. dollars that we used to translate local currency revenue for the comparable reporting period of the prior year.

~~Changes~~Management inbelieves ~~foreign~~adjusted ~~currency~~EBITDA ~~exchange~~from ~~rates~~continuing ~~had~~operations anprovides ~~unfavorable~~a ~~impact~~useful onmeasure of our operating results, a meaningful comparison with historical results and with the results of ~~operations~~other companies, and ~~cash~~insight ~~flow~~into ~~from~~our ongoing operating performance. Further, management and our board of directors utilize adjusted EBITDA from continuing operations into ~~EMEA~~gain a better understanding of our comparative operating performance from period-to-period and ~~APAC~~as ~~during~~a ~~the~~basis ~~year~~for ~~ended~~planning ~~December 31, 2024~~and forecasting future periods. ~~Our~~Adjusted ~~revenue~~EBITDA ~~would~~from ~~have~~continuing ~~been~~operations $0is also a significant performance measure used by us in connection with our incentive compensation programs.3 Management ~~million~~believes ~~higher~~adjusted EBITDA from continuing operations, when read in ~~constant~~conjunction ~~currency~~with our U.S. GAAP financials, is useful to investors because it provides a basis for ~~the~~meaningful ~~year~~period-to-period ~~ended~~comparisons ~~December 31~~of our ongoing operating results, ~~2024~~ including results of operations, against investor and analyst financial models, identifying trends in our underlying business and performing related trend analyses, and it provides a better understanding of how management plans and measures our underlying business.

~~However,~~A wereconciliation ~~also believe that data on constant currency period-over-period changes have limitations, particularly as the currency effects that are eliminated could constitute a significant element~~ of ~~our~~adjusted ~~revenue~~EBITDA ~~and~~from ~~could~~continuing ~~significantly~~operations ~~impact our performance. We therefore limit our use of constant currency period-over-period changes~~ to aloss ~~measure~~from ~~for~~continuing ~~the~~operations, ~~impact of currency fluctuations on~~ the ~~translation~~most ofdirectly ~~local~~comparable ~~currency revenue into~~ U.S. ~~dollars. We do not evaluate our results and performance without considering both period-over-period changes in non-~~GAAP ~~constant~~financial currency revenue on the one hand and changes in revenue prepared in accordance with U.S. GAAP on the other. We caution the readers of this report to follow a similar approach by considering revenue on constant currency period-over-period changes only in addition tomeasure, ~~and~~is ~~not~~presented ~~as a substitute for, or superior to, changes in revenue prepared in accordance with U~~below.~~S. GAAP.~~

Cryoport, Inc. and Subsidiaries

~~Revenues~~Adjusted byEBITDA ~~Market~~From atContinuing ~~Constant~~Operations ~~Currency~~Reconciliation

(Unaudited, in thousands)


	Three Months Ended				Year Ended
	December 31,				December 31,
	2025		2024		2025		2024
GAAP loss from continuing operations	$	(8,521)	$	(17,172)	$	(33,969)	$	(104,708)
Non-GAAP adjustments to loss:
Depreciation and amortization expense		6,355		5,992		25,153		23,565
Acquisition and integration costs		6		3		75		655
Cost reduction initiatives		—		310		642		842
Investment income		(3,357)		(1,427)		(9,798)		(9,895)
Unrealized loss on investments		82		2,445		702		5,038
Foreign currency loss		248		3,130		2,769		2,352
Interest expense, net		634		579		2,361		3,977
Stock-based compensation expense		2,431		3,644		10,066		16,567
Gain on extinguishment of debt, net		—		—		—		(18,505)
Impairment loss		—		—		—		63,809
Change in fair value of contingent consideration		—		(225)		(5,178)		(1,827)
Income taxes		1,126		(134)		1,799		359
Other adjustments		(401)		—		(401)		—
Adjusted EBITDA from continuing operations	$	(1,397)	$	(2,855)	$	(5,779)	$	(17,771)


	Year Ended December 31, 2024
	Life Sciences			Life Sciences
	Services			Products			Total
As Reported	$	153,660		$	74,725		$	228,385
Non-GAAP Constant Currency		153,879			74,807			228,685
FX Impact [$]	$	(219)		$	(82)		$	(300)
FX Impact [%]		(0.1)	%		(0.1)	%		(0.1)	%

Liquidity and Capital Resources

As of December 31, ~~2024~~2025, the Company had cash and cash equivalents of $45250.35 million, short-term investments of $~~216~~160.57 million and working capital of $~~277~~257.02 million. We expect to continue to incur significant expenses for the foreseeable future and to incur operating losses in the near term while we make investments in new supply chain initiatives, geographic expansion and technology to support our anticipated growth. Historically, we have financed our operations primarily through sales of equity securities and debt instruments. Following the divestiture of the CRYOPDP business, we also expect to use the net proceeds from the divestiture for general corporate purposes.

The Company’s management recognizes that the Company may need to obtain additional capital to fund its operations and potential acquisitions until sustained profitable operations are achieved. Additional funding plans may include obtaining additional capital through equity and/or debt funding sources. No assurance can be given that additional capital, if needed, will be available when required or upon terms acceptable to the Company. The Company’s management believes that, based on its current plans and assumptions, the current cash and cash equivalents on hand, short-term investments, together with projected cash flows, will satisfy our operational and capital requirements for at least the next twelve months.38

Table of Contents

The Company’s management recognizes that the Company may need to obtain additional capital to fund its operations and potential acquisitions until sustained profitable operations are achieved. Additional funding plans may include obtaining additional capital through equity and/or debt funding sources. No assurance can be given that additional capital, if needed, will be available when required or upon terms acceptable to the Company. The Company’s management believes that, based on its current plans and assumptions, which include the repayment of the 2026 Convertible Senior Notes at maturity, the current cash and cash equivalents on hand, short-term investments, together with projected cash flows, will satisfy our operational and capital requirements for at least the next twelve months.

Cash flows Summary


	For the Year Ended December 31,
	~~2024~~2025		~~2023~~2024		$ Change
	(in thousands)
Operating activities	$	(168,~~323~~580)	$	(~~757~~16,323)	$	~~(15~~7,~~566)~~743
Investing activities		~~176~~250,~~815~~323		36176,~~045~~815		~~140~~73,~~770~~508
Financing activities		(~~161~~21,~~531~~074)		(23161,~~798~~531)		~~(137~~140,~~733)~~457
Effect of exchange rate changes on cash and cash equivalents		(1815,464)		(~~1,739~~18)		1(15,~~721~~446)
Net increase (decrease) in cash and cash equivalents	$	(1205,~~057)~~205	$	9(1,~~751~~057)	$	~~(10~~206,~~808)~~262

Operating activities

For the year ended December 31, ~~2024~~2025, our operating ~~acitivities~~activities used $168.36 million of cash, reflecting the net ~~loss~~income of $~~114~~78.83 million offset by non-cash ~~expenses~~gains of $~~107~~73.02 million primarily comprised of $63117.80 million of ~~impairment~~gain ~~loss~~on divested business and $5.2 million change in contingent consideration, which was partially offset by $3027.87 million of depreciation and amortization, $1911.70 million of stock-based compensation, $56.86 million of non-cash operating lease expense, ~~which~~and ~~was~~$2.2 ~~partially~~million ~~offset~~of byrealized aloss ~~gain~~ on ~~the~~available-for-sale ~~extinguishment of debt of $18~~investments.5 ~~million.~~ Also contributing to the cash ~~impact~~used ofin ~~our net~~ operating ~~loss~~activities, excluding non-cash items, was ~~a decrease in operating lease liabilities of $5.3 million,~~ an increase in accounts receivable of $46.15 million, ana ~~increase~~decrease in ~~prepaid~~operating ~~expenses~~lease ~~and~~liabilities ~~other current assets~~ of $25.10 million, a decrease in accounts payable and other accrued expenses of $03.15 million, and an increase in ~~deposits~~inventories of $12.42 million ~~and a decrease in net deferred tax liability of $0.4 million~~, which were partially offset by aan ~~decrease~~increase in ~~inventories~~accrued compensation and related expenses of $31.39 million, and ana ~~increase~~decrease in ~~accrued~~prepaid ~~compensation~~expenses and ~~related~~other ~~expenses~~current assets of $1.94 million.

Investing activities

Net cash provided by investing activities of $~~176~~250.83 million during the year ended December 31, ~~2024~~2025 was primarily due to the ~~$249.1~~proceeds ~~million~~from ~~maturity~~the divestiture of ~~short-term~~the ~~investments.~~CRYOPDP ~~These~~business ~~proceeds~~of ~~were~~$210.2 ~~partially~~million ~~offset~~and by the ~~purchase~~maturity of short-term investments of $5059.76 million,. ~~and~~These proceeds were partially offset by facility expansions (including leasehold improvements, furniture and equipment) and additional purchases of Cryoport Express® Shippers, Smart Pak IITM Condition Monitoring Systems, freezers and computer equipment for $1716.34 million, software development costs of $1.8 million, and patent and trademark costs of $1.2 million.

Financing ~~Activity~~activities

Net cash used in financing activities totaled $~~161~~21.51 million during the year ended December 31, ~~2024~~2025, primarily as a result of $~~163~~14.83 million paid for the ~~repurchase~~repayment ~~2026~~of 2025 Convertible Senior Notes and $10.0 million paid for the repurchase of common stock, partially offset by proceeds of $24.80 million from the exercise of stock options.

4739

Table of Contents

Repurchase Program

In March 2022, the Company’s Board of Directors authorized athe ~~repurchase~~2022 ~~program~~Repurchase Program through December 31, 2025, authorizing the repurchase of common stock and/or convertible senior notes in the amount of up to $100.0 million from time to time, on the open market or otherwise, in such quantities, at such prices, and in such manner as determined by the Company’s management at its discretion ~~(the “2022 Repurchase Program”)~~. The ~~size and timing repurchases under the~~ 2022 Repurchase Program ~~were~~expired ~~dependant~~ on aDecember ~~number of factors~~31, ~~including~~2025 ~~the~~pursuant ~~market~~to ~~price~~its ~~of the Company’s common stock, general market and economic conditions, and applicable legal requirements~~terms.

In ~~July~~August 2024, ~~May~~the Company’s Board of Directors authorized the 2024 ~~and~~Repurchase ~~September~~Program ~~2023~~through December 31, 2027, authorizing the ~~Company~~repurchase ~~repurchased~~of common stock and/or convertible senior notes in the amount of up to $15200.0 million from time to time, ~~$10.0~~on ~~million~~the ~~and~~open ~~$31.3~~market ~~million~~or otherwise, ~~respectively~~in such quantities, at such prices, and in ~~aggregate~~such ~~principal~~manner ~~amount~~as ofdetermined by the ~~2026~~Company’s ~~Convertible~~management ~~Senior~~at ~~Notes~~its ~~for~~discretion. aThe ~~repurchase~~authorized ~~price~~amount ofunder ~~$12.9~~the ~~million,~~2024 ~~$8.7~~Repurchase ~~million~~Program was in addition to the 2022 Repurchase Program and ~~$25~~did not modify the 2022 Repurchase Program.0 The ~~million,~~size ~~respectively,~~and intiming ~~cash~~of any repurchases under the ~~2022~~2024 Repurchase Program will depend on a number of factors, including the market price of the Company’s common stock, general market and economic conditions, and applicable legal requirements.

In ~~August~~July 2024, ~~the~~May ~~Company’s~~2024 ~~Board~~and ofSeptember ~~Directors authorized a Repurchase Program through December 31~~2023, ~~2027, authorizing~~ the ~~repurchase~~Company ofrepurchased ~~common stock and/or convertible senior notes in the amount of up to~~ $~~200~~15.0 million ~~from time to time~~, on$10.0 ~~the~~million ~~open~~and ~~market~~$31.3 ~~or otherwise~~million, ~~in such quantities~~respectively, ~~at such prices, and~~ in ~~such~~aggregate ~~manner~~principal asamount ~~determined~~of by the ~~Company’s~~2026 ~~management~~Convertible atSenior ~~its~~Notes ~~discretion~~for ~~(the~~a ~~“2024~~cash ~~Repurchase~~repurchase ~~Program”~~price ~~and,~~of ~~together~~$12.9 ~~with the 2022 Repurchase Program~~million, ~~the “Repurchase Programs”)~~$8.7 ~~The~~million ~~size~~ and ~~timing~~$25.0 ofmillion, ~~any~~respectively, ~~repurchase~~plus ~~under~~accrued ~~the~~and ~~2024~~unpaid ~~Repurchase~~interest. ~~Programs~~The ~~will~~repurchases ~~depend~~were onmade apursuant ~~number~~to ~~of factors, including~~ the ~~market~~2022 ~~price~~Repurchase ~~of the Company’s common stock, general market and economic conditions, and applicable legal requirements~~Program.

~~Also~~ inIn August 2024, the Company repurchased approximately $160.0 million aggregate principal amount of the 2026 Convertible Senior Notes for a cash repurchase price of $141.6 million, plus accrued and unpaid interest ~~under the 2024 Repurchase Programs~~. AsThe ~~of December 31, 2024, the Company has approximately $73.9 million of~~ repurchase ~~authorization~~was ~~available~~made ~~under~~pursuant to the 2024 Repurchase ~~Programs~~Program.

There were no ~~shares~~repurchases ~~repurchased~~of the 2026 Convertible Senior Notes during the ~~years~~year ended December 31, ~~2024 and 2023~~2025.

AsDuring ofthe ~~December~~year ended December 31, ~~2024~~2025, the Company ~~has~~purchased ~~approximately~~1,340,608 ~~$200.5~~shares ~~million~~of ~~aggregate~~its ~~principal~~common ~~amount~~stock ofunder the ~~2025~~Repurchase ~~Senior~~Programs ~~Notes~~at ~~and~~an ~~2026~~average ~~Senior~~price ~~Notes~~of ~~outstanding~~$7.45 ~~and~~per ~~has~~share, ~~approximately~~for an aggregate purchase price of $7310.90 million. ofThese ~~repurchase~~shares ~~authorization~~were ~~available~~returned ~~under~~to the ~~Repurchase~~status ~~Programs~~of authorized but unissued shares of common stock. ~~For~~All ~~additional~~share ~~information~~repurchases ~~about~~were ~~the~~made ~~Convertible~~using ~~Senior~~cash ~~Notes,~~resources ~~see~~and ~~Note~~are 12reported in ~~our~~the ~~accompanying~~period ~~consolidated~~based ~~financial~~on ~~statements~~the settlement date of the applicable repurchase.

There were no shares of common stock repurchased during the years ended December 31, 2024 and 2023.

As of December 31, 2025, the Company has approximately $186.2 million in aggregate principal amount of the 2026 Convertible Senior Notes outstanding and has approximately $63.9 million of repurchase authorization available under the 2024 Repurchase Program. For additional information about the 2026 Convertible Senior Notes, see Note 12 – Convertible Senior Notes to our consolidated financial statements included under Part II, Item 8 “Financial Statements and Supplementary Data.”

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

We are exposed to market risk for the effect of interest rate changes, foreign currency fluctuations, and changes in the market values of our investments.

Interest Rate Risk

Our exposure to market risk for changes in interest rates relates primarily to our investment portfolio and our short-term and long-term debt. Our short-term and long-term debt is carried at amortized cost and fluctuations in interest rates do not impact our consolidated financial statements. However, the fair value of our debt, which pays interest at a fixed rate, will generally fluctuate with movements of interest rates, increasing when interest rates are declining and declining when interest rates are increasing. We invest our excess cash in high investment grade money market funds and investment grade short to intermediate-term fixed income securities. Fixed income securities may have their fair market value adversely affected due to a rise in interest rates, and we may suffer losses if forced to sell securities that have declined in market value due to changes in interest rates. As of December 31, ~~2024~~2025, the estimated fair value of the 2026 Convertible Senior Notes was $~~178~~176.76 million. For additional information about the 2026 Convertible Senior Notes, see Note 12 in– ~~our~~Convertible ~~accompanying~~Senior Notes to our consolidated financial statements included under Part II, Item 8 “Financial Statements and Supplementary Data”.

~~Foreign Exchange Risk~~40

We operate in the United States and other foreign countries, which creates exposure to foreign currency exchange fluctuations. Net sales and related expenses generated from our international business are primarily denominated in the functional currencies of the corresponding subsidiaries and primarily include Euros, British Pounds, Chinese Yuan, and Indian Rupee. The results of operations of, and certain of our intercompany balances associated with, our internationally focused business are exposed to foreign exchange rate

Table of Contents

~~fluctuations.~~Foreign ~~Upon~~Exchange consolidation, as foreign exchange rates vary, revenues and other operating results may differ materially from expectations and we may record material gain or losses on the remeasurement of intercompany balances. For example, for the year ended December 31, 2024, revenues from our international business, which accounted for 38.2% of our consolidated revenues, decreased by $0.3 million in comparison with the same period in the prior year as a result of fluctuations in foreign exchange rates. The impact of fluctuations in foreign exchange rates is derived by applying the average currency rates for the same period of the prior year to the current period revenues.Risk

We ~~have~~operate in the United States and other foreign ~~exchange~~countries, ~~risk~~which ~~related~~creates exposure to foreign- currency exchange fluctuations. Net sales and related expenses generated from our international business are primarily denominated ~~cash~~in the functional currencies of the corresponding subsidiaries and ~~cash~~primarily ~~equivalents~~include Euros, British Pounds, and Chinese Yuan. ~~Based~~The onresults ~~the~~of operations of, and certain of our intercompany balances associated with, our internationally focused business are exposed to foreign~~-dominated~~ ~~cash~~exchange ~~balance~~rate fluctuations. Upon consolidation, as foreign exchange rates vary, revenue and other operating results may differ materially from expectations and we may record material gain or losses on the remeasurement of intercompany balances. For example, for the year ended December 31, ~~2024~~2025, revenue from our international business, which accounted for 18% of our consolidated revenues, increased by $300.69 million, anin ~~assumed~~comparison ~~5%,~~with ~~10%,~~the ~~and~~same ~~20%~~period ~~adverse~~in ~~change~~the toprior ~~foreign~~year ~~exchange~~as ~~would~~a result of fluctuations in ~~declines~~foreign ofexchange $1rates.5 ~~million,~~The ~~$3.1~~impact ~~million,~~of ~~and~~fluctuations ~~$6.1~~in ~~million,~~foreign ~~respectively,~~exchange ~~recorded~~rates tois ~~“Accumulated~~derived ~~other~~by ~~comprehensive~~applying ~~income~~the ~~(loss)”,~~average acurrency ~~separate~~rates ~~component~~for the same period of ~~stockholders’~~the ~~equity~~prior year to the current period revenue.

We have foreign exchange risk related to ~~our long and short-term~~ foreign-denominated ~~intercompany~~cash ~~loan~~and ~~balances~~cash equivalents. Based on the ~~long~~foreign-~~term~~denominated ~~intercompany~~cash ~~loan~~balance ~~balances~~ as of December 31, ~~2024~~2025 of $31.9 million, an assumed 5%, 10%, and 20% adverse change to foreign exchange would result in ~~losses~~declines of $41.6 million, $93.12 million, and $186.24 million, respectively, recorded to “Accumulated other comprehensive income (loss)”~~. Based on the short-term intercompany loan balances as of December 31~~, ~~2024,~~ ana ~~assumed~~separate ~~5%,~~component ~~10%, and 20% adverse change to foreign exchange would result in losses~~ of ~~$1.0~~stockholders’ ~~million, $1~~equity.~~9 million, and $3.8 million, respectively, reported as “Other income (expense), net”.~~

We have foreign exchange risk related to our long and short-term foreign-denominated intercompany loan balances. Based on the short-term intercompany loan balances as of December 31, 2025, an assumed 5%, 10%, and 20% adverse change to foreign exchange would result in losses of $1.6 million, $3.2 million, and $6.4 million, respectively, reported as “Other income (expense), net”.

Item 8. Financial Statements and Supplementary Data

Our annual consolidated financial statements are included in Part IV, Item 15 of this Form 10-K and are incorporated into this Item 8 by reference.

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

None.

Item 9A. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

The term “disclosure controls and procedures” (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) refers to the controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we have conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of December 31, ~~2024~~ 2025. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of December 31, ~~2024~~ 2025.

(b) Management’s Report on Internal Control Over Financial Reporting.

Management’s Report on Internal Control Over Financial Reporting which appears on the following page is incorporated herein by reference.

Deloitte & Touche LLP, an independent registered public accounting firm, has audited the effectiveness of our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) as of December 31, ~~2024~~ 2025, as stated in its attestation report included in Part II, Item 8. “Financial Statements and Supplementary Data” included elsewhere in this Form 10-K.

4941

Table of Contents

During the quarter ended December 31, ~~2023~~ 2025, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Item 9B. Other Information

Insider Trading Arrangements and Policies

OnNo ~~December~~directors ~~13,~~or ~~2024,~~officers ~~Ramkumar~~(as ~~Mandalam,~~defined ain ~~member~~Exchange ofAct ~~our Board of Directors, entered into a trading plan intended to satisfy the affirmative defense conditions of~~ Rule ~~10b5~~16a-1(cf).) adopted or terminated a ~~Dr.~~“Rule ~~Mandalam’s~~10b5–1 ~~plan~~trading ~~covers~~arrangement” ~~the~~or ~~potential~~a ~~sale~~“non-Rule of10b5–1 uptrading ~~to 14~~arrangement,~~078~~” ~~shares~~each ofas ~~our~~defined ~~common~~in ~~stock~~Item to408 ~~be acquired upon the exercise~~ of ~~stock~~Regulation ~~options or settlement of restricted stock units. Transactions under Dr. Mandalam’s plan are based upon pre~~S-~~established~~K ~~dates and stock price thresholds and will only occur upon the expiration~~ of the ~~applicable~~Securities ~~mandatory~~Act ~~cooling-off period. Dr. Mandalam’s plan will terminate on the earlier~~ of ~~June 13~~1933, ~~2025~~as oramended, during the ~~date~~three ~~all~~months ~~shares~~ended ~~subject~~December to31, ~~the plan have been sold~~2025.

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Not applicable.

Table of Contents

CRYOPORT, INC.

MANAGEMENT’S REPORT ON

INTERNAL CONTROL OVER FINANCIAL REPORTING

The management of the Company is responsible for establishing and maintaining effective internal control over financial reporting and for the assessment of the effectiveness of internal control over financial reporting. The Company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America.

The Company’s internal control over financial reporting is supported by written policies and procedures that:

●

pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the Company’s assets;

●

provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and that receipts and expenditures of the Company are being made only in accordance with authorizations of the Company’s management and directors; and

●

provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the consolidated financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In connection with the preparation of the Company’s annual consolidated financial statements, management of the Company has undertaken an assessment of the effectiveness of the Company’s internal control over financial reporting based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Management’s assessment included an evaluation of the design of the Company’s internal control over financial reporting and testing of the operational effectiveness of the Company’s internal control over financial reporting.

Based on this assessment, management has concluded that the Company’s internal control over financial reporting was effective as of December 31, ~~2024~~ 2025.


By:	/s/ JERRELL W. SHELTON
	Jerrell W. Shelton,
	President and Chief Executive Officer


By:	/s/ ROBERT STEFANOVICH
	Robert Stefanovich,
	Chief Financial Officer

March 75, ~~2025~~2026

5143

Table of Contents

PART III

Item 10. Directors, Executive Officers and Corporate Governance

A list of our executive officers and their respective biographical information appears in Part I, Item 1 of this Form 10-K.

We have adopted a corporate code of conduct that applies to our directors and all employees, including our Chief Executive Officer and Chief Financial Officer. We have posted the text of our corporate code of conduct on our website at www.cryoportinc.com.

on the “Investor Relations: Governance” page under the heading “Governance Documents.” We intend to satisfy the requirement under Item 5.05 of Form 8-K regarding disclosure of amendments to, or waivers from, provisions of our corporate code of conduct by posting such information on our website.

The other information required under this item is incorporated by reference from our definitive proxy statement related to our ~~2025~~2026 Annual Meeting of Stockholders, or the Proxy Statement, to be filed with the SEC within 120 days of our fiscal year ended December 31, ~~2024~~ 2025.

Item 11. Executive Compensation

The information required by this item can be found in our Proxy Statement and is incorporated herein by reference.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The information required by this item can be found in our Proxy Statement and is incorporated herein by reference.

Item 13. Certain Relationships and Related Transactions, and Director Independence

The information required by this item can be found in our Proxy Statement and is incorporated herein by reference.

Item 14. Principal Accountant Fees and Services

The information required by this item can be found in our Proxy Statement and is incorporated herein by reference.

5244

Table of Contents

PART IV

Item 15. Exhibits and Financial Statement Schedules

(a)(1) Consolidated Financial Statements:

	Page
Report of Independent Registered Public Accounting Firm (PCAOB ID No. 34)	F-2
Report of Independent Registered Public Accounting Firm (PCAOB ID No. 42)	F-5
Consolidated Balance Sheets as of December 31, 2025 and 2024	F-5
Consolidated Balance Sheets as of December 31, 2024 and 2023	F-6
Consolidated Statements of Operations for the years ended December 31, 2025, 2024 and 2023	F-6
Consolidated Statements of Operations for the years ended December 31, 2024, 2023 and 2022	F-7
Consolidated Statements of Comprehensive Loss for the years ended December 31, 2025, 2024 and 2023	F-7
Consolidated Statements of Comprehensive Loss for the years ended December 31, 2024, 2023 and 2022	F-8
Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2025, 2024 and 2023	F-8
Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2024, 2023 and 2022	F-9
Consolidated Statements of Cash Flows for the years ended December 31, 2025, 2024 and 2023	F-9
Consolidated Statements of Cash Flows for the years ended December 31, 2024, 2023 and 2022	F-10
Notes to Consolidated Financial Statements	F-10
Notes to Consolidated Financial Statements	F-11

(a)(2) Financial Statement Schedules: All financial statement schedules are omitted because they are not applicable or the required information is included in the Consolidated Financial Statements or notes thereto.

(a)(3) Exhibits.

Table of Contents

Index to Exhibits


Exhibit No.		Description
2.1^˄		Asset Purchase Agreement, dated May 14, 2019, by and between Cryogene, Inc. and CryoGene Partners. Incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K dated May 14, 2019.

2.2^˄		Purchase Agreement, dated as of August 24, 2020, by and between Cryoport, Inc. and Chart Industries, Inc. Incorporated by reference to Exhibit 2.1 of the Company’s Current Report on Form 8-K dated August 25, 2020.

2.3^˄		Sale and Purchase Agreement, dated as of March 31, 2025, by and among Cryoport, Inc., Cryoport Netherlands BV, Cryoport Germany GmbH, and DHL Supply Chain International Holding B.V. Incorporated by reference to Exhibit 2.1 of the Company’s Current Report on Form 8-K dated March 31, 2025.

3.1		Amended and Restated Articles of Incorporation of the Company, as amended. Incorporated by reference to Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2012.

3.2		Amended and Restated Bylaws of the Company. Incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K dated November 15, 2023.

3.3		Amended and Restated Certificate of Designation of Class A Preferred Stock. Incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K dated March 30, 2015.

3.4		Certificate of Designation of Class B Preferred Stock. Incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K dated February 20, 2015.

3.5		Amendment to Certificate of Designation of Class B Preferred Stock. Incorporated by reference to the Company’s Amendment No. 1 to Registration Statement on Form S-1 dated April 17, 2015 and referred to as Exhibit 3.6.

3.6		Certificate of Change filed with the Nevada Secretary of State on May 12, 2015. Incorporated by reference to Exhibit 3.7 of the Company’s Annual Report on Form 10-K filed with the SEC on May 19, 2015.

3.7		Amendment to Certificate of Designation of Class A Preferred Stock. Incorporated by reference to the Company’s Amendment No. 4 to Registration Statement on Form S-1 dated June 22, 2015 and referred to as Exhibit 3.8.

3.8		Amendment to Certificate of Designation of Class B Preferred Stock. Incorporated by reference to the Company’s Amendment No. 4 to Registration Statement on Form S-1 dated June 22, 2015 and referred to as Exhibit 3.9.

3.9		Amendment to Certificate of Designation of Class A Preferred Stock. Incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K dated September 1, 2015.

3.10		Amendment to Certificate of Designation of Class B Preferred Stock. Incorporated by reference to Exhibit 3.2 of the Company’s Current Report on Form 8-K dated September 1, 2015.

3.11		Certificate of Amendment filed with the Nevada Secretary of State on November 23, 2015. Incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K dated November 23, 2015.

3.12		Certificate of Amendment filed with the Nevada Secretary of State on May 30, 2018. Incorporated by reference to Exhibit 3.12 of the Company’s Annual Report on Form 10-K filed with the SEC on March 13, 2019.

3.13		Certificate of Designation of 4.0% Series C Convertible Preferred Stock of the Company. Incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K dated October 1, 2020.

4.1		Description of the Company’s securities. Incorporated by reference to Exhibit 4.1 of the Company’s Annual Report on Form 10-K filed with the SEC on March 1, 2021.

4.2		Indenture, dated as of November 12, 2021, between Cryoport, Inc. and U.S. Bank National Association, as trustee. Incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K dated November 12, 2021.


Exhibit No.		Description
2.1˄		Asset Purchase Agreement, dated May 14, 2019, by and between Cryogene, Inc. and CryoGene Partners. Incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K dated May 14, 2019.

2.2˄		Purchase Agreement, dated as of August 24, 2020, by and between Cryoport, Inc. and Chart Industries, Inc. Incorporated by reference to Exhibit 2.1 of the Company’s Current Report on Form 8-K dated August 25, 2020.

3.1		Amended and Restated Articles of Incorporation of the Company, as amended. Incorporated by reference to Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2012.

3.2		Amended and Restated Bylaws of the Company. Incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K dated November 15, 2023.

3.3		Amended and Restated Certificate of Designation of Class A Preferred Stock. Incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K dated March 30, 2015.

3.4		Certificate of Designation of Class B Preferred Stock. Incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K dated February 20, 2015.

3.5		Amendment to Certificate of Designation of Class B Preferred Stock. Incorporated by reference to the Company’s Amendment No. 1 to Registration Statement on Form S-1 dated April 17, 2015 and referred to as Exhibit 3.6.

3.6		Certificate of Change filed with the Nevada Secretary of State on May 12, 2015. Incorporated by reference to Exhibit 3.7 of the Company’s Annual Report on Form 10-K filed with the SEC on May 19, 2015.

3.7		Amendment to Certificate of Designation of Class A Preferred Stock. Incorporated by reference to the Company’s Amendment No. 4 to Registration Statement on Form S-1 dated June 22, 2015 and referred to as Exhibit 3.8.

3.8		Amendment to Certificate of Designation of Class B Preferred Stock. Incorporated by reference to the Company’s Amendment No. 4 to Registration Statement on Form S-1 dated June 22, 2015 and referred to as Exhibit 3.9.

3.9		Amendment to Certificate of Designation of Class A Preferred Stock. Incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K dated September 1, 2015.

3.10		Amendment to Certificate of Designation of Class B Preferred Stock. Incorporated by reference to Exhibit 3.2 of the Company’s Current Report on Form 8-K dated September 1, 2015.

3.11		Certificate of Amendment filed with the Nevada Secretary of State on November 23, 2015. Incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K dated November 23, 2015.

3.12		Certificate of Amendment filed with the Nevada Secretary of State on May 30, 2018. Incorporated by reference to Exhibit 3.12 of the Company’s Annual Report on Form 10-K filed with the SEC on March 13, 2019.

3.13		Certificate of Designation of 4.0% Series C Convertible Preferred Stock of the Company. Incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K dated October 1, 2020.

4.1		Description of the Company’s securities. Incorporated by reference to Exhibit 4.1 of the Company’s Annual Report on Form 10-K filed with the SEC on March 1, 2021.

4.2		Indenture, dated May 26, 2020, between Cryoport, Inc. and U.S. Bank National Association, as trustee. Incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K dated May 27, 2020.

4.3		Form of certificate representing the 3.00% Convertible Senior Notes due 2025. Incorporated by reference to Exhibit 4.2 of the Company’s Current Report on Form 8-K dated May 27, 2020.

Table of Contents


Exhibit No.		Description
4.4		Indenture, dated as of November 12, 2021, between Cryoport, Inc. and U.S. Bank National Association, as trustee. Incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K dated November 12, 2021.
4.3		Form of certificate representing the 0.75% Convertible Senior Notes due 2026. Incorporated by reference to Exhibit A of Exhibit 4.1 of the Company’s Current Report on Form 8-K dated November 12, 2021.

4.5		Form of certificate representing the 0.75% Convertible Senior Notes due 2026. Incorporated by reference to Exhibit 4.2 of the Company’s Current Report on Form 8-K dated November 12, 2021.

10.1*		2011 Stock Incentive Plan (as amended and restated). Incorporated by reference to Exhibit A of the Company’s Definitive Proxy Statement on Schedule 14A filed with the SEC on July 30, 2012.

10.2*		Stock Option Agreement dated December 18, 2014 between the Company and Jerrell Shelton. Incorporated by reference to Exhibit 10.42 of the Company’s Annual Report on Form 10-K filed with the SEC on May 19, 2015.

10.3*		2015 Omnibus Equity Incentive Plan. Incorporated by reference to Appendix A of the Company’s Definitive Proxy Statement on Schedule 14A filed with the SEC on October 1, 2015.

10.4*		Cryoport, Inc. 2018 Omnibus Equity Incentive Plan (as amended by the First Amendment, Second Amendment and Third Amendment, effective May 17, 2024). Incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K dated May 22, 2024.

10.5*		Form of Stock Option Award Agreement under the 2018 Omnibus Equity Incentive Plan. Incorporated by reference to Exhibit 10.6 of the Company’s Annual Report on Form 10-K filed with the SEC on March 1, 2021.

10.6*		Form of Non-Qualified Stock Option Award Agreement under the 2018 Omnibus Equity Incentive Plan. Incorporated by reference to Exhibit 10.7 of the Company’s Annual Report on Form 10-K filed with the SEC on March 1, 2021.

10.7*		Form of Restrictive Stock Right Award Agreement under the 2018 Omnibus Equity Incentive Plan. Incorporated by reference to Exhibit 10.8 of the Company’s Annual Report on Form 10-K filed with the SEC on March 1, 2021.

10.8*		Amended and Restated Employment Agreement dated February 15, 2024 between the Company and Jerrell W. Shelton. Incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K dated February 15, 2024.

10.9*		Amended and Restated Employment Agreement dated February 15, 2024 between the Company and Robert S. Stefanovich. Incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K dated February 15, 2024.

10.10*		Amended and Restated Employment Agreement dated February 15, 2024 between the Company and Mark Sawicki. Incorporated by reference to Exhibit 10.3 of the Company’s Current Report on Form 8-K dated February 15, 2024.

10.11*+		Employment Agreement dated February 19, 2024 between the Company and Edward Zecchini. ~~Incoropration~~Incorporation by reference to Exhibit 10.11 of the Company’s Annual Report on Form 10-K filed with the SEC on March 13, 2024.

10.12		Registration Rights Agreement, dated May 26, 2020, among Cryoport, Inc., Jefferies LLC and SVB Leerink LLC. Incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K dated May 27, 2020.

10.13		Securities Purchase Agreement, dated August 21, 2020, between Cryoport, Inc. and each of the Sellers identified therein. Incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K dated August 21, 2020.

10.14˄		Securities Purchase Agreement, dated as of August 24, 2020, by and between Cryoport, Inc. and BTO Freeze Parent L.P. Incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K dated August 25, 2020.

10.15		Registration Rights Agreement, dated as of October 1, 2020, by and among Cryoport, Inc., BTO Freeze Parent L.P. and Blackstone Tactical Opportunities Fund – FD L.P. Incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K dated October 1, 2020.

10.16		Amendment No. 1 to Securities Purchase Agreement, dated October 1, 2020, by and among Cryoport Inc., Cryoport Netherlands B.V. and the other parties thereto. Incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K dated October 1, 2020.

10.17+		Form of Stock Option Agreement Issued by Cryoport, Inc. to certain employees on May 7, 2015. Incorporated by reference to Exhibit 10.17 of the Company’s Annual Report on Form 10-K filed with the SEC on March 7, 2025.

5547

Table of Contents


Exhibit No.		Description
10.17+		Form of Stock Option Agreement Issued by Cryoport, Inc. to certain employees on May 7, 2015.
19+		Cryoport, Inc. Insider Trading Policy. Incorporated by reference to Exhibit 19 of the Company’s Annual Report on Form 10-K filed with the SEC on March 7, 2025.

16.1		Letter to Securities and Exchange Commission from Ernst & Young LLP dated March 15, 2023. Incorporated by reference to Exhibit 16.1 of the Company’s Current Report on Form 8-K dated March 15, 2023.

19+		Cryoport, Inc. Insider Trading Policy.

21+		Subsidiaries of Registrant.

23.1+		Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm.

23.2+		Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm.
23.1+		Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm.

31.1+		Certification of Principal Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934.

31.2+		Certification of Principal Financial Officer, pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934.

32.1+		Certification of Principal Executive Officer, pursuant to Rule 13a-14(b)/15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350.

32.2+		Certification of Principal Financial Officer, pursuant to Rule 13a-14(b)/15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350.

97		Cryoport, Inc. Clawback Policy. Incorporated by reference to Exhibit 97 foof the Company’s Annual Report on Form 10-K filed with the SEC on March 13, 2024.

101.INS+		Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH+		Inline XBRL Taxonomy Extension Schema Document.

101.CAL+		Inline XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF+		Inline XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB+		Inline XBRL Taxonomy Extension Label Linkbase Document.

101.PRE+		Inline XBRL Taxonomy Extension Presentation Linkbase Document.

104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

˄Certain exhibits and schedules have been omitted pursuant to Item 601(~~b)(2) or Item 601(~~a)(5) of Regulation S-K. The Company hereby undertakes to furnish copies of such omitted materials supplementally upon request by the SEC.

*	Indicates a management contract or compensatory plan or arrangement.

+	Filed or furnished herewith.

Item 16. Form 10-K Summary

None.

5648

Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.


	Cryoport, Inc.

	By:	/s/ JERRELL W. SHELTON
		Jerrell W. Shelton
		President and Chief Executive Officer

Date: March 75, ~~2025~~2026

Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:

Signature	Title	Date

/s/ JERRELL W. SHELTON	President, Chief Executive Officer and Director	March 75, ~~2025~~2026
Jerrell W. Shelton	(Principal Executive Officer)

/s/ ROBERT S. STEFANOVICH	Chief Financial Officer	March 75, ~~2025~~2026
Robert S. Stefanovich	(Principal Financial and Accounting Officer)

/s/ DANIEL M. HANCOCK	Director	March 75, ~~2025~~2026
Daniel M. Hancock

/s/ ROBERT HARIRI, M.D., PH.D.	Director	March 75, ~~2025~~2026
Robert Hariri, M.D., Ph.D.

/s/ RAMKUMAR MANDALAM, PH.D.	Director	March 75, ~~2025~~2026
Ramkumar Mandalam, Ph.D.

/s/ RAM JAGANNATH	Director	March 75, ~~2025~~2026
Ram Jagannath

/s/ LINDA BADDOUR	Director	March 75, ~~2025~~2026
Linda Baddour

5749

Table of Contents

Cryoport, Inc. and Subsidiaries

Consolidated Financial Statements

As of December 31, 2025 ~~2024~~ and ~~2023~~2024

Years Ended December 31, 2025, 2024, ~~2023~~ and ~~2022~~2023

Table of Contents

Cryoport, Inc. and Subsidiaries

Consolidated Financial Statements

INDEX TO FINANCIAL STATEMENTS

	Page
Report of Independent Registered Public Accounting Firm (PCAOB ID No. 34)	F-2
Report of Independent Registered Public Accounting Firm (PCAOB ID No. 42)	F-5
Consolidated Balance Sheets as of December 31, 2025 and 2024	F-5
Consolidated Balance Sheets as of December 31, 2024 and 2023	F-6
Consolidated Statements of Operations for the years ended December 31, 2025, 2024 and 2023	F-6
Consolidated Statements of Operations for the years ended December 31, 2024, 2023 and 2022	F-7
Consolidated Statements of Comprehensive Loss for the years ended December 31, 2025, 2024 and 2023	F-7
Consolidated Statements of Comprehensive Loss for the years ended December 31, 2024, 2023 and 2022	F-8
Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2025, 2024 and 2023	F-8
Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2024, 2023 and 2022	F-9
Consolidated Statements of Cash Flows for the years ended December 31, 2025, 2024 and 2023	F-9
Consolidated Statements of Cash Flows for the years ended December 31, 2024, 2023 and 2022	F-10
Notes to Consolidated Financial Statements	F-10
Notes to Consolidated Financial Statements	F-11

F-1

Table of Contents

Report of Independent Registered Public Accounting Firm

To the Stockholders and the Board of Directors of Cryoport, Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Cryoport, Inc. and subsidiaries (the "Company") as of December 31, ~~2024~~2025 and ~~December 31~~2024, ~~2023,~~ the related consolidated statements of operations, comprehensive loss, stockholders’' equity, and cash flows, for each of the ~~two~~three years in the period ended December 31, ~~2024~~2025, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, ~~2024~~2025 and ~~December 31~~2024, ~~2023,~~ and the results of its operations and its cash flows for each of the ~~two~~three years in the period ended December 31, ~~2024~~2025, in conformity with accounting principles generally accepted in the United States of America.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, ~~2024~~2025, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated March 75, ~~2025~~2026, expressed an unqualified opinion on the Company's internal control over financial reporting.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matter

The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

~~Goodwill and~~ Trademark ~~Impairment~~Valuation— MVE ~~Reporting Unit~~ — Refer to ~~Notes~~Note 210 ~~and~~in ~~8 to~~ the financial statements

Critical Audit Matter Description

~~The~~Indefinite-lived ~~Company~~intangible ~~evaluates~~assets ~~goodwill~~are oncomprised anof ~~annual~~trademarks ~~basis~~and inare ~~the~~tested ~~fourth~~for ~~quarter or more frequently if management believes indicators of~~ impairment ~~exist.~~annually Inusing ~~this~~a ~~evaluation,~~relief ~~for~~from ~~each~~royalty ~~reporting~~method ~~unit,~~that ~~the~~relies ~~Company~~on ~~compares~~estimates ~~the fair value~~ of the ~~reporting~~future ~~unit~~revenue ~~with~~growth ~~its~~rate, ~~carrying~~royalty ~~amount~~rate, and ~~then~~discount ~~recognizes~~rate. anIf ~~impairment charge for~~ the ~~amount~~asset byis ~~which~~not ~~the~~found ~~carrying~~to ~~amount~~be ~~exceeds~~recoverable, ~~the~~it ~~reporting~~is ~~unit’s~~written ~~fair~~down ~~value up~~ to the ~~total~~estimated ~~amount~~fair ofvalue. ~~goodwill~~Based ~~allocated~~on to the ~~reporting unit. The Company’s interim~~ quantitative impairment ~~test~~assessment ~~was~~ performed ~~using~~in ~~a combination of both an income and a market approach to determine~~ the ~~fair~~fourth ~~value~~quarter of ~~the reporting unit. In doing this~~2025, ~~the~~there ~~Company~~has ~~was~~been ~~assisted~~no byimpairment anrecognized ~~independent~~for ~~third~~indefinite-~~party~~lived ~~specialist.~~intangible ~~The~~assets ~~income approach~~ for ~~goodwill utilized~~ the ~~estimated~~current ~~discounted cash flows for the reporting unit and the market approach utilized comparable peer group information~~period. Estimates and assumptions used in the income approach included projected cash flows for the reporting unit and a discount rate determined using a weighted average cost of capital for risk factors specific to the reporting unit and other market and industry data. The other key estimates and assumptions used in the discounted cash flow method include, but are not limited to, sales growth rates terminal growth rate, EBITDA/EBITDA

We identified the trademark for MVE as a critical audit matter because of the significant judgments made by management to estimate the fair value of the MVE trademark that are affected by future market and economic conditions. This required a high degree of auditor judgment and an increased extent of effort, including the need to involve our fair value specialists, when performing audit procedures to evaluate the reasonableness of management’s estimates and assumptions.

F-2

Table of Contents

margin, and the discount rate. As a result of the Company’s 2024 quantitative assessment, the Company concluded that for the MVE reporting unit, goodwill was fully impaired. The Company recorded an impairment charge of $55M for goodwill in the consolidated statement of operations for the year ended December 31, 2024.

Indefinite-lived intangible assets are comprised of trademarks and are tested for impairment annually using a relief from royalty method that relies on estimates of future revenues, royalty rates, and discount rates. If the asset is not found to be recoverable, it is written down to the estimated fair value. As a result of the Company’s 2024 quantitative assessment, they recorded a $9M impairment charge related to the partial write-off of the MVE trademark in the consolidated statement of operations for the year ended December 31, 2024.

We identified goodwill and trademark impairment for MVE as a critical audit matter because of the significant judgments made by management to estimate the fair value of this reporting unit and fair value of trademark that are affected by future market and economic conditions. This required a high degree of auditor judgment and an increased extent of effort, including the need to involve our fair value specialists, when performing audit procedures to evaluate the reasonableness of management’s estimates and assumptions related to forecasts of revenues, EBITDA margins, discount rates, royalty rate, terminal growth rate, and selection of market multiples.

How the Critical Audit Matter Was Addressed in the Audit

Our audit procedures related to the Company’s significant assumptions and estimates related to ~~goodwill~~the ~~impairment~~valuation ~~for~~of ~~this~~the ~~reporting~~MVE ~~unit~~trademark included the following, among others:

● We tested the effectiveness of controls over management’s ~~goodwill~~trademark impairment evaluation, including those over the determination of the ~~fair~~revenue ~~value of the related goodwill reporting unit, such as controls related to management’s selection of the sales~~ growth ~~rates~~rate, ~~terminal~~royalty ~~growth~~ rate, ~~EBITDA/EBITDA margin,~~ and discount rate.

● We evaluated the reasonableness of management’s ~~ability~~revenue togrowth ~~accurately~~rate ~~forecast~~forecasts ~~revenues~~through ~~and~~inquiry ~~EBITDA~~of ~~margins~~management and by comparing ~~actual~~the ~~results~~forecasts to ~~management’s historical forecasts.~~:

●– WeHistorical ~~evaluated the reasonableness of management’s revenue and EBITDA margin forecasts through inquiry of non-management personnel and by comparing the forecasts to:~~revenues.

– Historical revenues and EBITDA margins.

–

Internal communications to management and the Board of Directors.

– Forecasted information included in ~~Company~~analyst ~~press~~and ~~releases~~industry reports for the Company.

–● ~~Forecasted~~With ~~information~~the ~~included~~assistance inof ~~analyst~~our ~~and~~fair ~~industry~~value ~~reports~~specialists, ~~for~~we evaluated the ~~Company~~reasonableness ~~and~~of ~~certain~~the ofdiscount ~~its~~rate ~~peer~~and ~~companies.~~royalty rate by:

●– ~~With~~Testing the ~~assistance~~source ofinformation ~~our~~underlying ~~fair value specialists, we evaluated~~ the ~~reasonableness~~determination of the discount ~~rate,~~and ~~terminal~~royalty ~~growth~~rates ~~rate,~~and ~~valuation~~the ~~methodology,~~mathematical ~~and~~accuracy ~~market~~of ~~multiples~~the ~~by:~~calculations.

– Testing the source information underlying the determination of the discount rates and the mathematical accuracy of the calculation.

– Developing a range of independent estimates and comparing those to the discount rate selected by management.

– Evaluating the market multiples by considering the selected comparable industry grouping of publicly traded companies.

Our audit procedures related to the Company’s significant assumptions and estimates related to trademark impairment:

● We tested the effectiveness of controls over management’s trademark impairment evaluation, including those over the determination of the sales growth rates, royalty rate, and discount rate.

● We evaluated the reasonableness of management’s revenue forecasts and confirmed that the revenue projections were consistent with those used in the MVE reporting unit goodwill impairment analysis.

● With the assistance of our fair value specialists, we evaluated the reasonableness of the discount rate, royalty rate, and valuation methodology by:

– Testing the source information underlying the determination of the discount and royalty rates and the mathematical accuracy of the calculation.

–

Developing a range of independent estimates and comparing those to the discount rate and royalty rate selected by management.

/s/ Deloitte & Touche LLP

Nashville, TennesseeMarch 75, ~~2025~~2026

We have served as the Company's auditor since 2023.

F-3

Table of Contents

Report of Independent Registered Public Accounting Firm

To the Stockholders and the Board of Directors of Cryoport, Inc.

Opinion on Internal Control over Financial Reporting

We have audited the internal control over financial reporting of Cryoport, Inc. and subsidiaries (the "Company") as of December 31, ~~2024~~2025, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, ~~2024~~2025, based on criteria established in Internal Control — Integrated Framework (2013) issued by COSO.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, ~~2024~~ 2025, of the Company and our report dated March 75, ~~2025~~2026, expressed an unqualified opinion on those financial statements.

Basis for Opinion

The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’'s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control over Financial Reporting

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ Deloitte & Touche LLP

Nashville, TennesseeMarch 75, ~~2025~~2026

F-4

Table of Contents

Report of Independent Registered Public Accounting Firm

To the Stockholders and the Board of Directors of Cryoport, Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated statements of operations, comprehensive loss, stockholders' equity and cash flows of Cryoport, Inc. and subsidiaries (the Company) for the year ended December 31, 2022, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the results of operations and cash flows of the Company for the year ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

/s/ Ernst & Young LLP

We served as the Company’s auditor from 2019 to 2023.

Irvine, California

February 28, 2023

except for the Revenue Disaggregation section of Note 3 and Note 20, Segment Reporting, as to which the date is

March 7, 2025

F-5

Table of Contents

Cryoport, Inc. and Subsidiaries

Consolidated Balance Sheets

(in thousands, except share data)


	December 31,
	2025		2024

ASSETS
Current Assets:
Cash and cash equivalents	$	250,494	$	34,137
Short-term investments		160,714		216,460
Accounts receivable, net		33,359		25,304
Inventories		23,188		21,476
Prepaid expenses and other current assets		8,419		7,943
Current assets held for sale		—		36,251
Total current assets		476,174		341,571
Property and equipment, net		85,448		80,013
Operating lease right-of-use assets		39,720		39,920
Intangible assets, net		138,082		147,927
Goodwill		22,400		20,569
Deposits		2,092		1,951
Deferred tax assets		1,073		842
Long-term assets held for sale		—		70,699
Total assets	$	764,989	$	703,492

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts payable and other accrued expenses	$	15,283	$	15,895
Accrued compensation and related expenses		12,980		11,209
Deferred revenue		943		1,061
Current portion of operating lease liabilities		4,133		3,399
Current portion of finance lease liabilities		422		315
Current portion of convertible senior notes, net of discount of $1.1 million and $0.1 million, respectively		185,094		14,298
Current portion of notes payable		163		143
Current portion of contingent consideration		—		2,808
Current liabilities held for sale		—		15,435
Total current liabilities		219,018		64,563
Convertible senior notes, net of current portion and discount of $0 and $2.3 million, respectively		—		183,919
Notes payable, net of current portion		1,087		1,114
Operating lease liabilities, net of current portion		39,078		38,551
Finance lease liabilities, net of current portion		741		800
Deferred tax liabilities		1,354		804
Other long-term liabilities		444		295
Contingent consideration, net of current portion		629		3,751
Long-term liabilities held for sale		—		7,797
Total liabilities		262,351		301,594

Commitments and contingencies
Stockholders’ Equity:
Preferred stock, $0.001 par value; 2,500,000 shares authorized:
Class A convertible preferred stock - $0.001 par value; 800,000 shares authorized; none issued and outstanding		—		—
Class B convertible preferred stock - $0.001 par value; 585,000 shares authorized; none issued and outstanding		—		—
Class C convertible preferred stock - $0.001 par value; 250,000 shares authorized; 200,000 issued and outstanding		42,275		34,275
Common stock, $0.001 par value; 100,000,000 shares authorized; 49,850,793 and 49,908,254 issued and outstanding at December 31, 2025 and December 31, 2024, respectively		50		50
Additional paid-in capital		1,152,680		1,145,677
Accumulated deficit		(688,884)		(757,175)
Accumulated other comprehensive loss		(3,483)		(20,929)
Total stockholders’ equity		502,638		401,898
Total liabilities and stockholders’ equity	$	764,989	$	703,492


	December 31,
	2024		2023

ASSETS
Current Assets:
Cash and cash equivalents	$	45,289	$	46,346
Short-term investments		216,460		410,409
Accounts receivable, net		45,778		42,074
Inventories		22,470		26,206
Prepaid expenses and other current assets		11,574		10,077
Total current assets		341,571		535,112
Property and equipment, net		88,839		84,858
Operating lease right-of-use assets		47,188		32,653
Intangible assets, net		170,464		194,382
Goodwill		51,660		108,403
Deposits		2,902		1,680
Deferred tax assets		868		656
Total assets	$	703,492	$	957,744

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts payable and other accrued expenses	$	27,208	$	26,995
Accrued compensation and related expenses		13,093		11,409
Deferred revenue		1,106		1,308
Current portion of operating lease liabilities		5,419		5,371
Current portion of finance lease liabilities		488		286
Current portion of convertible senior notes, net of discount of $0.1 million		14,298		—
Current portion of notes payable		143		149
Current portion of contingent consideration		2,808		92
Total current liabilities		64,563		45,610
Convertible senior notes, net of current portion and discount of $2.3 million and $7.0 million, respectively		183,919		378,553
Notes payable, net of current portion		1,114		1,335
Operating lease liabilities, net of current portion		44,077		29,355
Finance lease liabilities, net of current portion		1,245		954
Deferred tax liabilities		2,531		2,816
Other long-term liabilities		394		601
Contingent consideration, net of current portion		3,751		9,497
Total liabilities		301,594		468,721

Commitments and contingencies
Stockholders’ Equity:
Preferred stock, $0.001 par value; 2,500,000 shares authorized:
Class A convertible preferred stock - $0.001 par value; 800,000 shares authorized; none issued and outstanding		—		—
Class B convertible preferred stock - $0.001 par value; 585,000 shares authorized; none issued and outstanding		—		—
Class C convertible preferred stock - $0.001 par value; 250,000 shares authorized; 200,000 issued and outstanding		34,275		26,275
Common stock, $0.001 par value; 100,000,000 shares authorized; 49,908,254 and 48,971,026 issued and outstanding at December 31, 2024 and December 31, 2023, respectively		50		49
Additional paid-in capital		1,145,677		1,131,183
Accumulated deficit		(757,175)		(642,419)
Accumulated other comprehensive loss		(20,929)		(26,065)
Total stockholders’ equity		401,898		489,023
Total liabilities and stockholders’ equity	$	703,492	$	957,744

See accompanying notes to consolidated financial statements.

F-65

Table of Contents

Cryoport, Inc. and Subsidiaries

Consolidated Statements of Operations

(in thousands, except per share data)



	Years Ended
	~~2024~~December 31,		~~2023~~		~~2022~~
Life sciences services revenue	$	153,660	$	144,087	$	133,879
	2025		2024		2023
Life sciences products revenue		74,725		89,168		103,398
Life sciences services revenue	$	96,497	$	82,044	$	79,494
Total revenue		228,385		233,255		237,277
Life sciences products revenue		79,680		74,725		89,168
Total revenue		176,177		156,769		168,662

Cost of services revenue		8549,~~206~~429		8143,~~820~~564		7541,~~187~~226
Cost of products revenue		43,~~548~~694		5243,~~103~~548		5852,~~217~~103
Total cost of revenue		~~128~~93,~~754~~123		~~133~~87,~~923~~112		~~133~~93,~~404~~329
Gross margin		9983,~~631~~054		9969,~~332~~657		~~103~~75,~~873~~333

Operating costs and expenses:
Selling, general and administrative		~~148~~102,~~978~~819		~~146~~109,~~880~~809		~~120~~108,~~055~~261
Engineering and development		17,~~710~~041		1817,~~040~~710		1518,~~722~~040
Impairment loss		~~63,809~~—		4963,~~569~~809		—49,569

Total operating costs and expenses		119,860		191,328		175,870
Total operating costs and expenses		230,497		214,489		135,777


Loss from operations		(36,806)		(121,671)		(100,537)
Loss from operations		(130,866)		(115,157)		(31,904)
Other income (expense):
Other income (expense):
Investment income		9,798		9,895		10,577
Investment income		9,895		10,577		8,474
Interest expense, net		(2,361)		(3,977)		(5,580)
Interest expense		(4,108)		(5,503)		(6,142)
Gain on extinguishment of debt, net		—		18,505		5,679
Gain on extinguishment of debt, net		18,505		5,679		—
Other income (expense), net		(2,801)		(7,101)		5,647
Other income (expense), net		(6,906)		5,056		(5,522)
Total other income, net		4,636		17,322		16,323
Total other income (expense), net		17,386		15,809		(3,190)
Loss from continuing operations before provision for income taxes		(32,170)		(104,349)		(84,214)
Loss before provision for income taxes		(113,480)		(99,348)		(35,094)
Provision for income taxes		(1,799)		(359)		(345)
Provision for income taxes		(1,276)		(239)		(2,239)
Loss from continuing operations		(33,969)		(104,708)		(84,559)
Net loss	$	(114,756)	$	(99,587)	$	(37,333)
Income (loss) from discontinued operations, net		112,270		(10,048)		(15,028)
Net income (loss)	$	78,301	$	(114,756)	$	(99,587)
Paid-in-kind dividend on Series C convertible preferred stock		(8,000)		(8,000)		(8,000)
Net loss attributable to common stockholders		(122,756)	$	(107,587)	$	(45,333)
Net income (loss) attributable to common stockholders	$	70,301	$	(122,756)	$	(107,587)
Net loss per share - basic and diluted	$	(2.49)	$	(2.21)	$	(0.93)
Net loss per share from continuing operations — basic and diluted	$	(0.84)	$	(2.29)	$	(1.90)
Weighted average shares outstanding – basic and diluted		49,349,624		48,737,377		48,987,295
Net income (loss) per share from discontinued operations — basic and diluted	$	2.24	$	(0.20)	$	(0.31)
Net income (loss) per share — basic and diluted	$	1.40	$	(2.49)	$	(2.21)
Weighted average common shares issued and outstanding — basic and diluted		50,071,665		49,349,624		48,737,377

See accompanying notes to consolidated financial statements.

F-76

Table of Contents

Cryoport, Inc. and Subsidiaries

Consolidated Statements of Comprehensive Loss

(in thousands)



	Years Ended December 31,
	~~2024~~2025		~~2023~~2024		~~2022~~2023
Net loss	$	(114,756)	$	(99,587)	$	(37,333)
Net income (loss)	$	78,301	$	(114,756)	$	(99,587)
Other comprehensive income (loss), net of tax:
Other comprehensive income, net of tax:
Net unrealized gain on available-for-sale debt securities		21,~~860~~532		62,~~742~~860		~~(23~~6,~~439)~~742
Reclassification of realized (gain) loss on available-for-sale debt securities to earnings		6,625		3,008		(46)
Reclassification of realized loss on available-for-sale debt securities to earnings		3,013		6,625		3,008
Foreign currency translation adjustments		(412,~~349)~~901		(14,~~266~~349)		(91,~~821~~266)
Other comprehensive income (loss)		5,136		8,484		(33,306)
Other comprehensive income		17,446		5,136		8,484
Total comprehensive loss	$	(109,620)	$	(91,103)	$	(70,639)
Total comprehensive income (loss)	$	95,747	$	(109,620)	$	(91,103)

See accompanying notes to consolidated financial statements.

F-87

Table of Contents

Cryoport, Inc. and Subsidiaries

Consolidated Statements of Stockholders’ Equity

(in thousands, except share data)


																	Accumulated
																	Other
	Class A			Class B			Class C										Comprehensive		Total
	Preferred Stock			Preferred Stock			Preferred Stock			Common Stock			Additional		Accumulated		Income		Stockholders’
	Shares	Amount		Shares	Amount		Shares	Amount		Shares	Amount		Paid–In Capital		Deficit		(Loss)		Equity (Deficit)

Balance at December 31, 2021	—	$	—	—	$	—	200,000	$	10,275	49,616,154	$	50	$	1,100,287	$	(467,541)	$	(1,243)	$	641,828
Net loss	—		—	—		—	—		—	—		—		—		(37,333)		—		(37,333)
Other comprehensive loss, net of taxes	—		—	—		—	—		—	—		—		—		—		(33,306)		(33,306)
Stock-based compensation expense	—		—	—		—	—		—	—		—		20,082		—		—		20,082
Paid-in-kind preferred stock dividend	—		—	—		—	—		8,000	—		—		(8,000)		—		—		—
Issuance of common stock for Cell&Co acquisition	—		—	—		—	—		—	15,152		—		479		—		—		479
Repurchase of common stock	—		—	—		—	—		—	(1,604,994)		(2)		—		(37,958)		—		(37,960)
Vesting of restricted stock units	—		—	—		—	—		—	101,070		—		—		—		—		—
Proceeds from exercise of stock options	—		—	—		—	—		—	206,898		—		2,048		—		—		2,048

Balance at December 31, 2022	—	$	—	—	$	—	200,000	$	18,275	48,334,280	$	48	$	1,114,896	$	(542,832)	$	(34,549)	$	555,838
Net loss	—		—	—		—	—		—	—		—		—		(99,587)		—		(99,587)
Other comprehensive income, net of taxes	—		—	—		—	—		—	—		—		—		—		8,484		8,484
Stock-based compensation expense	—		—	—		—	—		—	—		—		22,808		—		—		22,808
Paid-in-kind preferred stock dividend	—		—	—		—	—		8,000	—		—		(8,000)		—		—		—
Vesting of restricted stock units	—		—	—		—	—		—	228,932		—		—		—		—		—
Proceeds from exercise of stock options	—		—	—		—	—		—	407,814		1		1,479		—		—		1,480

Balance at December 31, 2023	—	$	—	—	$	—	200,000	$	26,275	48,971,026	$	49	$	1,131,183	$	(642,419)	$	(26,065)	$	489,023
Net loss	—		—	—		—	—		—	—		—		—		(114,756)		—		(114,756)
Other comprehensive loss, net of taxes	—		—	—		—	—		—	—		—		—		—		5,136		5,136
Other comprehensive income, net of taxes	—		—	—		—	—		—	—		—		—		—		5,136		5,136
Stock-based compensation expense	—		—	—		—	—		—	—		—		19,704		—		—		19,704
Paid-in-kind preferred stock dividend	—		—	—		—	—		8,000	—		—		(8,000)		—		—		—
Vesting of restricted stock units	—		—	—		—	—		—	355,058		—		—		—		—		—
Proceeds from exercise of stock options	—		—	—		—	—		—	582,170		1		2,790		—		—		2,791
Balance at December 31, 2024	—	$	—	—	$	—	200,000	$	34,275	49,908,254	$	50	$	1,145,677	$	(757,175)	$	(20,929)	$	401,898

Balance at December 31, 2024	—	$	—	—	$	—	200,000	$	34,275	49,908,254	$	50	$	1,145,677	$	(757,175)	$	(20,929)	$	401,898
Net income	—		—	—		—	—		—	—		—		—		78,301		—		78,301
Other comprehensive income, net of taxes	—		—	—		—	—		—	—		—		—		—		17,446		17,446
Stock-based compensation expense	—		—	—		—	—		—	—		—		11,032		—		—		11,032
Paid-in-kind preferred stock dividend	—		—	—		—	—		8,000	—		—		(8,000)		—		—		—
Repurchase of common stock	—		—	—		—	—		—	(1,340,608)		(1)		—		(10,010)		—		(10,011)
Vesting of restricted stock units	—		—	—		—	—		—	394,840		—		—		—		—		—
Proceeds from exercise of stock options	—		—	—		—	—		—	888,307		1		3,971		—		—		3,972
Balance at December 31, 2025	—	$	—	—	$	—	200,000	$	42,275	49,850,793	$	50	$	1,152,680	$	(688,884)	$	(3,483)	$	502,638

See accompanying notes to consolidated financial statements.

F-98

Table of Contents

Cryoport, Inc. and Subsidiaries

Consolidated Statements of Cash Flows

(in thousands)



		Years Ended December 31,
		2025			2024			2023
Cash Flows From Operating Activities:
Net income (loss)		$	78,301		$	(114,756)		$	(99,587)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Impairment loss			—			63,809			49,569
Depreciation and amortization			27,712			30,757			27,487
Amortization of debt discount			1,221			1,940			2,526
Non-cash operating lease expense			6,596			5,770			5,103
Unrealized (gain) loss on investments in equity securities			(1,506)			899			(1,308)
Realized loss on investments in equity securities			—			48			—
Realized loss on available-for-sale investments			2,209			4,091			67
Gain on extinguishment of debt			—			(18,505)			(5,679)
Gain on divested business			(116,953)			—			—
Stock-based compensation expense			11,032			19,704			22,808
Loss on disposal of property and equipment			1,012			384			954
Gain on insurance settlement			—			—			(2,642)
Change in credit losses			304			(242)			822
Excess and obsolete inventory			393			234			—
Insurance proceeds for operations			—			—			1,212
Change in contingent consideration			(5,207)			(1,847)			(890)
Changes in operating assets and liabilities:
Accounts receivable			(6,527)			(4,149)			3,673
Inventories			(2,185)			3,252			1,508
Prepaid expenses and other current assets			1,353			(2,149)			(103)
Deposits			(189)			(1,443)			(663)
Operating lease liabilities			(5,036)			(5,340)			(4,595)
Accounts payable and other accrued expenses			(3,464)			(76)			(2,766)
Accrued compensation and related expenses			1,909			1,852			2,884
Deferred revenue			(216)			(179)			842
Net deferred tax liability			661			(377)			(1,979)
Net cash used in operating activities			(8,580)			(16,323)			(757)

Cash Flows From Investing Activities:
Purchases of property and equipment			(16,439)			(17,254)			(38,785)
Insurance proceeds for loss of fixed assets			—			—			976
Software development costs			(1,832)			(2,886)			(5,244)
Purchases of short-term investments			—			(50,721)			(42,677)
Proceeds from divested business			210,239			—			—
Cash paid for acquisitions			—			(313)			(7,341)
Sales/maturities of short-term investments			59,589			249,116			129,987
Patent and trademark costs			(1,234)			(1,127)			(871)
Net cash provided by investing activities			250,323			176,815			36,045

Cash Flows From Financing Activities:
Proceeds from exercise of stock options			3,972			2,790			1,478
Repurchase of common stock			(10,011)			—			—
Cash paid for repurchase of 2026 Convertible Senior Notes			—			(163,772)			(25,003)
Repayment of 2025 Convertible Senior Notes			(14,344)			—			—
Repayment of notes payable			(161)			(141)			(71)
Repayment of finance lease liabilities			(530)			(408)			(202)
Net cash used in financing activities			(21,074)			(161,531)			(23,798)

Effect of exchange rates on cash and cash equivalents			(15,464)			(18)			(1,739)
Net change in cash and cash equivalents			205,205			(1,057)			9,751
Cash and cash equivalents — beginning of period			45,289			46,346			36,595
Cash and cash equivalents — end of period		$	250,494		$	45,289		$	46,346

Reconciliation of cash and cash equivalents to the consolidated balance sheets:
Cash and cash equivalents from continuing operations		$	34,137		$	35,192		$	29,233
Cash and cash equivalents from discontinued operations (included in current assets held for sale)			11,152			11,154			7,362
Total cash and cash equivalents — beginning of period		$	45,289		$	46,346		$	36,595

Cash and cash equivalents from continuing operations		$	250,494		$	34,137		$	35,192
Cash and cash equivalents from discontinued operations (included in current assets held for sale)			—			11,152			11,154
Total cash and cash equivalents — end of period		$	250,494		$	45,289		$	46,346

Supplemental Disclosure of Cash Flow Information:

Cash paid for interest		$	1,628		$	2,693		$	3,399

Cash paid for income taxes		$	2,191		$	1,422		$	1,462

Supplemental Disclosure of Non-Cash Financing Activities:
Operating lease right-of-use assets and operating lease liabilities		$	6,582		$	20,989		$	11,109

Net unrealized gain on available-for-sale debt securities		$	1,532		$	2,860		$	6,742

Reclassification of realized gain (loss) on available-for-sale debt securities to earnings		$	3,014		$	(6,624)		$	(3,008)

Paid-in-kind preferred stock dividend, including beneficial conversion feature		$	8,000		$	8,000		$	8,000

Fixed assets included in accounts payable and accrued liabilities		$	218		$	103		$	442

Intangible assets included in property and equipment		$	—		$	252		$	8,710

Contingent consideration reclassed to accounts payable and accrued liabilities		$	881		$	—		$	—

Purchase of equipment through finance lease obligation		$	388		$	936		$	1,112




		Years Ended December 31,
	2024		2023		2022
Cash Flows From Operating Activities:
Net loss	$	(114,756)	$	(99,587)	$	(37,333)
Adjustments to reconcile net loss to net cash used in operating activities:
Impairment loss		63,809		49,569		—
Depreciation and amortization		30,757		27,487		22,765
Amortization of debt discount		1,940		2,526		2,581
Non-cash operating lease expense		5,770		5,103		3,645
Unrealized (gain) loss on investments in equity securities		899		(1,308)		11,406
Realized loss on investments in equity securities		48		—		—
Realized loss on available-for-sale investments		4,091		67		102
Gain on extinguishment of debt		(18,505)		(5,679)		—
Stock-based compensation expense		19,704		22,808		20,082
Loss on disposal of property and equipment		384		954		800
Gain on insurance settlement		—		(2,642)		(4,815)
Change in credit losses		(242)		822		234
Excess and obsolete inventory		234		—		651
Insurance proceeds for operations		—		1,212		9,883
Change in contingent consideration		(1,847)		(890)		216
Changes in operating assets and liabilities:
Accounts receivable		(4,149)		3,673		(4,137)
Inventories		3,252		1,508		(14,204)
Prepaid expenses and other current assets		(2,149)		(103)		(1,598)
Deposits		(1,443)		(663)		(60)
Operating lease liabilities		(5,340)		(4,595)		(3,076)
Accounts payable and other accrued expenses		(76)		(2,766)		(6,483)
Accrued compensation and related expenses		1,852		2,884		(1,569)
Deferred revenue		(179)		842		(530)
Net deferred tax liability		(377)		(1,979)		(411)
Net cash used in operating activities		(16,323)		(757)		(1,851)

Cash Flows From Investing Activities:
Purchases of property and equipment		(17,254)		(38,785)		(22,107)
Insurance proceeds for loss of fixed assets		—		976		3,000
Software development costs		(2,886)		(5,244)		(1,476)
Purchases of short-term investments		(50,721)		(42,677)		(163,788)
Cash paid for acquisitions		(313)		(7,341)		(6,554)
Sales/maturities of short-term investments		249,116		129,987		131,858
Patent and trademark costs		(1,127)		(871)		(614)
Net cash provided by (used in) investing activities		176,815		36,045		(59,681)

Cash Flows From Financing Activities:
Proceeds from exercise of stock options		2,790		1,478		2,048
Repurchase of common stock		—		—		(37,960)
Cash paid for repurchase of 2026 Senior Notes		(163,772)		(25,003)		—
Repayment of notes payable		(141)		(71)		(3,180)
Repayment of finance lease liabilities		(408)		(202)		(82)
Net cash used in financing activities		(161,531)		(23,798)		(39,174)

Effect of exchange rates on cash and cash equivalents		(18)		(1,739)		(1,800)
Net change in cash and cash equivalents		(1,057)		9,751		(102,506)
Cash and cash equivalents — beginning of period		46,346		36,595		139,101
Cash and cash equivalents — end of period	$	45,289	$	46,346	$	36,595

Supplemental Disclosure of Cash Flow Information:

Cash paid for interest	$	2,693	$	3,399	$	3,628

Cash paid for income taxes	$	1,422	$	1,462	$	1,979

Supplemental Disclosure of Non-Cash Financing Activities:
Operating lease right-of-use assets and operating lease liabilities	$	20,989	$	11,109	$	12,384

Net unrealized gain on available-for-sale debt securities	$	2,860	$	6,742	$	23,439

Reclassification of realized gain (loss) on available-for-sale debt securities to earnings	$	(6,624)	$	(3,008)	$	46

Paid-in-kind preferred stock dividend, including beneficial conversion feature	$	8,000	$	8,000	$	8,000

Fixed assets included in accounts payable and accrued liabilities	$	103	$	442	$	1,003

Intangible assets included in property and equipment	$	252	$	8,710	$	—

Purchase of equipment through finance lease obligation	$	936	$	1,112	$	—

See accompanying notes to consolidated financial statements.

F-9

F-10

Table of Contents

Cryoport, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

Note 1. Nature of the Business

~~Cryoport~~We isare a leading global provider of ~~innovative~~integrated, ~~products~~temperature-controlled ~~and~~supply ~~services~~chain ~~supporting~~solutions for the life sciences., ~~Our~~with ~~mission~~a isstrong tofocus ~~enable~~on supporting the ~~future~~rapidly ofgrowing ~~medicine~~cell ~~for~~and agene ~~new~~therapy ~~era~~market of(“CGT ~~life sciences~~market”). ~~With~~Our ~~over~~solutions 50are ~~strategic~~purpose-built ~~locations~~to ~~covering~~support ~~the~~a ~~Americas,~~broad ~~EMEA~~range ~~(Europe,~~of ~~the~~global ~~Middle~~life ~~East~~sciences ~~and~~markets, ~~Africa)~~including biopharmaceutical and ~~APAC~~pharmaceutical ~~(Asia Pacific)~~companies, ~~Cryoport's~~the ~~global~~animal ~~platform~~health ~~provides~~markets, ~~mission-critical~~reproductive ~~bio-logistics~~medicine, ~~bio-storage~~academic institutions, ~~bio-processing~~research, and ~~cryogenic~~government ~~systems to over 3,000 customers worldwide~~agencies. Our ~~platform of~~ solutions ~~and~~help ~~services, together with~~ our ~~global~~customers ~~team~~ensure ofthe ~~over 1~~safe,~~100~~ ~~dedicated~~compliant ~~colleagues~~storage, ~~delivers~~handling, aand ~~unique~~delivery ~~combination~~ of ~~innovative~~high ~~supply~~value, ~~chain~~temperature ~~technologies~~sensitive ~~and~~biological ~~services through our industry-leading brands~~materials, including ~~Cryoport~~cell ~~Systems,~~and ~~MVE~~gene ~~Biological~~therapies ~~Solutions (“MVE”), CRYOPDP,~~ and ~~CRYOGENE~~immunotherapies.

On June 11, 2025, the Company completed the previously disclosed divestiture of its specialty courier CRYOPDP business to designated affiliates of DHL Supply Chain International Holding B.V. (“DHL”) for $133.0 million. Pursuant to the terms of the sale and purchase agreement (the “Agreement”), DHL acquired 100% of the capital stock and voting rights of certain entities conducting business under the trade name “CryoPDP”, including each of PDP Courier Services (USA), Inc., Courier Polar Expres S.L., Advanced Therapy Logistics and Solutions, SAS and Cryo Express GmbH (collectively, the “Transaction”). The Transaction also included the repayment of approximately $77.2 million of outstanding intercompany loans owed by CRYOPDP to the Company. The Company and DHL also entered into certain related transaction agreements at the closing date of the Transaction, including a master partnership agreement, a transition services agreement and other customary agreements. The divestiture and strategic partnership with DHL are expected to enhance the Company’s ability to develop its business, particularly in the Europe, the Middle East, and Africa (EMEA) and Asia-Pacific (APAC) regions, and to provide differentiated and high-value services aligned with the Company’s long-term growth strategy.

The Transaction represents a strategic shift that has a major effect on the Company’s operations and financial results, and as a result, the results of the CRYOPDP business were classified as discontinued operations in our consolidated statements of operations and excluded from both continuing operations and segment results for all periods presented. Results of discontinued operations include all revenues and expenses directly derived from the CRYOPDP business. The CRYOPDP business was classified as held for sale in our consolidated balance sheet as of December 31, 2024. See Note 5 – Discontinued Operations for additional information about the divestiture of the CRYOPDP business.

The Company is a Nevada corporation and its common stock is traded on the NASDAQ Capital Market exchange under the ticker symbol “CYRX.”

Note 2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Cryoport, Inc. and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated.

Cash and Cash Equivalents

Our cash and cash equivalents represent demand deposits, and money market funds which are readily convertible into cash, have maturities of 90 days or less when purchased and are considered highly liquid and easily tradeable.

Short-Term Investments

Our investments in equity securities consist of mutual funds with readily determinable fair values which are carried at fair value with changes in fair value recognized in earnings.

F-10

Table of Contents

Investments in debt securities are classified as available-for-sale and are carried at fair value, with unrealized gains and losses, net of tax, reported as accumulated other comprehensive income (loss) and included as a separate component of stockholders’ equity.

Gains and losses are recognized when realized. When we have determined that an other than temporary decline in fair value has occurred, the amount related to a credit loss is recognized in earnings. Gains and losses are determined using the specific identification method.

Short-term investments are classified as current assets even though maturities may extend beyond one year because they represent investments of cash available for operations.

F-11

Table of Contents

Use of Estimates

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company’s significant estimates include ~~the fair value of short-term investments, valuations and purchase price allocations related to business combinations,~~ expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates, including valuation multiples utilized in the market approach used in impairment assessments, estimated fair values of intangible assets and goodwill, intangible asset useful lives and amortization methods, ~~contingent consideration liability,~~ equity-based instruments, tax reserves and recoverability of the Company’s net deferred tax assets and related valuation allowance.

Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.

Future events and their effects cannot be predicted with certainty, and, accordingly the Company’s accounting estimates require the exercise of judgment.

Credit Losses

The Company estimates and records a provision for its expected credit losses related to its financial instruments, including its trade receivables. The Company considers historical collection rates, the current financial status of its customers, macroeconomic factors, and other industry-specific factors when evaluating for current expected credit losses. Forward-looking information is also considered in the evaluation of current expected credit losses. However, because of the short time to the expected receipt of accounts receivable, the Company believes that the carrying value, net of excepted losses, approximates fair value and therefore, relies more on historical and current analysis of such financial instruments, including its trade receivables.

To determine the provision for credit losses for accounts receivable, the Company has disaggregated its accounts receivable by class of customer at the business component level, as the Company determined that risk profile of its customers is consistent based on the type and industry in which they operate, mainly in the life sciences industry. Each business component is analyzed for estimated credit losses individually. In doing so, the Company establishes a historical loss matrix, based on the previous collections of accounts receivable by the age of such receivables, and evaluates the current and forecasted financial position of its customers, as available. Further, the Company considers macroeconomic factors and the status of the life sciences industry to estimate if there are current expected credit losses within its trade receivables based on the trends and the Company’s expectation of the future status of such economic and industry-specific factors. Also, specific allowance amounts are established based on review of outstanding invoices to record the appropriate provision for customers that have a higher probability of default.

Discontinued Operations

We review the presentation of planned business dispositions in the consolidated financial statements based on the available information and events that have occurred. The review consists of evaluating whether the business meets the definition of a component for which the operations and cash flows are clearly distinguishable from the other components of the business, and if so, whether it is anticipated that after the disposal the cash flows of the component would be eliminated from continuing operations and whether the disposition represents a strategic shift that has a major effect on operations and financial results. In addition, we evaluate whether the business has met the criteria as a business held for sale. In order for a planned disposition to be classified as a business held for sale, the

F-11

Table of Contents

established criteria must be met as of the reporting date, including an active program to market the business and the expected disposition of the business within one year.

Fair Value of Financial Instruments

The Company’s financial instruments consist of cash and cash equivalents, short-term investments, accounts receivable, accounts payable and accrued expenses, finance lease liabilities, notes payable, contingent consideration, ~~and~~ the Company’s 0.75% Convertible Senior Notes due in 2026 (the “2026 Convertible Senior Notes”) and the Company’s previously outstanding 3.0% Convertible Senior Notes due in 2025 (the “2025 Convertible Senior Notes” and together with the 2026 Convertible Senior Notes, the “Convertible Senior Notes”). The carrying value for all such instruments, except finance lease liabilities, notes payable and the Convertible Senior Notes, approximates fair value because the interest rate approximates market rates available to us for similar obligations with the same maturities. For additional information related to fair value measurements, including the ~~notes payable and the~~ Convertible Senior Notes, see Notes 7, 12 and 1312.

Concentrations of Credit Risk

Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. From time to time, we maintain cash, cash equivalent and short-term investment balances in excess of amounts insured by the Federal Deposit Insurance Corporation (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”). Primarily all of our cash, cash equivalents and short-term investments at December 31, ~~2023~~2025 were in excess of amounts insured by the FDIC and SIPC. The Company performs ongoing evaluations of these institutions to limit its concentration risk exposure. We manage such risks in our portfolio by investing in highly liquid, highly rated instruments, and limit investing in long-term maturity instruments.

F-12

Table of Contents

SIPC. The Company performs ongoing evaluations of these institutions to limit its concentration risk exposure. We manage such risks in our portfolio by investing in highly liquid, highly rated instruments, and limit investing in long-term maturity instruments.

Our investment policy requires that purchased instruments in marketable securities may only be in highly rated instruments, which are primarily U.S. Treasury bills or treasury-backed securities, and also limits our investment in securities of any single issuer.

Inventories

Inventories are stated at the lower of cost and net realizable value. Cost is determined using the first-in, first-out (“FIFO”) method. Inventories are reviewed periodically for slow-moving or obsolete status. The Company writes down the carrying value of its inventories to reflect situations in which the cost of inventories is not expected to be recovered. Once established, write-downs of inventories are considered permanent adjustments to the cost basis of the obsolete or excess inventories. Raw materials and finished goods include material costs less adjustments for obsolete or excess inventories. The Company evaluates the current level of inventories considering historical trends and other factors, such as selling prices and costs of completion, disposal and transportation, and based on the evaluation, records adjustments to reflect inventories at net realizable value. These adjustments are estimates, which could vary significantly from actual results if future economic conditions, customer demand, competition or other relevant factors differ from expectations. These estimates require us to make assessments about future demand for the Company’s products in order to categorize the status of such inventories items as slow-moving, obsolete or in excess-of-need. These estimates are subject to the ongoing accuracy of the Company’s forecasts of market conditions, industry trends, competition and other factors.

Property and Equipment

Property and equipment are stated at cost, less accumulated depreciation. We compute depreciation using the straight-line method over the estimated useful lives of the assets which is generally three to twelve years for computer hardware and software, seven to ten years for freezers, four to ten years for trucks and autos, three to fifteen years for furniture and equipment and over the shorter of the lease term or useful lives of the assets for leasehold improvements. Buildings are depreciated over a useful life ranging from 20 to 45 years. Maintenance and repairs are expensed as incurred.

F-12

Table of Contents

Betterments, renewals and extraordinary repairs that extend the lives of the assets are capitalized; other repairs and maintenance charges are expensed as incurred. The cost and related accumulated depreciation and amortization applicable to assets retired are removed from the accounts, and the gain or loss on disposition is recognized in the consolidated statements of operations.

Leases

The Company determines if an arrangement is a lease at inception. Operating lease right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset during the lease term, and operating lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating leases are included in ROU assets, current operating lease liabilities, and long-term operating lease liabilities on our consolidated balance sheets. Finance leases are included in property and equipment, current finance lease liabilities, and long-term finance lease liabilities on our consolidated balance sheets.

Lease ROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at commencement date calculated using our incremental borrowing rate applicable to the lease asset, unless the implicit rate is readily determinable. ROU assets also include any lease payments made at or before lease commencement and exclude any lease incentives received. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. The Company’s leases do not contain any residual value guarantees. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.

The Company accounts for lease and non-lease components as a single lease component for all its leases.

F-13

Table of Contents

Business Combinations

Total consideration transferred for acquisitions is allocated to the assets acquired and liabilities assumed based on their fair values at the dates of acquisition. This purchase price allocation process requires management to make significant estimates and assumptions primarily with respect to intangible assets. The fair value of identifiable intangible assets is based on detailed valuations that use information and assumptions determined by management. Any excess of purchase price over the fair value of the net tangible and intangible assets acquired is allocated to goodwill. While the Company uses its best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date as well as any contingent consideration, where applicable, the Company’s estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company records adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill.

Goodwill

The Company evaluates goodwill on an annual basis in the fourth quarter or more frequently if management believes indicators of impairment exist. Such indicators could include, but are not limited to: (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. For each reporting unit being tested, the Company compares the fair value of the reporting unit with its carrying amount and then recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value up to the total amount of goodwill allocated to the reporting unit. As a result of our 2023 quantitative assessment, we concluded that goodwill related to the MVE reporting unit iswas impaired as of December 31, 2023, and recorded an impairment charge of $49.6 million in the consolidated statement of operations for the year ended December 31, 2023. As a result of an interim impairment assessment performed as of June 30, 2024, we concluded that ~~there has been no impairment of~~ the goodwill ~~associated with the CRYOPDP reporting unit as its carrying value did not exceed its estimated fair value. We further concluded that the goodwill~~ related to the MVE reporting unit was further impaired, and recorded an impairment charge of $54.6 million related to full impairment of the goodwill related to the MVE reporting unit in the consolidated statement of operations for the year ended December 31, 2024, (see Note 10) – Goodwill and Intangible Assets for additional information. As a result of our 2025 quantitative assessment, we concluded that goodwill is not impaired as of December 31, 2025.

Intangible Assets

Indefinite-lived intangible assets are comprised of trade name/trademarks acquired in the Company’s ~~recent~~ acquisitions, and are tested for impairment annually using a relief from royalty method that relies on estimates of future revenues, royalty rates, and discount rates. If the asset is not found to be recoverable, it is written down to the estimated fair value. As a result of an interim impairment assessment performed as of June 30, 2024, we recorded a $9.0 million impairment charge related to trademarks for our MVE reporting unit, and a $0.3 million impairment charge related to the write-off of Cell&Co’s trade name that is no longer in use as a result of the Company’s global rebranding initiative, (see Note 10) – Goodwill and Intangible Assets for additional information. The Company has

~~Intangible assets with a definite life are comprised of patents, trademarks, software development costs and the intangible assets acquired in the Company’s recent acquisitions which include a non~~F-compete agreement, technology, customer relationships, trade name/trademark, agent network, order backlog, developed technology and land use rights. Intangible assets with a definite life are amortized using the straight-line method over the estimated useful lives (see Note 10). The Company uses the following valuation methodologies to value the significant intangible assets with a definite life acquired: income approach for customer relationships, replacement cost for agent network and software, and relief from royalty for trade name/trademarks and developed technology. The Company capitalizes costs of obtaining patents and trademarks, which are amortized, using the straight-line method over their estimated useful life of five years once the patent or trademark has been issued.13

F-14

Table of Contents

~~The~~performed ~~Company evaluates the recoverability of identifiable intangible assets with~~ a ~~definite~~quantitative ~~life~~impairment ~~whenever~~assessment ~~events or changes~~ in ~~circumstances indicate that an intangible asset’s carrying amount may not be recoverable. Such circumstances could include, but are not limited to: (1) a significant decrease in~~ the ~~market~~fourth ~~value~~quarter of an2025 asset, (2) a significant adverse change in the extent or manner in which an asset is used, or (3) an accumulation of costs significantly in excess of the amount originally expected for the acquisition of an asset. The Company measures the carrying amount of the asset against the estimated undiscounted future cash flows associated with it. Should the sum of the expected future net cash flows be less than the carrying value of the asset being evaluated, an impairment loss would be recognized. The impairment loss would be calculated as the amount by which the carrying value of the asset exceeds its fair value. The estimate of fair value is based on various valuation techniques, including the discounted value of estimated future cash flows. The evaluation of asset impairment requires the Company to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and ~~actual~~concluded ~~results~~that ~~may~~there ~~differ~~has ~~from~~been ~~assumed~~no ~~and estimated amounts. During the year ended December 31, 2023, due to macroeconomic factors impacting results of operations, the Company performed an~~ impairment ~~analysis~~ of ~~its~~our ~~amortizable~~indefinite-lived intangible assets atfor the ~~reporting~~periods ~~unit level~~presented. The impairment analysis requires a comparison of undiscounted future cash flows expected to be generated over the useful life of an asset to the carrying value of the asset. Based on the impairment analysis performed, the estimated undiscounted cash flows exceeded the carrying amount of the assets and therefore no impairment charge was required. An interim impairment assessment was performed as of June 30, 2024, resulting in the estimated undiscounted cash flows exceeding the carrying amount of the assets and therefore no impairment charge was required.

Intangible assets with a definite life are comprised of patents, trademarks, software development costs and the intangible assets acquired in the Company’s acquisitions which include a non-compete agreement, technology, customer relationships, trade name/trademark, agent network, order backlog, developed technology and land use rights. Intangible assets with a definite life are amortized using the straight-line method over the estimated useful lives, see Note 10 – Goodwill and Intangible Assets for additional information. The Company uses the following valuation methodologies to value the significant intangible assets with a definite life acquired: income approach for customer relationships, replacement cost for agent network and software, and relief from royalty for trade name/trademarks and developed technology. The Company capitalizes costs of obtaining patents and trademarks, which are amortized, using the straight-line method over their estimated useful life of five years once the patent or trademark has been issued.

Other Long-lived Assets

Filing Compare · Cryoport, Inc.